ALPHABETICAL POISONS LIST

ALPHABETICAL LIST OF POISONS, RESTRICTED SUBSTANCES AND DRUGS OF ADDICTION - INCLUDES AMENDMENTS UP TO AND INCLUDING 1 JUNE 2015

The following alphabetical list has been prepared for the guidance of users but has no legal status. For exact reference, use should be made of the entries in the Poisons List itself, which except for a very small number of variations, adopts the Schedules of the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) as currently amended. (See http://www.tga.gov.au/industry/scheduling-poisons-standard.htm ) i.e. SUSMP No. 7. Consult the Poisons and Therapeutic Goods Act and Regulation and the SUSMP for further details on the interpretation of entries.

It should be noted that the entries are for substances (not for any particular products which may be available). In the Poisons and Therapeutic Goods Act, 1966, "substance" is defined to include preparation, admixture and all salts and derivatives. Note that the term “derivative” (page v of the SUSMP) has a broader meaning than that of the same term used in chemistry. However, scheduled substances when contained in certain products are exempt and these exemptions are listed at the end of each Schedule, and these products are generally those shown in Appendix A of the SUSMP. Some entries are chemical or pharmacological group entries; for common synonyms refer to the Index of the SUSMP.

Where a preparation containing multiple poisons is in two or more Schedules, the more or most restrictive Schedule applies (i.e. in order of Schedule 9, 8, 4, 7, 3, 2, 6, 5).

This list refers only to the NSW Poisons and Therapeutic Goods legislation, though the classifications are very similar in all other States and Territories. Other restrictions may apply under other State and Commonwealth legislation, e.g. the Drug Misuse and Trafficking Act and Regulations (prohibited drugs, prohibited plants, illicit drug precursors and reagents, substances in Schedule 9 of the SUSMP and other psychoactive substances); Dangerous Goods legislation; SafeWork Australia national code for labelling of workplace substances; Competition and Consumer legislation; Commonwealth Therapeutic Goods Act; National Industrial Chemicals Notification and Assessment Scheme (NICNAS); NSW and Commonwealth Food regulations; and Customs prohibited imports and exports regulations. The absence of a substance from this list does not imply that there is no legal restriction on its possession, supply, labelling, packaging or use.

Inclusion of a substance in a Schedule does not imply that it is available, approved or effective for any use mentioned in the Schedule entry, nor does it negate any obligation to register a therapeutic good, agricultural or veterinary product with the Therapeutic Goods Administration (TGA) or Australian Pesticides and Veterinary Medicines Authority (APVMA) respectively.

Certain entries in this List appear with a “Clause” or “Appendix” number in parentheses. These refer respectively to the Clauses of the Poisons and Therapeutic Goods Regulation 2008 under the Poisons and Therapeutic Goods Act 1966 which make special or additional reference to the substance concerned or to listing in the appropriate Appendix of the Poisons and Therapeutic Goods Regulation 2008. However no such indication is given for “highly dangerous substances” (Clause 20(9) of the Regulation) or for medicines requiring label warnings in Appendix F (other than those in Appendix K) of the SUSMP (Paragraph 3 of Appendix A of the Regulation.)

In the Index, number and single-letter prefixes are ignored for alphabetical listing.
<table>
<thead>
<tr>
<th>SCHEDULE</th>
<th>SUBSTANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>ABACAVIS.</td>
</tr>
<tr>
<td>7</td>
<td>ABAMECTIN <strong>except</strong> when included in Schedule 5 or 6.</td>
</tr>
</tbody>
</table>
| 6        | ABAMECTIN:  
|          | (a) in preparations for pesticidal use containing 4 per cent or less of abamectin **except** when included in Schedule 5; or  
|          | (b) in slow-release plastic matrix ear tags for livestock use containing 1 g or less of abamectin. |
| 5        | ABAMECTIN in preparations, for internal use for the treatment of animals, containing 1 per cent or less of abamectin. |
| 4        | ABATACEPT. |
| 4        | ABCIXIMAB. |
| 4        | ABIRATERONE ACETATE |
| 7        | ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use. |
| 5        | ABSICIC ACID. |
| 4        | ACAMPROSATE CALCIUM. |
| 4        | ACARBOSE. |
| 4        | ACEBUTOLOL. |
| 6        | ACEPHATE. |
| 4        | ACEPROMAZINE. |
| 6        | ACETAMIPRID **except** in preparations containing 1 per cent or less of acetamiprid. |
| 4        | ACETANILIDE and alkyl acetonilides (excluding when present as an excipient) for human therapeutic use. |
| 4        | ACETARSOL. |
| 4        | ACETAZOLAMIDE. |
| 6        | ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent acetic acid (CH₃COOH) **except** when included in Schedule 2. |
| 2        | ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH₃COOH) for therapeutic use. |
| 5        | ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30 per cent of acetic acid (CH₃COOH) **except**:  
|          | (a) when included in Schedule 2 or 6; or  
|          | (b) for therapeutic use. |
| 6        | ACETIC ANHYDRIDE excluding its derivatives. |
| 4        | ACETOHEXAMIDE. |
| 5        | ACETONE **except** in preparations containing 25 per cent or less of designated solvents. |
| 9        | ACETORPHINE. |
| 9        | ACETYL-ALPHA-METHYLFENTANYL. |
| 4        | ACETYL ISOVALERYLTYLOSIN. |
| 4        | ACETYLCARBROMAL. |
| 4        | ACETYLCOLINE. |
| 4        | ACETYLCYSTEINE **except**:  
|          | (a) when included in Schedule 2; or  
|          | (b) in preparations for oral use when labelled with a recommended daily dose of 1 g |
or less of acetylcysteine.

ACETYLCYSTEINE in preparations for oral use except when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACETYLDIGITOXIN.

ACETYLDIHYDROCODEINE.

ACETYL METHADOL.

ACETYL METHYL DIMETHYLOXIMIDOPHENYLHYDRAZINE.

ACETYL MORA PHINES.

ACETYLSTROPHANTHIDIN.

ACIBENZOLAR-S-METHYL.

ACICLOVIR except in preparations containing 5 per cent or less of aciclovir for the treatment of Herpes labialis in packs containing 10 g or less.

ACIFLUORFEN.

ACINITRAZOLE except in preparations containing 20 per cent or less of acinitrazole.

ACIPIMOX.

ACITRETIN. (Clauses 37,52,60)

ACLIDINIUM BROMIDE.

ACOKANTHERA OUABAIO.

ACOKANTHERA SCHIMPERI.

ACONITUM spp except:
(a) when included in Schedule 2;
(b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or
(c) in preparations for dermal use in adults containing 0.02 per cent or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.

ACONITUM spp for therapeutic use in adults:
(a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids; or
(b) in preparations for dermal use containing 0.02 per cent or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids.

ACORUS CALAMUS (calamus) for human therapeutic use.

ACRIFLAVINE for veterinary use except when included in Schedule 5.

ACRIFLAVINE in preparations for veterinary use containing 2.5 per cent or less of acriflavine.

ACRIVASTINE.

ACROLEIN.

ACRYLONITRILE.

ADALIMUMAB.

ADAPALENE.

ADEFOVIR.

ADENOSINE for human therapeutic use in preparations for injection.

ADIPHENINE.

ADONIS VERNALIS.

ADRAFINIL.
ADRENALINE except:
(a) when included in Schedule 3; or
(b) in preparations containing 0.02 per cent or less of adrenaline unless packed and labelled for injection.

ADRENALINE in preparations containing 1 per cent or less of adrenaline except in preparations containing 0.02 per cent or less of adrenaline unless packed and labelled for injection.

ADRENOCORTICAL HORMONES except when separately specified in these Schedules.

AFAMELANOTIDE (Melanocyte stimulating hormone).

AFATINIB DIMALEATE.

AFLIBERCEPT.

AFOXOLANER for the treatment and prevention of flea infestations and control of ticks in dogs in oral divided preparations each containing 140 mg or less of afoxolaner per dosage unit.

AGALSIDASE.

AGLEPRISTONE.

AGOMELATINE.

ALBENDAZOLE except:
(a) when included in Schedule 5 or 6; or
(b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.

ALBENDAZOLE for the treatment of animals except:
(a) when included in Schedule 5; or
(b) in intraruminal implants each containing 3.85 g or less of albendazole.

ALBENDAZOLE for the treatment of animals, in preparations containing 12.5 per cent or less of albendazole except in intraruminal implants each containing 3.85 g or less of albendazole.

ALCLOFENAC.

ALCLOMETASONE except when included in Schedule 3.

ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of aclometasone in packs containing 30 g or less of the preparation.

ALCOHOL - see METHYLATED SPIRIT.

ALCOHOL ANTAGONISTS - see individual entries.

ALCUCURONIUM.

ALDESLEUKIN.

ALDICARB.

ALDOSTERONE.

ALDOXYCARB.

ALDRIN.

ALEFACEPT.

ALEMTUZUMAB.
4 ALENDRONIC ACID.
4 ALFACALCIDOL.
8 ALFENTANIL.
4 ALFUZOSIN.

Exempt ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that do not fit the definition of an agvet chemical product.
4 ALGLUCERASE.
4 ALGLUCOSIDASE.
4 ALISKIREN.

5 ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:
   (a) in solid orthodontic device cleaning preparations, the pH of which as an "in-use" aqueous solution is more than 11.5;
   (b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solutions or mixture is more than 11.5 but less than or equal to 12.5;
   (c) in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or
   (d) in liquid or semi-solid preparations the pH of which is more than 11.5, unless:
      (i) in food additive preparations for domestic use; or
      (ii) in automatic dish washing preparations for domestic use with a pH of more than 12.5,
      except when separately specified in these Schedules.

6 ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non-domestic use:
   (a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
   (b) in liquid or semi-solid automatic dishwashing preparations the pH of which is more than 12.5.

7 ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium, alone or in any combination for domestic use:
   (a) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5;
   (b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solutions or mixture is more than 12.5; or
   (c) in liquid or semi-solid automatic dishwashing preparations the pH of which is more than 12.5.

6 ALKEXYLATED FATTY ALKYLAMINE POLYMER except:
   (a) when included in Schedule 5; or
   (b) in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.

5 ALKEXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50 per cent or less of alkoxylated fatty alkylamine polymer except in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.

9 ALKOXYAMPHETAMINES and substituted alkoxyamphetamine except when separately specified in these Schedules.

9 ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines except when separately specified in these Schedules.

9 ALKYLTHIOAMPHETAMINES and substituted alkylthioamphetamine except when separately specified in these Schedules.

4 ALLERGENS for therapeutic use.

6 ALLETHRIN except:
(a) when included in Schedule 5; or
(b) in insecticidal mats containing 20 per cent or less of allethin; or
(c) in other preparations containing 1 per cent or less of allethin.

5 ALLETHRIN in preparations containing 10 per cent or less of allethin except:
(a) in insecticidal mats; or
(b) in other preparations containing 1 per cent or less of allethin.

4 ALLOPURINOL.
5 ALLOXYDIM.
7 ALLYL ALCOHOL.
7 ALLYLISOPROPYLACETYLUREA for therapeutic use.
4 ALLYLOESTRENOL.
9 ALLYLPRODINE.
4 ALOGLIPTIN.
4 ALOSETRON.
2 ALOXIPRIN.
8 ALPHACETYL METHADOL.
7 ALPHA-CYPERMETHRIN except when included in Schedule 5 or 6.
6 ALPHA-CYPERMETHRIN
(a) in aqueous preparations containing 25 per cent or less of alpha-cypermethrin; or
(b) in other preparations containing 10 per cent or less of alpha-cypermethrin,
except when included in Schedule 5.

5 ALPHA-CYPERMETHRIN:
(a) in aqueous preparations containing 3 per cent or less of alpha-cypermethrin; or
(b) in other preparations containing 1.5 per cent or less of alpha-cypermethrin.

4 ALPHADOLONE.
9 ALPHAMEPRODINE.
9 ALPHA-METHYL FENTANYL.
9 ALPHA-METHYL THIOFENTANYL.
9 ALPHAMETHADOL.
8 ALPHAPRODINE.
4 ALPHA1-PROTEINASE INHIBITOR (HUMAN).
4 ALPHAXALONE.
8 ALPRAZOLAM. (Clause 123, Appendix A)
4 ALPRENOLOL.
4 ALPROSTADIL.
4 ALSEROXYLON.
4 ALTEPLASE.
4 ALTRENOGEST.
4 ALTRETAMINE (hexamethylmelamine).
4 AMANTADINE.
4 AMBENONIUM CHLORIDE.
4 AMBRISENTAN.
4 AMBUCETAMIDE.
4 AMBUTONIUM BROMIDE.
AMCINONIDE.

AMETHOCAIN\textit{e\ except:}
(a) when included in Schedule 2; or
(b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

AMETHOCAIN\textit{e in preparations for topical use other than eye drops, containing 10 per cent or less of total local anaesthetic substances, except in dermal preparations containing 2 per cent or less of total local anaesthetic substances.}

AMETRHYN.

AMICARBAZONE.

AMIDITHION.

AMIFOSTINE.

AMIKACIN.

AMILORIDE.

AMINACRINE for veterinary use \textit{except} when included in Schedule 5.

AMINACRINE in preparations for veterinary use containing 2.5 per cent or less of aminacrine.

AMINES for use as curing agents for epoxy resins \textit{except} when separately specified in these Schedules.

AMINOCAPROIC ACID.

AMINOCARB \textit{except} when included in Schedule 6.

AMINOCARB in preparations containing 25 per cent or less of aminocarb.

AMINOCYCLOPYRACHLOR.

2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE *(STP or DOM).

AMINOETHOXYVINYLGLYCINE \textit{except} in preparations containing 15 per cent or less of aminooethoxyvinylglycine.

AMINOLUTETHIMIDE.

5-AMINOLEVULINIC ACID.

1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.

AMINOMETRADINE.

AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.

AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.

AMINOPHYLLINE \textit{except} when included in Schedule 3.

AMINOPHYLLINE in liquid oral preparations containing 2 per cent or less of aminophylline.

AMINOPTERIN.

AMINOPYRALID \textit{except} when included in Schedule 5.

AMINOPYRALID in water soluble gel formulations containing 0.5 per cent or less of aminopyralid.

5-(2-AMINOPROPYL)INDAN and substituted 5-(2-aminopropyl)indans \textit{except} when separately specified in these Schedules.

4-AMINOPYRIDINE \textit{except} when included in Schedule 4.

4-AMINOPYRIDINE for therapeutic use.

AMINOREX.

AMINOSALICYLIC ACID.

AMIODARONE.

AMIPHENAZOLE.
AMISOMETRADINE.
AMISULPRIDE. (Appendix A)
AMITON.
AMITRAZ.
AMITRIPTYLINE. (Appendix A)
AMITROLE.
AMLODIPINE.
AMMI VISNAGA.
AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) except:
(a) when included in Schedule 5;
(b) in preparations for human internal therapeutic use;
(c) in preparations for inhalation when absorbed in an inert solid material; or
(d) in preparations containing 0.5 per cent or less of ammonia.
AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5 per cent or less of ammonia except:
(a) in preparations for human internal therapeutic use;
(b) in preparations for inhalation when absorbed in an inert solid material; or
(c) in preparations containing 0.5 per cent or less of free ammonia.
AMMONIUM BROMIDE for therapeutic use.
AMMONIUM PERSULFATE in hair preparations.
AMMONIUM THIOCYANATE except in preparations containing 10 per cent or less of ammonium thiocyanate.
AMODIAQUINE.
AMOXAPINE.
AMOXYCILLIN.
AMPHETAMINE. (Clauses 84,90,98,101,122, Appendix A)
AMPHOMYCIN.
AMPHOTERICIN.
AMPICILLIN.
AMPRENAVIR.
AMRINONE.
AMSACRINE.
AMYGDALIN for therapeutic use.
AMYL NITRITE.
AMYLOBARBITONE except when included in Schedule 4. (Appendix A)
AMYLOBARBITONE when packed and labelled for injection. (Appendix A, Appendix B, Appendix D)
AMYLOCAINE.
ANABOLIC STEROIDAL AGENTS. (Appendix B, Appendix D)
ANAESTHETICS - LOCAL - see individual entries.

ANAGRELIDE.

ANAKINRA.

ANALEPTICS - see individual entries.

ANASTROZOLE.

ANCESTIM.

ANCHUSA OFFICINALIS for therapeutic use.

ANCROD and its immunoglobulin antidote.

ANDROGENIC STEROIDAL AGENTS. (Appendix B, Appendix D)

ANDROISOXAZOLE. (Appendix B, Appendix D)

ANDROSTANOLONE. (Appendix B, Appendix D)

ANDROSTENEDIOL. (Appendix B, Appendix D)

ANDROSTENEDIONE. (Appendix B, Appendix D)

ANECORTAVE.

ANGIOTENSIN AMIDE.

ANHYDRIDES, ORGANIC ACID, for use as curing agents for epoxy resins except when separately specified in these Schedules.

ANIDULAFUNGIN.

ANILINE (excluding its salts and derivatives) except in preparations containing 1 per cent or less of aniline.

ANILERIDINE.

ANISE OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning: KEEP OUT OF THE REACH OF CHILDREN; or
(c) in preparations containing 50 per cent or less of anise oil.

ANISTREPLASE.

ANTAZOLINE except when included in Schedule 2.

ANTAZOLINE in eye drops.

ANTIBIOTIC SUBSTANCES except:
(a) when separately specified in these Schedules; or
(b) nisin.

ANTICHOLINERGICS - see individual entries.

ANTICHOLINESTERASES - see individual entries.

ANTICOAGULANTS - see individual entries.

ANTICONVULSANTS - see individual entries.

ANTIDIABETICS - see individual entries.

ANTIGENS for human therapeutic use except when separately specified in this Schedule.

ANTIHISTAMINES except:
(a) when included in Schedule 2 or 3; or
(b) when separately specified in this Schedule.
ANTILEPTOTICS - see individual entries.
ANTIMALARIALS - see individual entries.

4 ANTIMONY for therapeutic use **except** when separately specified in these Schedules.

6 ANTIMONY COMPOUNDS **except**:
(a) when included in Schedule 4;
(b) antimony chloride in polishes;
(c) antimony titanate pigments in paint; or
(d) in paints or tinters containing 5 per cent or less of antimony calculated on the non-volatile content of the paint or tinter.

ANTIPARKINSONIANS - see individual entries.

4 ANTISERA (immunosera) for human use by injection **except** when separately specified in these Schedules.

ANTITHYROIDs - see individual entries.

ANTITUBERCULARS - see individual entries.

4 AOD-9604 (CAS No. 221231-10-3)

4 APIXABAN.

4 APOCYNUM spp.

4 APOMORPHINE.

4 APRACLONIDINE.

4 APRAMYCIN.

4 APREMILAST

4 APREPITANT.

4 APRONAL.

4 APROTININ.

4 ARECOLINE.

4 ARIPIPRAZOLE. (Appendix A)

7 ARISTOLOCHIA spp. For therapeutic use.

7 ARISTOLOCHIC ACID(S) for human therapeutic use.

AROMATIC EXTRACT OILS see HYDROCARBONS LIQUID AROMATIC.

7 ARPRINOCID.

7 ARSENIC **except**:
(a) when separately specified in this Schedule;
(b) when included in Schedule 4 or 6;
(c) as selenium arsenide in photocopier drums;
(d) as 10,10'-oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic;
(e) as 10,10'-oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other than when included in articles:
   (i) in contact with food stuffs, animal feeds or potable water;
   (ii) of clothing and footwear in contact with the skin;
   (iii) used as infant wear; or
   (iv) intended for use as packaging materials;
(f) in animal feeds containing 75 g/tonne or less of arsenic; or
(g) in paints containing 0.1 per cent or less of arsenic calculated on the non-volatile
ARSENIC:
(a) in ant poisons containing 0.4 per cent or less of arsenic;
(b) in animal feed premixes containing 4 per cent or less of arsenic; or
(c) in preparations for the treatment of animals except thiacetarsamide when included in Schedule 4, except when separately specified in this Schedule.

ARSENIC for human therapeutic use except when separately specified in these Schedules.

ARTICAIN.

ASARUM spp. containing aristolochic acid(s) for human therapeutic use.

ASENAPINE. (Appendix A)

ASPIRIN except:
(a) when included in Schedule 4, 5 or 6;
(b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than an effervescent agent when:
   (i) enclosed in a primary pack that contains 12 or less such powders or sachets of granules; and
   (ii) compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(c) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:
   (i) packed in blister or strip packaging or in a container with a child-resistant closure;
   (ii) in a primary pack of not more than 25 tablets or capsules, each containing 325 mg or less of aspirin, or in a primary pack of not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; and
   (iii) compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(d) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:
   (i) packed in blister or strip packaging or in a container with a child-resistant closure;
   (ii) in a primary pack containing 100 or less tablets or capsules, each containing 100 mg or less of aspirin when packed and labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and
   (iii) compliant with the requirements of the Required Advisory Statements for Medicine Labels.

ASPIRIN for the treatment of animals except when included in Schedule 4 or 5.

ASPIRIN for the treatment of animals in divided preparations when packed in blister or strip packaging or in a container with a child-resistant closure.

ASPIRIN:
(a) when combined with caffeine, paracetamol or salicylamide or any derivative of these substances; or
(b) for injection.

ASTEMIZOLE.

ASUNAPREVIR.

ATAMESTANE. (Appendix B, Appendix D)

ATAZANAVIR.
ATENOLOL.
ATIPAMEZOLE.
ATOMOXETINE.
ATORVASTATIN.
ATOSIBAN.
ATOVAQUONE.
ATRACURIUM BESYLYATE.
ATRAZINE.

ATROPA BELLADONNA (belladonna) except when included in Schedule 2.

ATROPA BELLADONNA (belladonna):
(a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
(b) for oral use:
(i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ATROPINE except when included in Schedule 2.

ATROPINE (excluding atropine methonitrate) for oral use:
(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ATROPINE METHONITRATE.

AURANOFIN.

AUROTHIOMALATE SODIUM.

AVILAMYCIN, except:
(a) in animal feed premixes containing 15 per cent or less of avilamycin activity; or
(b) in animal feeds containing 50 mg/kg or less of avilamycin activity.

AVIPTADIL.

AVOPARCIN.

AXITINIB.

AZACITIDINE.

AZACONAZOLE except in preparations containing 1 per cent or less of azaconazole.

AZACYCLONOL.

AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use except 'debitterised neem seed oil'.

AZADIRACHTA INDICA (neem) including its extracts and derivatives except:
(a) when included in Schedule 5;
(b) in preparations for human internal use;
(c) debitterised neem seed oil;
(d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a child-resistant closure and compliant with the requirements of the Requited Advisory Statements for Medicine Labels; or
(e) in preparations for dermal use containing 1 per cent or less of cold pressed neem seed oil.

5 AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5 per cent or less of total limonoids, for agricultural use.

AZAFENDIN.

6 AZAMETHIPHOS.

4 AZAPERONE.

4 AZAPROPAZONE.

4 AZARIBINE.

AZATADINE except when included in Schedule 3. (Appendix A)

3 AZATADINE in oral preparations. (Appendix A)

AZATHIOPRINE.

4 AZELAIC ACID except:
   (a) when included in Schedule 2; or
   (b) in preparations containing 1 percent or less of azelaic acid for non-human use.

AZELASTINE except when included in Schedule 2.

AZELASTINE
   (a) in preparations for nasal use; or
   (b) in topical eye preparations containing 0.05 per cent or less of azelastine.

AZINPHOS-ETHYL.

7 AZINPHOS-METHYL.

4 AZITHROMYCIN.

4 AZLOCILLIN.

AZOBENZENE.

7 AZOCYCLOTIN.

5 AZOXYSTROBIN.

4 AZTREONAM.

4 BACAMPICILLIN.

5 BACILLUS THURINGIENSIS DELTA ENDOTOXIN encapsulated in killed Pseudomonas fluorescens.

4 BACITRACIN.

4 BACLOFEN. (Appendix A)

Exempt BACTERIAL CULTURE MEDIA containing antibiotics.

4 BALSALAZIDE.

4 BAMBERMYCIN (flavophospholipol) except:
   (a) when included in Schedule 6; or
   (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

6 BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.

4 BAMBUTEROL.
BAMETHAN.

BARBITURATES except when separately specified in these Schedules. (Appendix A, Appendix D)

BARIUM SALTS except:
(a) when included in Schedule 5;
(b) barium sulfate; or
(c) in paints or tinters containing 5 per cent or less of barium calculated on the non-volatile content of the paint or tinter.

BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq. cm.

BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) except:
(a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or
(b) in hair dye preparations containing 1 per cent or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN;
If in eyes wash out immediately with water; and
WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height.

BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows.

BASIL OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c) in preparations containing 5 per cent or less of methyl chavicol.

BASILIXIMAB.

BAY OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF THE REACH OF CHILDREN; and
NOT TO BE TAKEN;
(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF THE REACH OF CHILDREN; and
NOT TO BE TAKEN; or
(e) in preparations containing 25 per cent or less of bay oil.

BAZEDOXIFENE.

BEAUVERIA BASSIANA except when included in Schedule 5.

BEAUVERIA BASSIANA in preparations containing 1 x 10⁸ Colony Forming Units (CFu)/mL or less of Beauvaria bassiana.

BECAPLERMIN.

BECLAMIDE.

BECLOMETHASONE except when included in Schedule 2.

BECLOMETHASONE in aqueous nasal sprays delivering 50 micrograms or less of beclomethasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

BELATACEPT.

BELIMUMAB.

BEMEGRIDE.

BENACTYZINE.

BENALAXYL.

BENAZEPRIL.

BENDAMUSTINE

BENDIOCARB except when included in Schedule 5 or 6.

BENDIOCARB:
(a) in wettable powders containing 80 per cent or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb;
(b) in wettable powders containing 20 per cent or less of bendiocarb and not less than 0.002 per cent of denatonium benzoate when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation;
(c) in insoluble granular preparations containing 5 per cent or less of bendiocarb; or
(d) when impregnated in plastic resin strip material containing 10 per cent or less of bendiocarb, except when included in Schedule 5.

BENDIOCARB in preparations containing 2 per cent or less of bendiocarb.

BENDROFLUAZIDE.

BENETHAMINE PENICILLIN.

BENOMYL except in paints containing 0.5 per cent of less of benomyl.

BENORYLATE.

BENOXAPROFEN.

BENPERIDOL.

BENQUINOX.

BENSERAZIDE.

BENSULIDE.
5 BENTAZONE.

6 BENZALKONIUM CHLORIDE except:
   (a) when included in Schedule 5; or
   (b) in preparations containing 5 per cent or less of benzalkonium chloride.

5 BENZALKONIUM CHLORIDE in preparations containing 10 per cent or less of benzalkonium chloride except in preparations containing 5 per cent or less of benzalkonium chloride.

4 BENZATHINE PENICILLIN.

7 BENZENE (excluding its derivatives) except:
   (a) preparations containing 15 mL/L or less of benzene; or
   (b) petrol containing 50 mL/L or less of benzene.

7 1,2-BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).

7 1,3-BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).

6 1,2-BENZENEDIOL.

4 BENZHEXOL.

9 BENZETHIDINE.

7 BENZIDINE-

7 BENZIDINE-BASED AZO DYES being:

2,2'-(1,1'-biphenyl)-4,4'-diylbis(azo)bis[N-(4-chlorophenyl)-3-oxobutanamide]
CAS No. 94249-03-3 Acid Red 85 (Acid Fast Red A)
1,3-Naphthalenedisulfonic acid, 7-hydroxy-6-[[4'-[[4-[[4-methylphenyl)sulfonyl]oxy]phenyl]azo][1,1'-biphenyl]-4-y[azo]-, disodium salt CAS No. 3567-65-5 Direct Black 38
2,7-Naphthalenedisulfonic acid, 4-amino-3-[[2,4-diaminophenyl]azo][1,1'-biphenyl]-4-y[azo]-5-hydroxy-6-(phenylazo)-, disodium salt CAS No. 1937-37-7 Direct Blue 2
2,7-Naphthalenedisulfonic acid, 5-amino-3-[[4'-[[7-amino-1-hydroxy-3-sulfo-2-naphthalenyl]azo][1,1'-biphenyl]-4-y[azo]-4-hydroxy-, trisodium salt CAS No. 2429-73-4 Direct Blue 6
2,7-Naphthalenedisulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[5-amino-4-hydroxy-, tetrasodium salt CAS No. 2602-46-2 Direct Brown 2
5-[4'-[(7-amino-1-hydroxy-3-sulfo-2-naphthalenyl)azo][1,1'-biphenyl]-4-y[azo]-2-hydroxy- benzoic acid disodium salt CAS No. 2429-82-5 Direct Brown 95 Cuprate(2-), [5-[4'-[[2,6-dihydroxy-3-[[2-hydroxy-5-sulfophenyl]azo]phenyl]azo][1,1'-biphenyl]-4-y[azo]-2-hydroxybenzoato(4-)], disodium salt CAS No. 16071-86-6 Direct Green 1
2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[[4'-[(4-hydroxyphenyl)azo][1,1'-biphenyl]-4-y[azo]-6-(phenylazo)-, disodium salt CAS No. 3626-28-6 Direct Green 6
2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-6-[[4'-[(4-hydroxyphenyl)azo][1,1'-biphenyl]-4-y[azo]-3-[[4-nitrophenyl]azo]-, disodium salt CAS No. 4335-09-5 Direct Red 28 (Congo Red)
1-Naphthalenesulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[4-amino-, disodium salt CAS No. 573-58-0 Direct Red 37
1,3-Naphthalenedisulfonic acid, 8-[4'-[(4-ethoxyphenyl)azo][1,1'-biphenyl]-4-y[azo]-7-hydroxy-, disodium salt CAS No. 3530-19-6 C.I Acid Black 29 CAS No. 12217-14-0

7 BENZIDINE-CONGENER (3,3'-disubstituted) AZO DYES.

4 BENZILONIUM.

4 BENZOCAINEx except:
(a) when included in Schedule 2;
(b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
(c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

2 BENZOCAINE in preparations for topical use other than eye drops:
(a) containing 10 per cent or less of total local anaesthetic substances, except in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
(b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

4 BENZODIAZEPINE derivatives except when separately specified in these Schedules. (Appendix A, Appendix D)

5 BENZOFENAP.

9 BENZOYLINDOLES except when separately specified in these Schedules.

5 BENZOYL PEROXIDE except:
(a) when included in Schedule 2 or 4; or
(b) in preparations containing 5 per cent or less of benzoyl peroxide.

4 BENZOYL PEROXIDE in preparations for human therapeutic use except:
(a) when included in Schedule 2; or
(b) in preparations for external use containing 5 per cent or less of benzoyl peroxide.

2 BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10 per cent or less of benzoyl peroxide except in preparations containing 5 per cent or less of benzoyl peroxide.

4 BENZPHETAMINE. (Appendix D)

4 BENZTHIAZIDE.

4 BENZTROPINE (benzatropine). (Appendix A)

4 BENZYMADINE except:
(a) when included in Schedule 2;
(b) in preparations for dermal use;
(c) in divided topical oral preparations containing 3 mg or less of benzydamine; or
(d) in undivided topical oral preparations containing 0.3 per cent or less of benzydamine in a primary pack containing not more than 50 mL.

2 BENZYMADINE in preparations for topical use, except:
(a) in preparations for dermal use;
(b) in divided topical oral preparations containing 3 mg or less of benzydamine; or
(c) in undivided topical oral preparations containing 0.3 per cent or less of benzydamine in a primary pack containing not more than 50 mL.

6 6-BENZYLADENINE except in preparations containing 2 per cent or less of 6-benzyladenine.
9 BENZYLPIPERAZINE *(BZP).
8 BENZYMORPHINE.
4 BENZYLPENICILLIN.
2 BEPHENIUM SALTS.
4 BEPRIDIL.
4 BERACTANT.
5 BERGAMOT OIL except:
(a) when steam distilled or rectified;
(b) in preparations for internal use;
(c) in preparations containing 0.4 per cent or less of bergamot oil;
(d) in soaps or bath or shower gels that are washed off the skin;
(e) in preparations other than medicines for human therapeutic use, when packed in containers labelled with the statement: Application to the skin may increase sensitivity to sunlight; or
(f) in medicines for human therapeutic use, when packed in containers and compliant with the requirements of the Required Advisory Statements for Medicine Labels.

BERYLLIUM.

BESIFLOXACINE.

BETACETYLMETHADOL.

BETACYFLUTHRIN except when included in Schedule 5 or 6.

BETACYFLUTHRIN in preparations containing 12.5 per cent or less of betacyfluthrin except when included in Schedule 5.

BETACYFLUTHRIN:
(a) in aqueous preparations containing 2.5 per cent or less of betacyfluthrin; or
(b) in solid preparations containing 8 per cent or less of betacyfluthrin in a plastic matrix.

BETACETYLMETHADOL.

BETACYFLUTHRIN.

BETA-CYPERMETHRIN.

BETAHISTINE.

BETA-HYDROXYFENTANYL.

BETA-HYDROXY-3-METHYLFENTANYL.

BETAMETHADOL.

BETAMETHASONE.

BETAPRODINE.

BETAXOLOL.

BETHANECHOL CHLORIDE.

BETHANIDINE.

BEVACIZUMAB.

BEVANTOLOL.

BEXAROTENE.

BEZAFIBRATE.

BEZITRAMIDE.

BHC (excluding lindane).

BICALUTAMIDE.

BIFENTHRIN except:
(a) when included in Schedule 6; or
(b) in preparations containing 0.5 per cent or less of bifenthrin.

BIFENTHRIN in preparations containing 25 per cent or less of bifenthrin except in preparations containing 0.5 per cent or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium, and sodium salts) except when included in Schedule 5 or 6.
BIFLUORIDES (including ammonium, potassium, and sodium salts) in preparations containing 3 per cent or less of total bifluorides except when included in Schedule 5.

BIFLUORIDES (including ammonium, potassium, and sodium salts) in preparations containing 0.3 per cent or less of total bifluorides.

BIFONAZOLE except:
(a) when included in Schedule 2;
(b) in preparations for dermal use containing 1 per cent or less of bifonazole for the treatment of the scalp; or
(a) in preparations for dermal use for the treatment of tinea pedis.

BIFONAZOLE in preparations for dermal use except:
(a) in preparations containing 1 percent or less of bifonazole for the treatment of the scalp; or
(b) in preparations for the treatment of tinea pedis.

BIMATOPROST.

BIOALLETHRIN except:
(a) when included in Schedule 5; or
(b) in preparations containing 1 per cent or less of bioallethrin.

BIOALLETHRIN in preparations containing 10 per cent or less of bioallethrin except in preparations containing 1 per cent or less of bioallethrin.

BIORESMETHRIN except in preparations containing 10 per cent or less of bioresmethrin.

BIPERIDEN.

BISMUTH COMPOUNDS for cosmetic use, except:
(a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5 per cent or less; or
(b) bismuth oxychloride.

BISMUTH COMPOUNDS for human therapeutic use, except bismuth formic iodide or bismuth subiodide in dusting powders containing 3 per cent or less of bismuth.

BISOPROLOL.

BISPYRIBAC except in preparations containing 10 per cent or less of bispyribac.

BITHIONOL for treatment of animals.

BITHIONOL for human therapeutic use.

BIVALIRUDIN.

BLEACHES - see CHLORINATING COMPOUNDS

BLEOMYCIN.

Exempt BLOOD (WHOLE) AND BLOOD COMPONENTS except when separately specified in these Schedules.

BOCEPREVIR.

BOLANDIOL. (Appendix B, Appendix D)

BOLASTERONE. (Appendix B, Appendix D)

BOLAZINE. (Appendix B, Appendix D)

BOLDENONE (dehydrotestosterone). (Appendix B, Appendix D)

BOLENOL. (Appendix B, Appendix D)

BOLMANTALATE. (Appendix B, Appendix D)

BORAGO OFFICINALIS (Borage) for therapeutic use except the fixed oil derived from the seeds of Borago officinalis.

BORAGA OFFICINALIS (Borage) for therapeutic use except the fixed oil derived from the seeds of Borago officinalis.

BORIC ACID (excluding its salts) and BORAX except:
(a) when included in Schedule 4;
(b) in preparations, other than insect baits, containing 1 per cent or less of boron; or
(c) in hand cleaning preparations.

BORON, including boric acid and borax, for human therapeutic use except:
(a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose;
(b) in preparations for dermal use containing 0.35 per cent or less of boron, which are not for paediatric or antifungal use; or
(c) when present as an excipient.

BORON TRIFLUORIDE except when included in Schedule 5 or 6.

BORON TRIFLUORIDE in preparations containing 1 per cent or less of boron trifluoride (BF₃) except when included in Schedule 5.

BORON TRIFLUORIDE in preparations containing 0.1 per cent or less of boron trifluoride (BF₃).

BORTEZOMIB.

BOSENTAN.

BOSUTINIB.

BOTULINUM TOXINS for human use except when separately specified in these Schedules.

BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.

BRENTUXIMAB VEDOTIN.

BRETYLIUM TOSYLATE.

BRIMONIDINE.

BRINZOLAMIDE.

BRODIFACOUM except when included in Schedule 6.

BRODIFACOUM in preparations containing 0.25 per cent or less of brodifacoum.

BROMADIOLONE except when included in Schedule 6.

BROMADIOLONE in preparations containing 0.25 per cent or less of bromadiolone.

BROMATE - see individual bromates.

BROMAZEPAM. (Appendix A, Appendix D)

BROMETHALIN except when included in Schedule 6.

BROMETHALIN in rodent baits containing 0.01 per cent or less of bromethalin.

BROMHEXINE.

BROMIDES, inorganic, for therapeutic use except when separately specified in these Schedules.

BROMINE (excluding its salts and derivatives).

BROMOCRIPTINE.

1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE *(Bromo-Dragonfly).

4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE *(BDMPEA).

BROMOFORM except when included in Schedule 4.

BROMOFORM for therapeutic use.

BROMOPHOS.

BROMOPHOS-ETHYL.

BROMOXYNIL.

BROMPHENIRAMINE except when included in Schedule 2 or 3. (Appendix A)
BROMPHENIRAMINE in oral preparations except:
(a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age. (Appendix A)

BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b) in a day-night pack containing brompheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper, except in preparations for the treatment of children under 2 years of age. (Appendix A)

BROMUCONAZOLE except when included in Schedule 5.

BROMUCONAZOLE in preparations containing 20 per cent or less of bromuconazole.

BROMVALETONE.

BROTIANIDE.

BRUCINE except in alcohol containing 0.02 per cent or less of brucine as a denaturant.

BRUGMANSIA spp.

BUCLIZINE except when included in Schedule 3. (Appendix A)

BUCLIZINE in oral preparations. (Appendix A)

BUCLOSAMIDE for therapeutic use.

BUDESONIDE except when included in Schedule 2.

BUDESONIDE in aqueous nasal sprays delivering 50 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

BUFEXAMAC except:
(a) in preparations for dermal use containing 5 per cent or less of bufexamac; or
(b) in suppositories.

BUFOTENINE.

BUMETANIDE.

BUNAMIDINE.

BUNIODYL SODIUM for therapeutic use.

BUPHENINE.

BUPIVACAINE except when included in Schedule 5.

BUPIVACAINE in aqueous gel preparations containing 0.5 per cent or less of bupivacaine, for the dermal spray-on treatment of wounds associated with 'mulesing' of sheep.

BUPRENORPHINE. (Appendix A, Clauses 91 to 94A, 123)

BUPROFEZIN except in preparations containing 40 per cent or less of buprofezin.

BUPROPION.

BUSERELIN.

BUSPIRONE.

BUSULPHAN.

BUTACAINE.
BUTACARB.

1,4-BUTANEDIOl (excluding its derivatives) in non-polymerised form in preparations for domestic use.

BUTHIDAZOLE.

BUTOBARBITONE. (Appendix A)

BUTOCONAZOLE except when included in Schedule 3.

BUTOCONAZOLE in preparations for vaginal use.

BUTORPHANOL.

BUTOXYCARBOXIM except when included in Schedule 5.

BUTOXYCARBOXIM in solid preparations containing 10 per cent or less of butoxycarboxim.

2-BUTOXYETHANOL and its ACETATES except in preparations containing 10 per cent or less of such substances.

2-BUTOXY-2'-THIOCYANO-DIETHYL ETHER.

BUTRACONAZOLE.

BUTRALIN.

BUTROXYDIM.

BUTYL AMINOBENZOATE except in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

BUTYLCHLORAL HYDRATE.

BUTYL NITRITE.

BUTYRIC ACID in preparations for use as insect lures.

CABAZITAXEL.

CABERGOLINE.

CACALIA spp. for therapeutic use.

CACODYLIC ACID except:
(a) when included in Schedule 6; or
(b) in animal feeds containing 75 g/tonne or less of arsenic.

CACODYLIC ACID:
(a) in animal feed premixes containing 4 per cent or less of arsenic; or
(b) in herbicide or defoliant preparations containing 10 per cent or less of cacodylic acid.

CADMIUM COMPOUNDS except:
(a) when included in Schedule 4; or
(b) in paints or tinters containing 0.1 per cent or less of cadmium calculated on the non-volatile content of the paint or tinter.

CADMIUM COMPOUNDS for human therapeutic use.

CADUSAfos except when included in Schedule 6.

CADUSAfos in aqueous preparations containing 20 per cent or less of microencapsulated cadusafos.

CAFFEINE - see entries for ASPIRIN, PARACETAMOL and SALICYLAMIDE.

CAJUPUT OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF THE REACH OF CHILDREN; and
NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure, and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

(e) in preparations containing 25 per cent or less of cajuput oil; or

(f) in oils containing 25 per cent or less of cajuput oil.

7 CALCIFEROL for use as a rodenticide except when included in Schedule 6.

6 CALCIFEROL in rodent baits containing 0.1 per cent or less of calciferol.

4 CALCIPOTRIOL.

4 CALCITONIN.

4 CALCITRIOL.

4 CALCIUM CARBIMIDE for therapeutic use.

4 CALCIUM HYDROXYLAPATITE in preparations for injection or implantation:
   (a) for tissue augmentation; or
   (b) for cosmetic use.

4 CALCIUM POLYSTYRENE SULPHONATE.

4 CALOTROPIS GIGANTEA.

4 CALOTROPIS PROCERA.

4 CALUSTERONE. (Appendix B, Appendix D)

6 CAMBENDAZOLE.

6 CAMPHOR except:
   (a) when included in Schedule 4 or 5;
   (b) when enclosed in an inhaler device which prevents ingestion of its contents;
   (c) in solid or semi-solid preparations containing 12.5 per cent or less of camphor;
   (d) in liquid preparations containing 2.5 per cent or less of camphor;
   (e) in essential oils when the camphor is present as a natural component of the oil:
      (i) in medicines for human therapeutic use, packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
      (ii) in medicines for human therapeutic use, packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
      (iii) in essential oils other than medicines for human therapeutic use, packed in containers having a nominal capacity 15 mL or less fitted with a restricted flow insert, and labelled with the warnings:
KEEP OUT OF THE REACH OF CHILDREN; and
NOT TO BE TAKEN;
(iv) in essential oils other than medicines for human therapeutic use, packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure, and labelled with the warnings: KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(f) in rosemary oil, sage oil (Spanish), or lavandin oil as such.

CAMPHOR as a natural component in essential oils containing 10 per cent or less of camphor except:

(a) in medicines for human therapeutic use, in essential oils packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;

(b) in preparations other than medicines for human therapeutic use, in essential oils packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings: KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(c) in rosemary oil, sage oil (Spanish), or lavandin oils; or

(d) in preparations containing 2.5 per cent or less of camphor.

CAMPHORATED OIL for therapeutic use.

CAMPHOTAMIDE.

CANAGLIFLOZIN.

CANAKINUMAB.

CANDESARTAN CILEXETIL.

CANDIDIDIN.

CANINE TICK ANTI-SERUM.

CANNABIDIOIL in preparations for therapeutic use containing 2 per cent or less of other cannabinoids found in cannabis.

CANNABIS except:

(a) when separately specified in these Schedules; or

(b) processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinol and products manufactured from such fibre.

CANTHARIDIN.

CAPECITABINE.

CAPREOMYCIN.

CAPTAFOL.

CAPTAN.

CAPTODIAME.

CAPTOPRIL.

CAPURIDE.

CARAMIPHEN.

CARBACHOL.

CARBADOX.

CARBAMAZEPINE except:

(a) when included in Schedule 5; or

(b) in other preparations containing 9 per cent or less of carbamide peroxide.
CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 18 per cent of carbamide peroxide except in preparations manufactured for and supplied solely by registered dental practitioners as part of their dental practice. (Clause 20)

CARBAMIDE PEROXIDE in preparations containing 18 per cent or less of carbamide peroxide except in preparations containing 9 per cent or less of carbamide peroxide.

CARBARYL except when included in Schedule 4 or 5.

CARBARYL:
(a) in preparations containing 10 per cent or less of carbaryl except when included in Schedule 4; or
(b) when impregnated into plastic resin material containing 20 per cent or less of carbaryl.

CARBARYL for human therapeutic use.

CARBAZOCHROME.

CARBENDAZIM except in paints, jointing compounds and sealants containing 0.1 per cent or less of carbendazim.

CARBENICILLIN.

CARBENOXOLONE for internal use.

CARBETAPENTANE except in preparations containing 0.5 per cent or less of carbetapentane.

CARBETOCIN.

CARBETAPENTANE.

CARBICARBOCROMEN.

CARBOLARSAN.

CARBON DISULFIDE.

CARBON TETRACHLORIDE except in chlorinated rubber based paint containing 1 per cent or less of carbon tetrachloride.

CARBONIC ANHYDRASE INHIBITORS - see individual entries.

CARBONYL SULFIDE when packed and labelled for use as a fumigant.

CARBOPHENOTHION.

CARBOPLATIN.

CARBOPROST.

CARBOSULFAN.

CARBOMAL.

CARBUTAMIDE.

CARBUTEROL.

CARFENENYLAN.

CARGLUMIC ACID (N-carbomoyl-L-glutamic acid).

CARINDACILLIN.

CARISOPRODOL.

CARMUSTINE.

CARNIDAZOLE.

CARPROFEN.

CARVEDILOL.
CASPOFUNGIN.

CASSIA OIL except:
(a) in food additives;
(b) in preparations for dermal use as a rubefacient containing 5 per cent or less of cassia oil; or
(c) in other preparations containing 2 per cent or less of cassia oil.

CASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic use except in wash-off preparations containing 1 per cent or less of castor oil, monomaleate.

CATALIN - see PIRFENOXONE SODIUM.

CATHINE. (Appendix D)

CATHINONE.

CATUMAXOMAB.

CEFACLOR.

CEFADroxil.

CEFALORIDINE.

CEFAMANDOLE.

CEFAPIRIN.

CEFAZOLIN.

CEFEPIME.

CEFETAMET.

CEFIXIME.

CEFODIZIME.

CEFONICID.

CEFOPERAZONE.

CEFOTAXIME.

CEFOTETAN.

CEFOTIAM.

CEFOTECIN for veterinary use.

CEFOXITIN.

CEFPIROME.

CEFPODOXIME.

CEFQUINOME.

CEFSULODIN.

CEFTAROLINE FOSAMIL.

CEFTAZIDIME.

CEFTIBUTEN.

CEFTIOFUR.

CEFTRIAXONE.

CEFUROXIME.

CELECOXIB.

CELIPROLOL.

CEPHAEILS ACUMINATA (ipecacuanha) except in preparations containing 0.2 per cent or less of emetine.
CEPHAELIS IPECACUANHA *except* in preparations containing 0.2 per cent or less of emetine.

CEPHALEXIN.

CEPHALONIUM.

CEPHALOTHIN.

CEPHRADINE.

Exempt CERAMICS.

CERIVASTATIN.

CERTOLIZUMAB PEGOL.

CERULETIDE.

CETIRIZINE *except*

(a) when included in Schedule 2; or

(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing not more than 5 days' supply; and

(ii) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

CETIRIZINE in preparations for oral use *except* in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(a) in a primary pack containing not more than 5 days' supply and;

(b) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

CETRORELIX.

CETUXIMAB.

Exempt CHEMISTRY SETS for toy and educational use, when complying with the requirements of Australian Standard AS 8124.4-2003 Safety of toys - Part 4: Experimental sets for chemistry and related activities.

CHENODEOXYCHOLIC ACID.

CHLOPHEDIANOL.

CHLORAL FORMAMIDE.

CHLORAL HYDRATE *except* in preparations for topical use containing 2 per cent or less of chloral hydrate. (Appendix A)

CHLORALOSE *except* when included in Schedule 6.

CHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide.

CHLORAMBUCIL.

CHLORAMPHENICOL *except* when included in Schedule 3.

CHLORAMPHENICOL for ophthalmic use only.

CHLORANDROSTENOLONE. (Appendix B, Appendix D)

CHLORAZANIL.

CHLORBUTOL in preparations for human use *except*:

(a) when included in Schedule 2; or

(b) in preparations containing 0.5 per cent or less of chlorbutol.

CHLORBUTOL for human use in topical preparations containing 5 per cent or less of chlorbutol, *except* in preparations containing 0.5 per cent or less of chlorbutol.

CHLORCYCLIZINE.

CHLORDANE.
CHLORDECONE.

CHLORDIAZEPoxide. (Appendix A, Appendix D)

CHLORDIMEFORM.

CHLORDIMETHYL.

CHLORDAPROXIDE in preparations containing 0.5 per cent or less of chlorfenapyr.

CHLORDAPROXIDE except when included in Schedules 5 or 6.

CHLORDAPROXIDE in preparations containing 36 per cent or less of chlorfenapyr except when included in Schedule 5.

CHLORFENETHOL.

CHLORFENSON.

CHLORFENVINPHOS.

CHLORFENVINPHOS.

CHLORHEXIDINE except:
(a) when included in Schedule 5 or 6;
(b) in preparations containing 1 per cent or less of chlorhexidine; or
(c) when in solid preparations.

CHLORHEXIDINE in preparations containing 7 per cent or less of chlorhexidine except:
(a) when included in Schedule 5;
(b) in preparations containing 1 per cent or less of chlorhexidine; or
(c) when in solid preparations.

CHLORHEXIDINE in preparations containing 3 per cent or less of chlorhexidine except:
(a) in preparations containing 1 per cent or less of chlorhexidine; or
(b) when in solid preparations.

CHLORINATING COMPOUNDS except:
(a) when included in Schedule 5;
(b) when separately specified in these Schedules;
(c) sodium hypochlorite preparations with a pH of less than 11.5;
(d) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:
WARNING - Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;
(e) in liquid preparations containing less than 2 per cent of available chlorine; or
(f) in other preparations containing 4 per cent or less of available chlorine.

CHLORINATING COMPOUNDS containing 20 per cent or less of available chlorine, except:
(a) when separately specified in these Schedules;
(b) sodium hypochlorite preparations with a pH of less than 11.5;
(c) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:
WARNING - Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;
(d) liquid preparations containing less than 2 per cent of available chlorine; or
(e) other preparations containing 4 per cent or less of available chlorine.

CHLORINE (excluding its salts and derivatives).

CHLORMEQUAT.
CHLORMERODRIN.

CHLORMETHIAZOLE. (Appendix A)

CHLORMEZANONE.

CHLORNIDINE.

CHLOROCRESOL except in preparations containing 3 per cent or less of chlorocresol.

CHLOROFORM except:
(a) when included in Schedule 2 or 4; or
(b) in preparations containing 10 per cent or less of chloroform.

CHLOROFORM in preparations for therapeutic use except:
(a) when included in Schedule 4; or
(b) in preparations containing 0.5 per cent or less of chloroform.

CHLOROFORM for use in anaesthesia.

alpha-CHLOROHYDRIN.

4-CHLOROMETHANDIENONE. (Appendix B, Appendix D)

CHLOROMETHIURON.

5-CHLORO-3-METHYL-4-NITROPYRAZOLE.

CHLOROPHACINONE.

(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL (uniconazole-p) except in preparations containing 5 per cent or less of (E)-(S)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol.

2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE.

CHLOROPICRIN except when included in Schedule 6.

CHLOROPICRIN in preparations containing 5 per cent or less of chloropicrin.

CHLOROQUINE.

CHLOROTHALONIL except in water-based paint containing 0.5 per cent or less of chlorothalonil.

CHLOROTHIAZIDE.

4-CHLORO-o-TOLUIDINE.

CHLOROTRIANISENE.

2-CHLORO-6-(TRICHLOROMETHYL)-PYRIDINE.

CHLOROXYDIENONE. (Appendix B, Appendix D)

CHLORPHENIRAMINE except when included in Schedule 2 or 3. (Appendix A)

CHLORPHENIRAMINE in oral preparations except:
(a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age. (Appendix A)

CHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b) in a day-night pack containing chlorpheniramine in the bed-time dose, where the day and night doses are in the same immediate container or immediate wrapper, except in preparations for the treatment of children under 2 years of age. (Appendix A)

CHLORPHENTERMINE. (Appendix A)

CHLORPROMAZINE. (Appendix A)

CHLORPROPAMIDE.
5 CHLORPROPHAM.
4 CHLORPROTHIXENE.

6 CHLORPYRIFOS except:
   (a) when included in Schedule 5; or
   (b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

5 CHLORPYRIFOS:
   (a) in aqueous preparations containing 20 per cent or less of microencapsulated chlorpyrifos;
   (b) in controlled release granular preparations containing 10 per cent or less of chlorpyrifos; or
   (c) in other preparations containing 5 per cent or less of chlorpyrifos except in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

6 CHLORPYRIFOS-METHYL.
4 CHLORQUINALDOL for human topical use.
5 CHLORSULFURON.
4 CHLORTETRACYCLINE except when included in Schedule 5.
5 CHLORTETRACYCLINE in preparations:
   (a) for topical application to animals for ocular use only; or
   (b) containing 40 per cent or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

5 CHLORTHAL-DIMETHYL.
4 CHLORTHALIDONE.
6 CHLORTHIAMID.
7 CHLORTHIOPHOS.
4 CHLORZOXAZONE.
4 CHOLERA VACCINE.
4 CHOLESTYRAMINE (colestyramine) for human therapeutic use.

CHORIONIC ANTIBODY - see HUMAN CHORIONIC GONADOTROPHIN ANTIBODY.
6 CHROMATES (including dichromates) except in paints or tinters containing 5 per cent or less of chromium as the ammonium, barium, calcium, iron, potassium, sodium, strontium or zinc chromate calculated on the non-volatile content of the paint or tinter.
6 CHROMIUM TRIOXIDE (excluding its salts and derivatives).
4 CHYMOPAPAIN for human therapeutic use.
4 CICLACILLIN.
4 CICLESONIDE.
4 CICLOPIROX except:
   (a) when included in Schedule 2 or 3; or
   (b) in preparations for the treatment of tinea pedis.
3 CICLOPIROX in preparations for dermal use and for application to the nails except:
   (a) when included in Schedule 2; or
   (b) in preparations for the treatment of tinea pedis.
2 CICLOPIROX:
(a) in preparations for dermal use containing 2 per cent or less of ciclopirox except in preparations for the treatment of tinea pedis; or
(b) in preparations for application to the nails containing 8 per cent or less of ciclopirox.

CIDOFOVIR.

CILASTATIN.

CILAZAPRIL.

CILOSTAZOL.

CIMETIDINE except when included in Schedule 3.

CIMETIDINE in a primary pack containing not more than 14 days supply.

CINACALCET.

CINCHOCAINE except when included in Schedule 2.

CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5 per cent or less of total local anaesthetic substances.

CINCHOPHEN and its derivatives for therapeutic use.

CINEOLE except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings: KEEP OUT OF THE REACH OF CHILDREN; and NOT TO BE TAKEN;
(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings: KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN;
(e) in preparations containing 25 per cent or less of cineole;
(f) in oils containing 25 per cent or less of cineole; or
(g) in rosemary oil or camphor oil (white).

CINMETHYLIN.

CINNAMEDRINE.

CINNAMON BARK OIL except:
(a) in food additives; or
(b) in preparations containing 2 per cent or less of cinnamon bark oil.

CINNAMON LEAF OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF THE REACH OF CHILDREN; and
NOT TO BE TAKEN;
(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure, and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
(e) in preparations containing 25 per cent or less of cinnamon leaf oil.

CINOXACIN.
CIPROFLOXACIN.
CISAPRIDE.
CISATRACURIUM BESYLATE.
CISPATIN.
CITALOPRAM.
CJC-1295 (CAS No. 863288-34-0)
CLADRIBINE.
CLANOBUTIN.
CLARITHROMYCIN.
CLAVULANIC ACID.
CLEMASTINE except when included in Schedule 3.
CLEMASTINE in preparations for oral use.
CLEMIZOLE.
CLENBUTEROL.
CLETHODIM.
CLEVIDIPINE.
CLIDINIUM BROMIDE.

CLIMBAZOLE except:
(a) when included in Schedule 5; or
(b) in preparations containing 2 per cent or less of climbazole.

CLIMBAZOLE in preparations containing 40 per cent or less of climbazole except in preparations containing 2 per cent or less of climbazole.
CLINDAMYCIN.

CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human internal use except when being used solely for experimental purposes in humans and such use:
(a) is in accordance with an approval granted under paragraph 19(1)(b), and the requirements of subsection 19(4A), of the Therapeutic Goods Act 1989 (as amended from time to time) - otherwise known as the Clinical Trial Exemption (CTX) scheme; or
(b) is in accordance with the requirements of subsection 18(1) of the Therapeutic Goods Act 1989 and Regulation 12(1A) of the Therapeutic Goods Regulations 1990 (as amended from time to time) - otherwise known as the Clinical Trial Notification (CTN) scheme.

CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human topical use except when separately specified in this Schedule.
CLOBAZAM. (Appendix D)

CLOBETASOL.

CLOBETASONE (clobetasone-17-butyrate) except when included in Schedule 3.

CLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of clobetasone in packs containing 30 g or less of the preparation.

CLOCORTOLON.

CLODINAFOP-PROPARGYL.

CLODRONIC ACID (including sodium clodronate).

CLOFARABINE.

CLOFAZIMINE.

CLOFENAMIDE.

CLOFENTEZINE.

CLOFIBRATE.

CLOMAZONE.

CLOMIPHENE. (Clauses 37, 52, 60)

CLOMIPRAMINE. (Appendix A)

CLONITAZENE.

CLONAZEPAM (Appendix A, Appendix D)

CLONIDINE. (Appendix A)

CLOPAMIDE.

CLOPIDOGREL.

CLOPROSTENOL.

CLOPYRALID.

CLOQUINTOCET-MEXYL.

CLORAZEPATE. (Appendix A, Appendix D)

CLOREXOLONE.

CLORPRENALINE.

CLORSULON.

CLOSTEBOL (4-chlorotestosterone). (Appendix B, Appendix D)

CLOTHIANIDIN except when included in Schedule 5.

CLOTHIANIDIN in preparations containing 20 per cent or less of less of clothianidin.

CLOTRIMAZOLE except:

(a) when included in Schedule 2, 3 or 6; or
(b) in preparations for dermal use for the treatment of tinea pedis.

CLOTRIMAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.

CLOTRIMAZOLE in preparations for vaginal use.

CLOTRIMAZOLE for external treatment of animals.

CLOVE OIL except:

(a) when included in Schedule 5;
(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant
with the requirements of the Required Advisory Statements for Medicine Labels;

(c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF THE REACH OF CHILDREN; and
NOT TO BE TAKEN;

(e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure, and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

(f) in preparations containing 25 per cent or less of clove oil.

CLOVE OIL for topical use in the mouth In a pack containing 5 mL or less of clove oil except in preparations containing 25 per cent or less of clove oil.

CLOXACILLIN.

CLOZAPINE.

COAL TAR for cosmetic use other than in therapeutic goods.

COBALT for human therapeutic use except as dicobalt edetate in preparations for the treatment of cyanide poisoning.

Cobicistat.

COCAINE.

COCA LEAF.

N-COCO-1,3-DIAMINOPROPANE.

CODEINE except when included in Schedule 2, 3 or 4. (Appendix A)

CODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing 30 mg or less of codeine per dosage unit;
(Appendix A) or
(b) in undivided preparations containing 1 per cent or less of codeine, (Appendix A) except when included in Schedule 2 or 3.

CODEINE when:

(a) not combined with any other opiate substance;
(b) compounded with one or more other therapeutically active substances, of which not more than one is an analgesic substance:
(i) in divided preparations containing 12 mg or less of codeine per dosage unit; or
(ii) in undivided preparations containing 0.25 per cent or less of codeine;
(c) labelled with a recommended daily dose not exceeding 100 mg of codeine; and
(d) in packs containing not more than 5 days of supply at the maximum dose recommended on the label, except when included in Schedule 2.

CODEINE in preparations for the treatment of coughs and colds when:

(a) not combined with any other opiate substance;
(b) compounded with one or more other therapeutically active substances, of which at least one is phenylephrine and not more than one is an analgesic substance:

(i) in divided preparations containing 10 mg or less of codeine per dosage unit; or
(ii) in undivided preparations containing 0.25 per cent of less of codeine;

(c) labelled with a recommended daily dose not exceeding 60 mg of codeine; and

(d) in packs containing not more than 6 days of supply at the maximum dose recommended on the label.

8 CODEINE-N-OXIDE.
4 CO-DERGOCRINE.
9 CODOXIME.
4 COLASPASE.
4 COLCHICINE.
4 COLCHICUM AUTUMNALE.
7 COLECALCIFEROL for use as a rodenticide.
4 COLESTIPOIL.
4 COLFOSCERIL PALMITATE for human therapeutic use.
4 COLISTIN.
4 COLLAGEN in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.
4 COLLAGENASE CLOSTRIDIUM HISTOLYTICUM.
8 CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).
7 CONIUM MACULATUM (coniine) for therapeutic use.
4 CONVALLARIA KEISKI.
4 CONVALLARIA MAJALIS.
6 COPPER ACETATE except:

(a) when included in Schedule 5; or

(b) in preparations containing 5 per cent or less of copper acetate.
5 COPPER ACETATE in preparations containing 20 per cent or less of copper acetate except when in preparations containing 5 per cent or less of copper acetate.

Exempt COPPER COMPOUNDS in paints.
6 COPPER COMPOUNDS except:

(a) when separately specified in these Schedules;

(b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose;

(c) pigments where the solubility of the copper compound(s) in water is 1 gram per litre or less;

(d) in feed additives containing 1 per cent or less of copper; or

(e) in other preparations containing 5 per cent or less of copper compounds.
5 COPPER COMPOUNDS in animal feed additives containing 5 per cent or less of copper except in preparations containing 1 per cent or less of copper.
4 COPPER COMPOUNDS for human use except:

(a) when separately specified in these Schedules;

(b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or
(c) in other preparations containing 5 per cent or less of copper compound.

6 COPPER HYDROXIDE except:
   (a) when included in Schedule 5; or
   (b) in preparations containing 12.5 per cent or less of copper hydroxide.

5 COPPER HYDROXIDE in preparations containing 50 per cent or less of copper hydroxide except in preparations containing 12.5 per cent or less of copper hydroxide.

6 COPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep.

6 COPPER OXIDES except:
   (a) when included in Schedule 5;
   (b) in preparations containing 12.5 per cent or less of copper hydroxide.
   (c) in marine paints; or
   (d) in other preparations containing 5 per cent or less of copper oxides.

5 COPPER OXIDES in preparations containing 25 per cent or less of copper oxides except:
   (a) in preparations for internal use;
   (b) in marine paints; or
   (c) in other preparations containing 5 per cent or less of copper oxides.

6 COPPER OXYCHLORIDE except:
   (a) when included in Schedule 5; or
   (b) in preparations containing 12.5 per cent or less of copper oxychloride.

5 COPPER OXYCHLORIDE in preparations containing 50 per cent or less of copper oxychloride except in preparations containing 12.5 per cent or less of copper oxychloride.

6 COPPER SULFATE except:
   (a) when included in Schedule 5; or
   (b) in preparations containing 12.5 per cent or less of copper sulfate.

5 COPPER SULFATE in preparations containing 15 per cent or less of copper sulfate except:
   (a) in preparations for internal use; or
   (b) in other preparations containing 5 per cent or less of copper sulfate.

4 CORIFOLLITROPIN ALFA.

4 CORONILLA spp.

4 CORTICOSTERONE.

4 CORTICOTROPHIN.

4 CORTISONE.

7 COTARNINE for therapeutic use.

4 CO-TRIMOXAZOLE.

7 COUMAPHOS except when included in Schedule 6.

6 COUMAPHOS:
   (a) in slow-release plastic matrix ear tags for livestock use containing 6 g or less of coumaphos; or
   (b) in other preparations containing 5 per cent or less of coumaphos.

4 COUMARIN for therapeutic use (excluding when present as an excipient).
COUMATETRALYL except when included in Schedule 5 or 6.
COUMATETRALYL in rodenticides containing 1 per cent or less of coumatetralyl except when included in Schedule 5.
COUMATETRALYL in rodenticides containing 0.05 per cent or less of coumatetralyl.
4-CPA.
CREOSOTE derived from beechwood.
CREOSOTE derived from coal.
CREOSOTE derived from wood other than beechwood except:
(a) when included in Schedule 2;
(b) in preparations for human therapeutic use containing 10 per cent or less of creosote (derived from wood other than beechwood); or
(c) in other preparations containing 3 per cent or less of phenols and homologues of phenol boiling below 220°C.
CREOSOTE derived from wood other than beechwood for human therapeutic use, except in preparations containing 10 per cent or less of creosote derived from wood other than beechwood.
CRIZOTINIB.
CROFELEMER.
CROTALARIA spp. for therapeutic use.
CROTON TIGLIUM for therapeutic use.
CROTOXYPHOS.
CRUFOMATE.
CRYSTAL VIOLET for human use except when used as a dermal marker.
CUPRIMYXIN.
CURARE.
CURING AGENTS for resins - see ANHYDRIDES, ORGANIC ACID also AMINES.
CYANAMIDE.
CYANATRYN.
CYANAZINE.
CYANIDES, metallic except:
(a) ferricyanides;
(b) ferrocyanides; or
(c) when separately specified in these Schedules. (Clause 20)
CYANOACRYLATE ESTERS in contact adhesives except:
(a) when labelled with the warning:
KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water; or
(b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:
(i) labelled with the approved name or trade name of the poison, the quantity and the warning:
Can cause eye injury. Instantly bonds skin. and
(ii) enclosed in a primary pack labelled with the warning:
KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water.

7 CYANOGEN.
9 4-CYANO-2-DIMETHYLAMINO-4',4''-DIPHENYL BUTANE.
8 4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A).
5 CYANTRANILIPROLE.
5 CYANURIC ACID (excluding its salts and derivatives).
5 CYAZOFAMID.
4 CYCLANDELATE.
6 CYCLANILIDE.
4 CYCLIZINE except when included in Schedule 3. (Appendix A)
3 CYCLIZINE in divided preparations for oral use in primary packs containing 6 dosage units or less. (Appendix A)
8 CYCLOBARBITONE. (Appendix A)
4 CYCLOBENZAPRINE.
4 CYCLOFENIL. (Clauses 37,52,60)
5 CYCLOHEXANONE PEROXIDE.
4 CYCLOHEXIMIDE.
6 N-CYCLOHEXYLDIAZENIUM DIOXY-POTASSIUM.
9 CYCLOHEXYLPHENOLS except:
   a. when separately specified in these Schedules, or
   b. in preparations containing 0.5 per cent or less.
4 CYCLOPENTHAZIDE.
4 CYCLOPENTOLATE.
4 CYCLOPHOSPHAMIDE.
4 CYCLOPROPANE for therapeutic use.
5 CYCLOPROTHRIN except in preparations containing 10 per cent or less of cycloprothrin.
4 CYCLOSERINE. (Appendix A)
4 CYCLOSPORIN.
4 CYCLOTHIAZIDE.
5 CYCLOXYDIM.
4 CYCRIMINE.
5 CYFLUFENAMID.
6 CYFLUTHRIN except:
   (a) when included in Schedule 5; or
   (b) in pressurised spray packs containing 1 per cent or less of cyfluthrin.
5 CYFLUTHRIN:
   (a) in wettable powders containing 10 per cent or less of cyfluthrin;
   (b) in emulsifiable concentrates containing 2 per cent or less of cyfluthrin; or
   (c) in emulsions containing 5 per cent or less OF CYfluthrin.
5 CYHALOFOB-BUTYL.
7 CYHALOTHIRIN (aRS,IR,cis,Z):(aRS,IS,cis,Z)=50:50.
7 CYHEXatln.
4 CYMARIN.
5 CYMIAZOLE.
7 CYNOGLOSSUM spp. for therapeutic use.
6 CYOMETRINIL.
6 CYPERMETHRIN except when included in Schedule 5.
5 CYPERMETHRIN in preparations containing 10 per cent or less of cypermethrin.
6 CYPHENOTHIRIN except when included in Schedule 5.
5 CYPHENOTHIRIN in preparations containing 10 per cent or less of cyphenothrin.
5 CYPROCONAZOLE except in preparations containing 10 per cent or less of cyproconazole.
5 CYPRODINIL.
4 CYPROHEPTADINE except when included in Schedule 3. (Appendix A)
3 CYPROHEPTADINE in oral preparations. (Appendix A)
4 CYPHEROTHRIN.
5 CYPROHEPTADINE except when included in Schedule 5.
5 CYPROHEPTADINE in preparations containing 10 per cent or less of cyphenothrin.
5 CYPROHEPTADINE except when included in Schedule 3. (Appendix A)
3 CYPROHEPTADINE in oral preparations. (Appendix A)
4 CYPHEROTHRIN.
6 CYSTEAMINE for cosmetic use except:
(a) when included in Schedule 5; or
(b) in preparations containing 1 per cent or less of cysteamine.
5 CYSTEAMINE in cosmetic preparations containing 6 per cent or less of cysteamine except in preparations containing 1 per cent or less of cysteamine.
4 CYSTEAMINE for human therapeutic use. (Appendix A)
4 CYSTEAMINE.
6 CYTHEROATE except when included in Schedule 5.
5 CYTHEROATE for the treatment of animals:
(a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child-resistant closure; or
(b) in undivided preparations containing 5 per cent or less of cythioate.
6 2,4-D except when included in Schedule 5.
5 2,4-D in preparations containing 20 per cent or less of 2,4-D.
4 DABIGATRAN.
4 DABRAFENIB MESILATE.
4 DACARBazine.
4 DACLatasvir.
4 DACLizumab.
4 DACTINOMYCIN.
4 Dalfopristin.
4 DALTEPARIN (including dalteparin sodium).
5 DAMINoZIDE.
4 DANAPAROID (including danaparoid sodium).
4 DANAZOL.
4 DANTHRON for human use.
4 DANTROLENE. (Appendix A)
4 Dapoxetine.
4 Dapagliflozin.
4 Dapsone.
DAPTOMYCIN.
DARBEPOETIN. (Appendix D)
DARIFENACIN.
DARUNAVIR.
DASABUVIR.
DASATINIB.
DATURA spp. Except:
(a) when included in Schedule 2; or
(b) when separately specified in this Schedule.

DATURA spp. For oral use:
(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; except when separately specified in these Schedules.

DATURA STRAMONIUM (stramonium) except:
(a) when included in Schedule 2; or
(b) when separately specified in this Schedule.

DATURA STRAMONIUM (stramonium) for oral use when:
(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, except for smoking or burning.

DATURA TATULA (stramonium) except:
(a) when included in Schedule 2; or
(b) for smoking or burning.

DATURA TATULA (stramonium) for oral use:
(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, except for smoking or burning.

DAUNORUBICIN.
DAZOMET.
2,4-DB.
DEANOL for therapeutic use.
DEBRISOQUINE.
DECAMETHONIUM.
DECOQUINATE.
DEFERASIROX.
DEFERIPRONE.

DEFLAZACORT.

DEGARELIX.

DEHYDROCHLOROMETHYLTESTOSTERONE. (Appendix B, Appendix D)

DEHYDROCORTICOSTERONE.

DELAVIDRINE (includes delavirdine mesylate).

DELPHINIUM STAPHISAGRIA except in preparations containing 0.2 per cent or less of delphinium staphisagria.

DELTAMETHRIN except:
(a) when included in Schedules 5 or 6; or
(b) in factory prepared mosquito nets containing 1 per cent or less of deltamethrin; or
(c) in preparations containing 0.1 per cent or less of deltamethrin.

DELTAMETHRIN:
(a) in aqueous preparations containing 25 per cent or less of deltamethrin, when no organic solvent, other than 10 per cent or less of a glycol, is present;
(b) in wettable granular preparations containing 25 per cent or less of deltamethrin;
(c) in water-dispersible tablets each containing 500 mg or less of deltamethrin;
(d) in emulsifiable concentrates containing 11 per cent or less of deltamethrin in a solvent containing 40 per cent or less of acetophenone and 45 per cent or less of liquid hydrocarbons; or
(e) in other preparations containing 3 per cent or less of deltamethrin, except:
(a) when included in Schedule 5;
(b) in factory prepared mosquito nets containing 1 per cent or less of deltamethrin; or
(c) in preparations containing 0.1 per cent or less of deltamethrin.

DELTAMETHRIN:
(a) when impregnated in plastic resin strip material containing 4 per cent or less of deltamethrin;
(b) in aqueous preparations containing 5 per cent or less of deltamethrin when no organic solvent other than a glycol is present;
(c) in wettable granular preparations containing 25 per cent or less of deltamethrin when packed in child-resistant packaging each containing 3 grams or less of the formulation;
(d) in water-dispersible tablets each containing 500 mg or less of deltamethrin in child-resistant packaging; or
(e) in other preparations containing 0.5 per cent or less of deltamethrin, except:
(a) in factory prepared mosquito nets containing 1 per cent or less deltamethrin; or
(b) in preparations containing 0.1 per cent or less of deltamethrin.

DELBREXINE except when included Schedule 5.

DELBREXINE in oral preparations for the treatment of animals.

DEMECARIUM.

DEMECLOCYCLINE.
DEMETON-S-METHYL.
DENOSUMAB.
DEOXYCORTONE.
DEOXYRIBONUCLEASE except:
(a) when separately specified in this Schedule; or
(b) for external use.
DERACOXIB.
DERQUANTEL.
2,4-DES.
DESFERRIOXAMINE.
DESLANOSIDE.
DESLORATADINE except when included in Schedule 2.
DESLORATADINE in preparations for oral use.
DESLORELIN.
DESMOPRESSIN. (D.D.A.V.P.)
DESOGESTREL.
DESOMORPHINE.
DESONIDE.
DESOXYMETHASONE.
DESVENLAFAXINE.
DETOMIDINE.
DEXAMETHASONE.
DEXAMPHETAMINE. (Clauses 84,90,98,101,122, Appendix A)
DEXCHLORPHENIRAMINE except when included in Schedule 2 or 3. (Appendix A)
DEXCHLORPHENIRAMINE in oral preparations except:
(a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age. (Appendix A)
DEXCHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b) in a day-night pack containing dextchlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper, except in preparations for the treatment of children under 2 years of age. (Appendix A)
DEXFENFLURAMINE.
DEXMEDETOMIDINE.

Exempt
DEXTRANS, GELATIN - SUCCINYLATED & ETHERIFIED STARCHES used as plasma substitutes/ blood volume expanders.

DEXTROMETHORPHAN (excluding its stereoisomers) except when included in Schedule 2.
DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose
of 120 mg or less of dextromethorphan.

DEXTROMORAMIDE. (Appendix A, Clause 123)

DEXTROPROPOXYPHENE except when included in Schedule 4. (Appendix A)

DEXTROPROPOXYPHENE:
(a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or
(b) liquid preparations containing 2.5 per cent or less of dextropropoxyphene.
(Appendix A, Appendix D)

DEXTROPAMPHAN (excluding its stereoisomers).

DIAFENTHIURON.

DIALIFOS.

N,N-Diallyldichloroacetamide except in preparations containing 10 per cent or less of N,N-diallyldichloroacetamide.

4,4-Diaminodiphenylmethane (Methylene dianiline).

4,4-Diaminophenoxyethanol in hair dye preparations except in preparations containing 4 per cent or less of 2,4- diaminophenoxyethanol when the immediate container and primary pack are labelled with the following:

KEEP OUT OF REACH OF CHILDREN

WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height.

DIAMPROMIDE.

DIAMTHAZOLE.

DIAVERIDINE.

DIAZEPAM. (Appendix A, Appendix D)

DIAZINON except when included in Schedule 5.

DIAZINON in dust preparations containing 2 per cent or less of diazinon.

DIAZOXIDE.

DIBENZEPIN.

DIBENZOPYRANS except when separately specified in these Schedules.

DIBOTERMIN.

1,2-Dibromo-3-chloropropene.

Dibromopropamidine for therapeutic use except when included in Schedule 2.

Dibromopropamidine for ophthalmic use.

Dibutylphthalate for cosmetic use.

Dicamba (including its salts and derivatives) except when included in Schedule 5.

Dicamba (including its salts and derivatives) in preparations containing 20 per cent or less of dicamba.

Dichlobenil.

Dichlofenthion.

Dichlofluanid.

Dichlone.

Dichloralphenazone.
orthodichlorobenzene.
paradichlorobenzene.
3,4-dichloro-N-((1-(dimethylamino)cyclohexyl)methyl)benzamide

dichloroethyl ether.
dichloroisocyanuric acid except:
(a) when included in Schedule 5;
(b) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:
WARNING - Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;
(c) in liquid preparations containing less than 2 per cent of available chlorine; or
(d) in other preparations containing 4 per cent or less of available chlorine.
dichloroisocyanuric acid containing 40 per cent or less of available chlorine, except in:
(a) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:
WARNING - Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;
(b) liquid preparations containing less than 2 per cent of available chlorine; or
(c) other preparations containing 4 per cent or less of available chlorine.
dichloromethane (methylene chloride) except:
(a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10 per cent or less of dichloromethane;
(b) in other preparations in pressurised spray packs; or
(c) in paints and tinters containing 5 per cent or less of dichloromethane.
4,5-dichloro-2-n-octyl-3(2H)-isothiazolone.
dichlorophen except:
(a) when included in Schedule 4 or 5; or
(b) in fabrics other than when:
(i) for human therapeutic use; or
(ii) as part of a registered pesticidal product.
dichlorophen for the treatment of animals.
dichlorophen for human therapeutic use.
1,2-dichloropropane.
1,3-dichloropropane.
dichlorphenamide.
2,4-dichloroprop (including the R and S enantiomers).
dichlorvos except when included in Schedule 5 or 6.
dichlorvos in preparations containing 50 per cent or less of dichlorvos except when included in Schedule 5.
dichlorvos:
(a) when impregnated in plastic resin strip material containing 20 per cent or less dichlorvos;
(b) in sustained release resin pellets containing 20 per cent or less of dichlorvos for the treatment of animals; or
(c) in pressurised spray packs containing 10 grams or less of dichlorvos.
dichromates - see chromates
DICLOBUTRAZOL.

DICLOFENAC except:
(a) when included in Schedule 2 or 3; or
(b) in preparations for dermal use unless:
(i) for the treatment of solar keratosis; or
(ii) B1469 containing more than 4 per cent of diclofenac.

DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units except when included in Schedule 2.

DICLOFENAC when:
(a) in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac;
(b) in preparations for dermal use containing 4 per cent or less of diclofenac except in preparations for dermal use containing 1 per cent or less of diclofenac or for the treatment of solar keratosis; or
(c) in transdermal preparations for topical use containing 140 mg or less of diclofenac.

DICLOFOP-METHYL.

DICLORAN.

DICLOXACILLIN.

DICOFOL.

DICOPHANE (DDT) for therapeutic use.

DICROTOPHOS.

DICYCLANIL except in preparations containing 5 per cent or less of dicyclanil.

DICYCLOMINE.

DIDANOSINE.

DIDECYLDIMETHYLAMMONIUM SALTS except in preparations containing 1 per cent or less of didecyldimethylammonium salts labelled with the statement: Avoid contact with eyes.

DIELDRIN.

DIENESTROL.

DIENOGEST.

DIETHANOLAMINE (excluding its salts and derivatives) except:
(a) when included in Schedule 5; or
(b) in preparations containing 5 per cent or less of diethanolamine.

DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of diethanolamine except in preparations containing 5 per cent or less of diethanolamine.

DIETHAZINE.

DIETHYLCARBAMAZINE for human therapeutic use.

DIETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25 per cent or less of diethylene glycol.

DIETHYLENE GLYCOL (excluding its salts and derivatives) except:
(a) when included in Schedule 5;
(b) in paints or paint tinters;
(c) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene
glycol; or
(d) in other preparations containing 2.5 per cent or less of diethylene glycol.

5 DIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations
    containing not less than 10mg/kg of denatonium benzoate as a bittering agent
    **except:**
    (a) in paints or paint tinters;
    (b) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene
        glycol; or
    (c) in other preparations containing 2.5 per cent or less of diethylene glycol.

6 DIETHYLENE GLYCOL MONOBUTYL ETHER **except** in preparations containing 10
    per cent or less of diethylene glycol monobutyl ether.

7 DIETHYLENE GLYCOL MONOBUTYL ETHER for cosmetic use.

6 DIETHYLENE GLYCOL MONOMETHYL ETHER.

7 DIETHYLENE GLYCOL MONOMETHYL ETHER for cosmetic use.

7 DIETHYLHEXYL PHthalate for cosmetic use.

7 DIETHYLPHthalate in sunscreens, personal insect repellents or body lotion
    preparations for human use **except** in preparations containing 0.5 per cent or less of
    diethylphthalate.

4 DIETHYLPROPION. (Appendix A, Appendix D)

9 DIETHYLTHIAMBUTENE.

9 N,N-**DIETHYLTRYPTAMINE *(DET).*

5 DIETHYLTOluAMIDE (DEET) **except:**
    (a) in medicines for human therapeutic use containing 20 per cent or less of
        diethyltoluamide, when compliant with the requirements of the Required Advisory
        Statements for Medicine Labels;
    (b) in preparations for human use, other than medicines, containing 20 per cent or
        less of diethyltoluamide, when labelled with the warning statement:
        WARNING: May be dangerous, particularly to children, if you use large amounts on
        the skin, clothes or bedding or on large areas of the body, especially if you keep
        using it for a long time; or
    (c) in preparations other than for human use containing 20 per cent or less of
        diethyltoluamide.

7 DIFENACOUM **except** when included in Schedule 6.

6 DIFENACOUM in preparations containing 0.25 per cent or less of difenacoum.

5 DIFENOCONAZOLE.

8 DIFENOXIN **except** when included in Schedule 4. (Appendix A)

4 DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin
    and a quantity of atropine sulfate equivalent to at least 5 per cent of the dose of
    difenoxin. (Appendix A)

6 DIFENZOQUAT.

7 DIFETHIALONE **except** when included in Schedule 6.

6 DIFETHIALONE in rodent baits containing 0.0025 per cent or less of difethialone.

4 DIFLORASONE.

4 DIFLOXACIN.

5 DIFLUBENZURON.

4 DIFLUCORTOLONE.

4 DIFLUNISAL.

4 DIGITALIS LANATA.
DIGITALIS PURPUREA.
DIGITOXIN.
DIGOXIN.
DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab).
DIHYDRAZINE.

DIHYDROCODINE except when included in Schedule 2, 3 or 4. (Appendix A)

DIHYDROCODINE when compounded with one or more other therapeutically active substances:
(a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5 per cent of dihydrocodeine, except when included in Schedule 2 or 3. (Appendix A)

DIHYDROCODINE when compounded with one or more other therapeutically active substances:
(a) in divided preparations containing 10 mg or less per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or
(b) in undivided preparations containing 0.25 per cent or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine, except when included in Schedule 2. (Appendix A)

DIHYDROCODINE when compounded with aspirin and no other therapeutically active substance in divided preparations:
(a) containing 5 mg or less of dihydrocodeine per dosage unit;
(b) packed in blister or strip packaging or in a container with a child resistant closure;
(c) enclosed in primary packs containing 25 or less dosage units; and
(d) labelled with a recommended dose not exceeding 10 mg of dihydrocodeine. (Appendix A)

DIHYDROERGOTOXINE.
DIHYDROLONE. (Appendix B, Appendix D)
DIHYDROMORPHINE.
DIHYDROSTREPTOMYCIN.
DIHYDROTACHYSTEROL.

5,6-DIHYDROXYINDOLINE.

5,6-DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2 per cent of 5,6-dihydroxyindoline.

DI-IODOHYDROXYQUINOLINE (iodoquinol) except:
(a) when included in Schedule 3; or
(b) for human internal use.

DI-IODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.
DIISOBUTYL PHTHALATE for cosmetic use.
DIISOPROPYLAMINE DICHLOROACETATE.
DILTIAZEM.
DIMEFOX.

DIMENHYDRINATE except when included in Schedule 2 or 3. (Appendix A)

DIMENHYDRINATE in oral preparations except when included in Schedule 2. (Appendix A)
DIMENHYDRINATE in primary packs of 10 doses or less, for the prevention or treatment of motion sickness, except in preparations for the treatment of children under two years of age. (Appendix A)

DIMENOXADOL.

DIMEPHEPTANOL.

DIMERCAPROL.

DIMETHANDROSTANOLONE. (Appendix B, Appendix D)

DIMETHAZINE. (Appendix D)

DIMETHENAMID-P.

DIMETHICODIETHYLBENZALMALONATE except when included in preparations containing 10 per cent or less of dimethicodiethylbenzalmalonate.

DIMETHINDENE except when included in Schedule 3. (Appendix A)

DIMETHINDENE in oral preparations. (Appendix A)

DIMETHIPIN.

DIMETHIRIMOL.

DIMETHOATE.

DIMETHOMORPH except in preparations containing 10 per cent or less of dimethomorph.

DIMETHOTHIAZINE.

DIMETHOXANATE.

2,5-DIMETHOXYAMPHETAMINE *(DMA).

2,5-DIMETHOXY-4-BROMOAMPHETAMINE *(DOB).

2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE *(DOET).

2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE *(2C-T-2).

2,5-DIMETHOXY-4-IODOPHENETHYLAMINE *(2C-I).

2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE *(2C-T-7).

4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL except:
   (a) in leave-on cosmetic preparations containing 0.1 per cent of less of 4,4-dimethyl-1-cyclohexene-1-propanal;
   (b) in rinse-off cosmetic preparations containing 0.5 per cent of less of 4,4-dimethyl-1-cyclohexene-1-propanal; or
   (c) in other preparations containing 1 per cent of less of 4,4-dimethyl-1-cyclohexene-1-propanal.

3,7-DIMETHYL-2-6,-OCTADIENAL and its isomers in cosmetic and household cleaning preparations except in preparations containing 5 per cent or less of 3,7-DIMETHYL-2-6,-OCTADIENAL isomers.

DIMETHYLACETAMIDE except when included in Schedule 5.

DIMETHYLACETAMIDE in preparations containing 20 per cent or less of dimethylacetamide.

4-DIMETHYLAMINOazoBENZENE (N,N-dimethyl-4-[phenylazo]-benzenamine).

3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE *(PSILOCINE or PSILOTSIN).

1,3-DIMETHYLAMYLAMINE (DMAA).

DIMETHYLFORMAMIDE except:
   (a) when included in Schedule 5; or
   (b) in silicone rubber mastic containing 2 per cent or less of dimethylformamide.

DIMETHYLFORMAMIDE in preparations containing 10 per cent or less of dimethylformamide except in silicone rubber mastic containing 2 per cent or less of dimethylformamide.
9 3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-
     TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(DMHP).
9 N,a ‑DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA).
9 N,N-DIMETHYLAMPHETAMINE (Dimetamfetamine).
7 DIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion
     preparations for human use except in preparations containing 0.5 per cent or less of
     dimethylphthalate.
4 DIMETHYL FUMARATE.
9 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE *(PSILOCINE or PSILOTSIN).
7 DI(METHYOXYETHYL) PHTHALATE for cosmetic use.
7 DIMETHYL SULFATE.
4 DIMETHYL SULFOXIDE (excluding dimethyl sulfone) for therapeutic use except:
    (a) when included in Schedule 6; or
    (b) in in-vitro test kits.
6 DIMETHYL SULFOXIDE (excluding dimethyl sulfone):
    (a) when not for therapeutic use; or
    (b) for the treatment of animals:
       (i) when combined with no other therapeutic substance(s);
       (ii) in liquid preparations containing copper salicylate and 1 per cent or less of methyl
            salicylate as the only other therapeutic substances; or
       (iii) in clay poultices containing 2 per cent or less of dimethyl sulfoxide.
9 DIMETHYLTHIAMUBTENE.
9 N,N-DIMETHYLTRYPTAMINE *(DMT).
7 DIMETILAN.
4 DIMETRIDAZOLE.
5 DINICONAZOLE.
4 2,4-DINITROCHLOROBENZENE for therapeutic use.
7 DINITROCRESOLS except when included in Schedule 4 or 6.
6 DINITROCRESOLS and their homologues in preparations containing 5 per cent or
     less of such compounds except:
    (a) when included in Schedule 4; or
    (b) when separately specified in this Schedule.
4 DINITROCRESOLS for therapeutic use except when separately specified in these
    Schedules.
4 DINITRONAPHTHOLS for therapeutic use except when separately specified in
    these Schedules.
7 DINITROPHENOLS except when included in Schedule 4 or 6.
6 DINITROPHENOLS and their homologues in preparations containing 5 per cent or
     less of such compounds except:
    (a) when included in Schedule 4; or
    (b) when separately specified in this Schedule.
4 DINITROPHENOLS for therapeutic use.
4 DINITROTHERMOLS for therapeutic use except when separately specified in these
    Schedules.
7 DINOCAP.
4 DINOPROST. (Clauses 37,52,60)
4 DINOPROSTONE. (Clauses 37,52,60)
7 DINOSEB.
5 DI-N-PROPYL ISOCINCHOMERONATE except in preparations containing 25 per cent or less of di-N-propyl isocinchomeronate.
6 DIOXACARB.
6 DIOXANE.
9 DIOXAPHETYL BUTYRATE.
4 DIPERODON.
6 DIPHACINONE.
4 DIPHENAMIL except in preparations for dermal use.
5 DIPHENAMID.
4 DIPHENHYDRAMINE except when included in Schedule 2 or 3.
3 DIPHENHYDRAMINE in oral preparations except:
(a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age. (Appendix A)
2 DIPHENHYDRAMINE in oral preparations:
(a) in a primary pack containing ten dosage units or less, for the prevention or treatment of motion sickness; or
(b) when combined with one or more other therapeutically active substances when:
(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(ii) in a day-night pack containing diphenhydramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper, except in preparations for the treatment of children under 2 years of age. (Appendix A)
4 DIPHENIDOL.
8 DIPHENOXYLATE except when included in Schedule 3 or 4. (Appendix A)
4 DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate except when included in Schedule 3. (Appendix A)
3 DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate. (Appendix A)
4 DIPHENYLPYRALINE.
4 DIPHTHERIA TOXOID.
8 DIPIPANONE.
4 DIPIVEFRIN.
4 DISOPHENOL.
4 DISOPYRAMIDE.
4 DISTIGMINE.
6 DISULFIRAM except when included in Schedule 4.
4 DISULFIRAM for therapeutic use.
DISULFOTON except when included in Schedule 6.

DISULFOTON in granular preparations containing 5 per cent or less of disulfoton.

DISULPHAMIDE.

DITHIANON.

DITHIAZANINE except when included in Schedule 6.

DITHIAZANINE in preparations containing 2 per cent or less of dithiazanine for the treatment of animals.

DITHIOPYR.

DITHRANOL for therapeutic use.

DITIOCARB.

DIUREDOSAN.

DOBUTAMINE.

DOCETAXEL.

N-(N-DODECYL)-2-PYRROLIDONE except:

(a) when included in Schedule 5; or

(b) in preparations containing 25 per cent or less of designated solvents.

N-(N-DODECYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of N-(N-dodecyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-dodecyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or N-(N-octyl)-2-pyrrolidone except in preparations containing 25 per cent or less of designated solvents.

DODINE.

DOFETILIDE.

DOLASETRON.

DOLUTEGRAVIR.

DOMPERIDONE.

DONEPEZIL.

DOPAMINE.

DOPEXAMINE.

DORAMECTIN except when included in Schedule 5 or 6.

DORAMECTIN for external use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.

DORAMECTIN for internal use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.

DORIPENEM.

DORNASE.

DORZOLAMIDE.

DOTHIEPIN. (Appendix A)

DOXANTRAZOLE.

DOXAPRAM. (Appendix D)

DOXAZOSIN.

DOXEPIN. (Appendix A)

DOXORUBICIN.

DOXYCYCLINE.

DOXYLAMINE except when included in Schedule 2 or 3. (Appendix A)

DOXYLAMINE in oral preparations except:
(a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age. (Appendix A)

DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b) in a day-night pack containing doxylamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper, except in preparations for the treatment of children under 2 years of age. (Appendix A)

DRONABINOL (delta-9-tetrahydrocannabinol) when prepared and packed for therapeutic use.

DROPERIDOL. (Appendix A)

DROSPIRENONE.

DROSTANOLONE. (Appendix B, Appendix D)

DROTEBANOL.

DROTRECOGIN.

DSMA except when included in Schedule 6.

DSMA in herbicide or defoliant preparations containing 10 per cent or less of DSMA.

DUBOISIA LEICHHARDTI except when included in Schedule 2.

DUBOISIA LEICHHARDTI for oral use:
(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

DUBOISIA MYOPOROIDES except when included in Schedule 2.

DUBOISIA MYOPOROIDES for oral use:
(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

DULCIN for therapeutic use.

DULOXETINE. (Appendix A)

DUTASTERIDE.

DYDROGESTERONE.

ECGONINE.

ECONAZOLE except:
(a) when included in Schedule 2, 3 or 6; or
(b) in preparations for dermal use for the treatment of tinea pedis.

ECONAZOLE for human use in dermal preparations except in preparations for the treatment of tinea pedis.

ECONAZOLE in preparations for vaginal use.

ECONAZOLE for external treatment of animals.
ECOTHIOPATE (includes ecothiopate iodide).
ECTYLUREA.
ECULIZUMAB.
EDETIC ACID for human therapeutic use except:
(a) in preparations containing 0.25 per cent or less of edetic acid;
(b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or
(c) in contact lens preparations.
EDOXUDINE.
EDROPHONIUM.
EFALIZUMAB.
EFAVIRENZ.
EFLORNITHINE.
EFORMOTEROL.

Exempt ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS.
Exempt ELECTRONIC COMPONENTS.

ELETRIPTAN.
ELOSULFASE ALFA.
ELTENAC.
ELTROMBOPAG.
ELVITEGRAVIR.

EMAMECTIN except when included in Schedules 5 or 6.
EMAMECTIN in preparations containing 5 per cent or less of emamectin except when included in Schedule 5.
EMAMECTIN in preparations containing 2 per cent or less of emamectin.
EMEPRONIUM.

EMETINE except in preparations containing 0.2 per cent or less of emetine.
EMODEPSIDE for the treatment of animals except when included in Schedule 5.
EMODEPSIDE in preparations:
(a) containing 2.5 per cent or less of emodepside for the external treatment of animals; or
(b) containing 30 mg or less of emodepside per dosage unit for the oral treatment of animals.

EMPAGLIFLOZIN.
EMTRICITABINE.
ENALAPRIL.

ENDOSULFAN except when included in Schedule 6.
ENDOSULFAN in aqueous preparations containing 33 per cent or less of microencapsulated endosulfan.

ENDOTHAL except when included in Schedule 6.
ENDOTHAL in preparations containing 20 per cent or less of endothal.
ENDRIN.

ENESETEBOL. (Appendix B, Appendix D)
ENFLURANE for therapeutic use.
ENFUUVIRIDE.

Exempt ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging.
ENOBOSARM. (Appendix D)
ENOXACIN.
ENOXAPARIN.
ENOXIMONE.
ENPROSTIL.
ENROFLOXACIN.
ENTACAPONE.
ENTECAVIR.
ENZALUTAMIDE.
EPICHLOROHYDRIN.
EPEDRA spp. except in preparations containing 0.001 per cent or less of ephedrine.
EPHEDRINE. (Appendix A, Appendix D)
EPICILLIN.
EPIDERMAL GROWTH FACTOR except in preparations for human therapeutic use.
EPINASTINE.
EPIRUBICIN.
EPITIOSTANOL. (Appendix B, Appendix D)
EPLERENONE.
EPOETINS. (Appendix D)
EPOPROSTENOL.
EPOXICONAZOLE.
EPOXY RESINS, LIQUID. (see also Amines and Organic Anhydrides).
EPRINOMECTIN except when included in Schedule 5.
EPRINOMECTIN in preparations containing 0.5 per cent or less of eprinomectin.
EPROSARTAN.
EP TC.
EPTIFIBATIDE.
ERGOMETRINE.
ERGOT.
ERGOTAMINE.
ERGOTOXINE.
ERIBULIN MESYLATE.
ERLOTINIB.
ERTAPENEM.
ERYSIMUM spp.
ERYTHRITYL TETRANITRATE for therapeutic use.
ERYTHROMYCIN.
ERYTHROPOIETIN. (Appendix D)
ERYTHROPOIETINS except when separately specified in these Schedules. (Appendix D)
ESBIOTHRIN except:
(a) when included in Schedule 5; or
(b) in pressurised spray packs containing 1 per cent or less of esbiothrin.
ESBITHRIN in preparations containing 10 per cent or less of esbiothrin except in pressurised spray packs containing 1 per cent or less of esbiothrin.

ESCITALOPRAM.

ESFENVALERATE except when included in Schedule 5.

ESFENVALERATE in preparations containing 0.1 per cent or less of esfenvalerate.

ESMOLOL.

ESOMEPRAZOLE except when included in Schedule 3.

ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days supply.

ESTRAMUSTINE.

ESTROPIPATE (piperazine oestrone sulfate).

ETACONAZOLE.

ETAFEDRINE.

ETANERCEPT.

ETHACRYNIC ACID.

ETHAMBUTOL.

ETHAMIVAN.

1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE AND N-METHYLMETHANAMINE.

ETHANOLAMINE (excluding its salts and derivatives) except:
(a) when included in Schedule 4 or 5; or
(b) in preparations containing 5 per cent or less of ethanolamine.

ETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of ethanolamine except:
(a) when included in Schedule 4; or
(b) in preparations containing 5 per cent or less of ethanolamine.

ETHANOLAMINE in preparations for injection.

ETHCHLORVYNOL. (Appendix D)

ETHEPHON (excluding its salts and derivatives).

ETHER except:
(a) when included in Schedule 2, 4 or 5; or
(b) in preparations containing 10 per cent or less of ether.

ETHER for therapeutic use except:
(a) when included in Schedule 4; or
(b) in preparations containing 10 per cent or less of ether.

ETHER for use in anaesthesia.

ETHER in preparations containing more than 10 per cent of ether for use in internal combustion engines.

ETHINAMATE. (Appendix D)

ETHINOLOESTRADIOL.

ETHIOFENCARB.

ETHION.

ETHIONAMIDE.

ETHISTERONE.
6 ETHOATE-METHYL.
5 ETHOFUMESATE.
4 ETHOGLUCID.
4 ETHOHEPTAZINE.
4 ETHOPROPAZINE.
7 ETHOPROPHOS except when included in Schedule 6.
6 ETHOPROPHOS in granular formulations containing 10 per cent or less of ethoprophos and 2 per cent of linseed oil.
4 ETHOSUXIMIDE.
4 ETHOTOIN.
7 2-ETHOXYETHANOL and its acetates except in preparations containing 0.5 per cent or less of 2-ethoxyethanol.
5 ETHOXYQUIN except in preparations containing 10 per cent or less of ethoxyquin.
5 ETHOXSULFURON.
4 ETHOXZOLAMIDE.
8 ETHYLAMPHETAMINE.
6 ETHYL BROMIDE.
4 ETHYL CHLORIDE for human therapeutic use.
4 ETHYLDIENOLONE. (Appendix B, Appendix D)
6 ETHYLENE CHLOROHYDRIN.
7 ETHYLENE DIBROMIDE.
6 ETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25 per cent or less of ethylene glycol.
6 ETHYLENE GLYCOL (excluding its salts and derivatives) except:
(a) when included in Schedule 5;
(b) in paints or paint tinters; or
(c) in toothpastes or mouthwashes containing more than 0.25 per cent of ethylene glycol; or
(d) in other preparations containing 2.5 per cent or less of ethylene glycol.
5 ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except:
(a) in paints or paint tinters;
(b) in toothpastes or mouthwashes containing more than 0.25 per cent of ethylene glycol; or
(c) in other preparations containing 2.5 per cent or less of ethylene glycol.
6 ETHYLENE GLYCOL MONOALKYL Ethers and their ACETATES, except:
(a) when separately specified in these Schedules; or
(b) in preparations containing 10 per cent or less of such substances.
7 ETHYLENE OXIDE.
6 ETHYL FORMATE when packed and labelled for use as a fumigant.
4 ETHYLHEXANEDIOL for animal use.
7 ETHYLHEXANEDIOL for human use.
6 2-ETHYLHEXYL 2-ETHYLHEXANOATE except in preparations containing 10 per cent or less of 2-ethylhexyl 2-ethylhexanoate.
ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use except in preparations containing 1 per cent or less of ethyl methacrylate as residual monomer in a polymer.

N-ETHYL-a-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE *(N-ETHYL MDA).

ETHYLMETHYLTHIAMBUTENE.

ETHYLTHORPHINE except when included in Schedule 2 or 4. (Appendix A)

ETHYLTHORPHINE when compounded with one or more other therapeutically active substances:
(a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5 per cent of ethylmorphine, except when included in Schedule 2. (Appendix A)

ETHYLTHORPHINE when:
(a) compounded with one or more other therapeutically active substances:
   (i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or
   (ii) in undivided preparations containing 0.25 per cent or less of ethylmorphine; and
(b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine. (Appendix A)

ETHYLOESTRENOL. (Appendix B, Appendix D)

ETHYNODIOL.

ETICYCLIDINE (PCE).

ETIDOCaine.

ETIDRONIC ACID (includes disodium etidronate):
(a) for internal use; or
(b) in topical preparations except in preparations containing 1 per cent or less of etidronic acid.

ETILEFRIN.

ETIPROSTON.

ETODOLAC.

ETOFENAMATE except when included in Schedule 2.

ETOGENATE in preparations for external use.

ETONITAZENE.

ETONOGESTREL.

ETOPROFEN.

ETRETINATE. (Clauses 31, 51, 59)

ETRIDIAZOLE.

ETRIMFOS.

EUCALYPTUS OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF THE REACH OF CHILDREN; and
NOT TO BE TAKEN;
(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
(e) in preparations containing 25 per cent or less of eucalyptus oil.

6 EUGENOL except:
(a) when included in Schedule 5;
(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF THE REACH OF CHILDREN; and
NOT TO BE TAKEN;
(e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
(f) in preparations containing 25 per cent or less of eugenol.

5 EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol except in preparations containing 25 per cent or less of eugenol.

7 EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.

4 EVEROLIMUS.

4 EXEMESTANE.

4 EXENATIDE.

Exempt EXPLOSIVES.

5 EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (Corymbia citriodora), except in preparations containing 40 per cent or less of extract of lemon eucalyptus.

4 EZETIMIBE.
FAMCICLOVIR for oral use, in divided preparations, containing a total dose of 1500 mg or less of famciclovir for the treatment of herpes labialis (cold sores).

FAMCICLOVIR except when included in Schedule 3.

FAMOTIDINE except when included in Schedule 2.

FAMOTIDINE when sold in the manufacturer's original pack containing not more than 14 days supply.

FAMPHUR except when included in Schedule 6.

FAMPHUR in preparations containing 20 per cent or less of famphur.

FARFUGIUM JAPONICUM for therapeutic use.

FEBANTEL except:
(a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or
(b) in undivided preparations containing 10 per cent or less of febantel.

FEBUXOSTAT.

FELBINAC except when included in Schedule 2.

FELBINAC in preparations for external use.

FELODIPINE.

FELOPRESSIN.

FENAMIPHOS except when included in Schedule 6.

FENAMIPHOS in granular preparations containing 5 per cent or less of fenamiphos.

FENARIMOL.

FENAZAFLOR.

FENBENDAZOLE for the treatment of animals.

FENBUCONAZOLE.

FENBUFEN.

FENBUTATIN OXIDE.

FENCAMFAMIN. (Appendix D)

FENCHLORAZOLE-ETHYL.

FENCHLORPHOS.

FENCLOFENAC.

FENETHYLLINE.

FENFLURAMINE. (Appendix A)

FENITROTHION.

FENOFIBRATE.

FENOLDOPAM.

FENOPROP.

FENOPROFEN.

FENOTEROL.

FENOXACRIM except:
(a) when included in Schedule 6; or
(b) in treated carpets.

FENOXACRIM in preparations for the treatment of carpets during manufacture.

FENOXAPROP-ETHYL.

FENOXAPROP-P-ETHYL.

FENPIPRAMIDE.
4 FENPIPRANE.
4 FENPROPOREX. (Appendix D)
4 FENPROSTALENE.
5 FENPYRAZAMINE except in preparations containing 40 per cent or less of fenpyrazamine.
6 FENPYROXIMATE.
5 FENSON.
7 FENSULFOTHION.
8 FENTANYL. (Appendix A)
7 FENTHION except when included in Schedule 5 or 6.
6 FENTHION in preparations containing 60 per cent or less of fenthion except when included in Schedule 5.
5 FENTHION:
(a) in preparations containing 25 per cent or less of fenthion when packed in single-use containers having a capacity of 2 mL or less; or
(b) in preparations containing 10 per cent or less of fenthion.
7 FENTHION-ETHYL.
6 FENVALERATE.
4 FEXOFENADINE except:
(a) when included in Schedule 2; or
(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
   (i) in a primary pack containing 10 dosage units or less and not more than 5 days' supply; and
   (ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine.
2 FEXOFENADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
   (a) in a primary pack containing 10 dosage units or less and not more than 5 days' supply;
   (b) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine.
4 FIBRINOLYSIN except for external use.
4 FIDAXOMICIN
4 FILGRASTIM.
4 FINASTERIDE.
4 FINGOLIMOD.
6 FIPRONIL except:
(a) when included in Schedule 5; or
(b) in preparations containing 0.05 per cent or less of fipronil.
5 FIPRONIL in preparations containing 10 per cent or less of fipronil except in preparations containing 0.05 per cent or less of fipronil.
Exempt FIREWORKS containing substances in Schedules 1,2,3,5 or 6 other than arsenic.
4 FIROCOXIB.
5 FLAMPROP-METHYL.
5 FLAMPROP-M-METHYL.
3 FLAVOXATE.
5 FLAZASULFURON.
FLECAINIDE.

FLEROXACIN.

FLOCOUMAFEN except when included in Schedule 6.

FLOCOUMAFEN in preparations containing 0.005 per cent or less of flocoumafen.

FLOCTAFENINE.

FLONICAMID.

FLORASULAM.

FLORFENICOL.

FLUANISONE.

FLUAZIFOP-BUTYL.

FLUAZIFOP-P-BUTYL.

FLUAZINAM.

FLUAZURON.

FLUBENDAZOLE for the treatment of animals.

FLUBENDIAMIDE.

FLUCHLORALIN.

FLUCLOXACILLIN.

FLUCOFURON except:

(a) when included in Schedule 6; or

(b) in treated carpets.

FLUCOFURON in preparations for the treatment of carpets during manufacture.

FLUCONAZOLE except when included in Schedule 3.

FLUCONAZOLE in single-dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.

FLUCYTHRINATE.

FLUCYTOSINE.

FLUDARABINE.

FLUDIOXONIL except in preparations containing 10 per cent or less of fludioxonil.

FLUDROCORTISONE.

FLUENSULFONE.

FLUFENAMIC ACID.

FLUMAZENIL.

FLUMETHASONE.

FLUMETHIAZIDE.

FLUMETHRIN except when included in Schedule 5.

FLUMETHRIN:

(a) when impregnated in plastic resin strip material containing 3 per cent or less of flumethrin; or

(b) in oil based preparations containing 1 per cent or less of flumethrin.

FLUMICLORAC PENTYL.

FLUMIOXAZIN except when included in Schedule 6.

FLUMIOXAZIN when contained in water soluble bags individually packed in sealed sachets.

FLUNISOLIDE.
FLUNITRAZEPAM. (Appendix A, Clause 123)

FLUNIXIN MEGLUMINE.

FLUOCINOLONE.

FLUOCINONIDE.

FLUOCORTIN.

FLUOCORTOLONE.

FLUOPYRAM except in preparations containing 50 per cent or less of fluopyram.

FLUORESCEIN in preparations for injection.

FLUORIDES except:
(a) when included in Schedule 5;
(b) in preparations for human use; or
(c) in preparations containing 15 mg/kg or less of fluoride ion.

FLUORIDES in preparations containing 3 per cent or less of fluoride ion except in preparations:
(a) for human use; or
(b) containing 15 mg/kg or less of fluoride ion.

FLUORIDES in preparations for human use except when included in or expressly excluded from Schedule 2 or 3.

FLUORIDES for human topical use:
(a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child-resistant closure except when included in or expressly excluded from Schedule 2; or
(b) in non-liquid preparations containing 5500 mg/kg or less of fluoride ion except:
   (i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the requirements of the Required Advisory Statements for Medicine Labels;
   (ii) in preparations for non-therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with warnings to the following effect:
      (A) Do not swallow; and
      (B) Do not use [this product/name of product] in children six years of age or less; or
   (iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.

FLUORIDES for human use:
(a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or
(b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child-resistant closure:
   (i) for therapeutic use when compliant with the requirements of the Required Advisory Statements for Medicine Labels except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels; or
   (ii) for non-therapeutic use when labelled with warnings to the following effect:
      (A) Do not swallow; and
      (B) Do not use [this product/name of product] in children six years of age or less, except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child-resistant closure and labelled with warnings to the following effect:
(A) Do not swallow; and
(B) Do not use [this product/name of product] in children six years of age or less, except in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.

FLUOROACETAMIDE. (Clause 20)
FLUOROACETIC ACID. (Clause 20)
FLUOROMETHOLONE.
4-FLUORO-N-METHYLAMPHETAMINE.
FLUOROURACIL.
FLUOXETINE.
FLUOXYMESTERONE. (Appendix B, Appendix D)
FLUPENTHIXOL. (Appendix A)
FLUPHENAZINE. (Appendix A)
FLUPROSTENOL.
1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE *(AM-694).
FLURALANER for the treatment and prevention of flea infestations and control of ticks in dogs in oral divided preparations each containing 1400 mg or less of fluralaner per dosage unit.
FLUQUINCONAZOLE.
FLURANDRENOLONE.
FLURAZEPAM. (Appendix A, Appendix D)
FLURBIPROFEN except when included in Schedule 2.
FLURBIPROFEN in preparations for topical oral use when:
(a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit; or
(b) in undivided preparations containing 0.25 per cent or less, or 10 mg or less per dose, of flurbiprofen.
FLUROXENE for human therapeutic use.
FLUSILAZOL.
FLUSPIRILENE.
FLUTAMIDE.
FLUTICASONE except when included in Schedule 2.
FLUTICASONE in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
FLUTRIAFOL except in fertilisers containing 0.5 per cent or less of flutriafol.
FLUVASTATIN.
FLUVOXAMINE.
FLUXAPYROXAD.
FOLIC ACID in preparations for human use for injection.
FOLIC ACID for human therapeutic use except:
(a) when included in Schedule 4; or
(b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.

4 FOLINIC ACID in preparations for human use for injection.

2 FOLINIC ACID for human therapeutic use except:
(a) when included in Schedule 4; or
(b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.

4 FOLLICLE-STIMULATING HORMONE except when separately specified in this Schedule.
FOLLICLE-STIMULATING HORMONE (Human) - see UROFOLLITROPHIN.

4 FOLLISTATIN. (Appendix D)

4 FOLLITROPIN ALPHA.

4 FOLLITROPIN BETA. (Clauses 37,52,60)

7 FOLPET.

4 FOMIVIRSEN. (Appendix D)

4 FONDAPARINUX.

Exempt FOOD except:
(a) food additives before incorporation into food; or
(b) when used as a means of administering a poison for therapeutic use.

5 FORAMSULFURON.

7 FORMALDEHYDE (excluding its derivatives):
(a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;
(b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;
(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or
(d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde except in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
CONTAINS FORMALDEHYDE.

6 FORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde except:
(a) for human therapeutic use;
(b) in oral hygiene preparations;
(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;
(d) in all other cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:
PROTECT CUTICLES WITH GREASE OR OIL; or
(e) in all other cosmetic preparations; or
(f) in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
CONTAINS FORMALDEHYDE.

2 FORMALDEHYDE (excluding its derivatives) for human therapeutic use except:
(a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or
(b) in other preparations containing 0.2 per cent or less of free formaldehyde.

FORMEBOLONE. (Appendix B, Appendix D)

FORMANOL.

FORMIC ACID (excluding its salts and derivatives) except in preparations containing 0.5 per cent or less of formic acid.

FORMOTHION.

FOSAMPRENAVIR.

FOSAPREPTANT.

FOSCARNET.

FOSFESTROL (diethylstilboestrol diphosphate).

FOSINOPRIL.

FOSPHENYTOIN.

FOSPIRATE except when included in Schedule 5.

FOSPIRATE when impregnated in plastic resin strip material containing 20 per cent or less of fospirate.

F OSTHIAZATE.

FOTEMUSTINE.

FURAZABOL. (Appendix B, Appendix D)

FURAZOLIDONE.

FULVESTRANT.

FUMAGILLIN.

FURALAXYL.

FURALTADONE.

FURETHIDINE.

FURATHIOCARB except when included in Schedule 5.

FUR ATHIOCARB in microencapsulated suspensions containing 50 per cent or less of furathiocarb.

FURAZABOL. (Appendix B, Appendix D)

FURAZOLIDONE.

FURFURAL except in preparations containing 0.1 per cent or less of furfural.

FUROSEMIDE (frusemide).

FUSIDIC ACID.

GABAPENTIN. (Appendix A)

GALANTAMINE.

GALANTHUS spp.

GALLAMINE.

GALSULFASE.

GAMMA BUTYROLACTONE (excluding its derivatives) in non-polymerised form in preparations for domestic and cosmetic use.

GAMMA-CYHALOTHRIN except when included in Schedule 5.

GAMMA-CYHALOTHRIN in aqueous preparations containing 15 per cent or less of microencapsulated gamma-cyhalothrin.

GANCICLOVIR.

GANIRELIX.
GATIFLOXACIN.

GEFITINIB.

GELSEMIUM SEMPERVIRENS.

GEMCITABINE. (Appendix A)

GEMEPROST.

GEMFIBROZIL.

GEMIFLOXACIN.

GEMTUZUMAB OZOGAMICIN.

GENTAMICIN.

GESTODENE.

GESTONORONE.

GESTRINONE.

GHRH INJECTABLE PLASMID.

GITALIN.

Exempt GLASS (including CRYSTAL WARE).

Exempt GLATIRAMER ACETATE.

Exempt GLAZED POTTERY.

GLIBENCLAMIDE.

GLIBORNURIDE.

GLICLAZIDE.

GLIMEPIRIDE.

GLIPIZIDE.

GLISOXEPIDE.

GLUCAGON.

GLUFOSINATE-AMMONIUM.

GLUTARALDEHYDE except:

(a) when included in Schedule 2 or 5; or

(b) in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:

IRRITANT; and

Avoid contact with eyes.

GLUTARALDEHYDE in preparations containing 5 per cent or less of glutaraldehyde except:

(a) when included in Schedule 2; or

(b) in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:

IRRITANT; and

Avoid contact with eyes.

GLUTARALDEHYDE for human therapeutic use.

GLUTATHIONE for parenteral use.

GLUTATHIONE for parenteral use.

GLUTATHIONE for parenteral use.

GLUDETIMIDE. (Appendix A, Appendix D)

GLYCERYL THIOGLYCOLLATE in hair waving preparations except when labelled with directions for use that include the statement:

"Wear protective gloves when using. Keep out of eyes".

GLYCERYL TRINITRATE except when included in Schedule 3.
3 GLYCERYL TRINITRATE:
   (a) in preparations for oral use; or
   (b) in preparations for rectal use.
6 GLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical except:
   (a) in cosmetic preparations for salon use only which are labelled in accordance with the National Occupational Health and Safety Commission's National Code of Practice for the Labelling of Workplace Substances [NOHSC:2012 (1994)];
   (b) in preparations containing 5 per cent or less of glycolic acid; or
   (c) in preparations containing 20 per cent or less of glycolic acid with a pH of 3.5 or greater.
3 GLYCOPRYRONNIIUM except when included in Schedule 4.
4 GLYCOPYRONNIIUM in preparations for injection.
4 GLYCIDINE.
5 GLYPHOSATE.
4 GnRH VACCINE.
4 GOLIMUMAB.
4 GONADORELIN.
4 GONADOTROPHIC HORMONES except when separately specified in this Schedule.
4 GOSERELIN.
4 GRAMICIDIN.
4 GRANISETRON.
4 GREPAFLOXACIN.
4 GRISEOFULVIN.
4 GROWTH HORMONE RELEASING PEPTIDE-6 (GHRH-6)
4 GROWTH HORMONE RELEASING HORMONES *(GHRHs)
4 GROWTH HORMONE RELEASING PEPTIDES *(GHRPs)
4 GROWTH HORMONE SECRETAGOGUES *(GHSs)
4 GUAIPHENESIN for human therapeutic use except:
   (a) when included in Schedule 2;
   (b) in oral liquid preparations containing 2 per cent or less of guaiphenesin; or
   (c) in divided preparations containing 200 mg or less of guaiphenesin per dosage unit.
2 GUAIPHENESIN in a modified release dosage form of 1200 mg or less of guaiphenesin with a recommended daily dose of 2400 mg or less when not labelled for the treatment of children under 12 years of age.
4 GUANABENZ.
4 GUANACLINE.
4 GUANETHIDINE.
6 GUANIDINE except:
   (a) when included in Schedule 4; or
   (b) in preparations containing 1 per cent or less of guanidine.
4 GUANIDINE for therapeutic use.
6 GUAZATINE.
4 HACHIMYCN.
4 HAEMATIN.
HAEMOPHILUS INFLUENZAE VACCINE.
HALCINONIDE.
HALOFANTRINE.
HALOFENATE.
HALOFUGINONE except when included in Schedule 4.
HALOFUGINONE in preparations containing 0.1 per cent or less of halofuginone for the treatment of animals.
HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.
HALOPERIDOL. (Appendix A)
HALOSULFURON-METHYL.
HALOTHANE for therapeutic use.
HALOXON.
HALOXYFOP.
HARMALA ALKALOIDS except in herbs, or preparations, for therapeutic use:
(a) containing 0.1 per cent or less of harmala alkaloids; or
(b) in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose.
HCB.
HELIOTROPIUM spp. for therapeutic use.
HEMEROCALLIS (Hemerocallis flava).
HEPARINS for internal use except when separately specified in this Schedule.
HEPATITIS A VACCINE.
HEPATITIS B VACCINE.
HEPTACHLOR.
HEROIN.
HETACILLIN.
HEXACHLOROPHANE:
(a) in preparations for use on infants; or
(b) in other preparations except:
(i) when included in Schedule 2 or 6; or
(ii) in preparations containing 0.75 per cent or less of hexachlorophane.
HEXACHLOROPHANE in preparations for human use containing 3 per cent or less of hexachlorophane except:
(a) in preparations containing 0.75 per cent or less of hexachlorophane; or
(b) in preparations for use on infants, as specified in Schedule 4.
HEXACHLOROPHANE in preparations for the treatment of animals.
HEXACONAZOLE except in preparations containing 5 per cent or less of hexaconazole.
HEXAMETHONIUM.
HEXARELIN.
HEXAZINONE except when included in Schedule 5.
HEXAZINONE in preparations containing 25 per cent or less of hexazinone.
HEXETIDINE for human internal use.
HEXOBENDINE.
HEXOCYCLUM.
HEXOPRENALINE.

3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(PARAHEXYL).

HEXYLOXYETHANOL except in preparations containing 10 per cent or less of hexyloxyethanol.

HISTAMINE for therapeutic use except in preparations containing 0.5 per cent or less of histamine.

HMG-CoA REDUCTASE INHIBITORS (including "statins") except when separately specified in these Schedules.

HOMATROPINE.

Exempt HUMAN BLOOD PRODUCTS including:
(a) whole blood;
(b) blood components including red cells, white cells, platelets and plasma (including cryoprecipitate); and
(c) the following plasma-derived therapeutic proteins and their equivalent recombinant alternatives:
   (i) albumin;
   (ii) anticoagulation complex;
   (iii) C1 esterase inhibitors;
   (iv) clotting factors;
   (v) fibrinogen;
   (vi) protein C;
   (vii) prothrombin complex concentrate (PCC); and
   (viii) thrombin.

HUMAN CHORIONIC GONADOTROPHIN except in pregnancy test kits.

HUMAN PAPILLOMAVIRUS VACCINE.

HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation:
(a) for tissue augmentation;
(b) for cosmetic use; or
(c) for the treatment of animals.

HYDRAZINE.

HYDRAMETHYLNON except when included in Schedule 5.

HYDRAMETHYLNON in solid baits containing 2 per cent or less of hydramethylnon in welded plastic labyrinths.

HYDRAZINE.

HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), except:
(a) toluene and xylene when included in Schedule 6;
(b) benzene and liquid aromatic hydrocarbons when included in Schedule 7;
(c) food grade and pharmaceutical grade white mineral oils;
(d) in solid or semi-solid preparations;
(e) in preparations containing 25 per cent or less of designated solvents;
(f) in preparations packed in pressurised spray packs;
(g) in adhesives packed in containers each containing 50 grams or less of adhesive;
(h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or
(i) in other preparations when packed in containers with a capacity of 2 mL or less.

7 HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any fraction of which boils above 350°C except:
(a) when in solid polymers;
(b) when containing 1 per cent or less of total polycyclic aromatic compounds as measured by IP 346; or
(c) when having a Mutagenicity Index of zero as measured by ASTM E1687-95.

6 HYDROCHLORIC ACID (excluding its salts and derivatives) except:
(a) when included in Schedule 5;
(b) in preparations for therapeutic use; or
(c) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl).

5 HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of hydrochloric acid (HCl) except:
(a) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl); or
(b) for therapeutic use.

4 HYDROCHLOROTHIAZIDE.

8 HYDROCODONE. (Appendix A)

4 HYDROCORTISONE:
(a) for human use except when included in Schedule 2 or 3; or
(b) for the treatment of animals.

3 HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1 per cent or less of hydrocortisone:
(a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or
(b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except an unscheduled astringent:
(i) in undivided preparations, in packs of 35 g or less; or
(ii) in packs containing 12 or less suppositories, except when included in Schedule 2.

2 HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 0.5 per cent or less of hydrocortisone:
(a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or
(b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except an unscheduled astringent:
(i) in undivided preparations in packs of 35 g or less; or
(ii) in packs containing 12 or less suppositories.

7 HYDROCYANIC ACID except:
(a) when included in Schedule 4; or
(b) its salts and derivatives other than cyanides separately specified in this Schedule. (Clause 20)

4 HYDROCYANIC ACID for therapeutic use.

4 HYDROFLUMETHIAZIDE.

7 HYDROFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6.
HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1 per cent or less of hydrogen fluoride except when included in Schedule 5.

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1 per cent or less of hydrogen fluoride.

HYDROFLUORIC ACID - see also FLUORIDES, METALLIC

HYDROGEN PEROXIDE (excluding its salts and derivatives) except:

(a) when included in Schedule 5;
(b) in hair dye preparations containing 6 per cent or less of hydrogen peroxide; or
(c) in other preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.

HYDROGEN PEROXIDE (excluding its salts and derivatives):

(a) in hair dye preparations containing 12 per cent or less of hydrogen peroxide except in hair dyes containing 6 per cent or less of hydrogen peroxide; or
(b) in other preparations containing 6 per cent (20 volume) or less of hydrogen peroxide except in preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.

HYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6 per cent (20 volume) of hydrogen peroxide except in preparations manufactured for and supplied solely by registered dental practitioners as part of their dental practice.

HYDROGEN SULFIDE.

HYDROMORPHINOL.

HYDROMORPHONE. (Appendix A, Clause 123)

HYDROQUINONE except:

(a) when included in Schedule 2 or 4; or
(b) in preparations containing 10 per cent or less of hydroquinone.

HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use except:

(a) when included in Schedule 2; or
(b) in hair preparations containing 0.3 per cent or less of hydroquinone; or
(c) in cosmetic nail preparations containing 0.02 per cent or less of hydroquinone.

HYDROQUINONE (excluding monobenzone and alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2 per cent or less of hydroquinone except:

(a) in hair preparations containing 0.3 per cent or less of hydroquinone; or
(b) in cosmetic nail preparations containing 0.02 per cent or less of hydroquinone.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1 per cent or less of hydrosilicofluoric acid (H2SiF6) except when included in Schedule 5.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1 per cent or less of hydrosilicofluoric acid (H2SiF6).

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5.

4-HYDROXYBUTANOIC ACID and its salts except for sodium oxybate when in Schedule 8. *(GAMMA HYDROXYBUTYRATE (GHB)).

HYDROXYCHLOROQUINE.

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL *(Cannabicyclohexanol or CP 47,497 C8 homologue).
2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL *(CP 47,497).

HYDROXYPETHIDINE.

HYDROXYEPHEDRINE.

HYDROXYPHENAMATE.

HYDROXYPROGESTERONE.

8-HYDROXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, except in preparations for external use containing 1 per cent or less of such substances.

HYDROXYSTENÖZOL. (Appendix B, Appendix D)

HYDROXYUREA.

HYDROXYZINE. (Appendix A)

HYGROMYCIN.

HYOSCINE except when included in Schedule 2.

HYOSCINE (excluding hyoscine butylbromide)

(a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or

(b) for oral use:

(i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.

HYOSCYAMINE except when included in Schedule 2.

HYOSCYAMINE:

(a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or

(b) for oral use:

(i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

HYOSCYAMUS NIGER except:

(a) when included in Schedule 2; or

(b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.

HYOSCYAMUS NIGER for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, except in a pack containing 0.03 mg or less of total solanaceous alkaloids.
HYPOTHALAMIC RELEASING FACTORS except when separately specified in this Schedule.

HYPROMELLOSE in preparations for injection.

IBAFLOXACIN for veterinary use.

IBANDRONIC ACID.

IBOGAINE.

IBRITUMOMAB.

IBUFENAC.

IBUPROFEN except:
(a) when included in or expressly excluded from Schedule 2 or 3; or
(b) in preparations for dermal use.

IBUPROFEN in divided preparations, each containing 400 mg or less of ibuprofen, in a primary pack containing not more than 50 dosage units when labelled:
(a) with a recommended daily dose of 1200 mg or less of ibuprofen; and
(b) not for the treatment of children under 12 years of age, except when included in or expressly excluded from Schedule 2.

IBUPROFEN in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen:
(a) in liquid preparations when sold in the manufacturer's original pack containing 8 grams or less of ibuprofen; or
(b) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units except when:
(i) as the only therapeutically active constituent (other than phenylephrine or when combined with an effervescent agent);
(ii) packed in blister or strip packaging or in a container with a child-resistant closure;
(iii) in a primary pack containing not more than 25 dosage units;
(iv) compliant with the requirements of the Required Advisory Statements for Medicine Labels.
(v) not labelled for the treatment of children 6 years of age or less; and
(vi) not labelled for the treatment of children under 12 years of age when combined with phenylephrine.

IBUTEROL.

IBUTILIDE.

ICATIBANT.

IDARUBICIN.

IDOXURIDINE except in preparations containing 0.5 per cent or less of idoxuridine for dermal use.

IDURSULFASE.

IFOSFAMIDE.

ILOPROST.

IMATINIB.

IMAZALIL.

IMAZAMOX except in preparations containing 25 per cent or less of imazamox.

IMAZAPIC except in preparations containing 25 per cent or less of imazapic.

IMAZAPYR except in preparations containing 25 per cent or less of imazapyr.

IMAZETHAPYR except in preparations containing 25 per cent or less of
imazethapyr.

4 IMEPITOIN

6 IMIDACLOPRID except:
(a) when included in Schedule 5; or
(b) in preparations containing 5 per cent or less of imidacloprid

5 IMIDACLOPRID in preparations containing 20 per cent or less of imidacloprid except in preparations containing 5 per cent or less of imidacloprid.

4 IMIDAPRIL.

6 IMIDOCARB.

4 IMIGLUCERASE.

6 IMINODTABINE TRIALBESILATE.

4 IMIPENEM.

4 IMIPRAMINE. (Appendix A)

6 IMIPROTHRIN except:
(a) when included in Schedule 5; or
(b) in preparations containing 10 per cent or less of imiprothrin.

5 IMIPROTHRIN in preparations containing 50 per cent or less of imiprothrin except in preparations containing 10 per cent or less of imiprothrin.

4 IMIQUIMOD.

4 IMMUNOGLOBULINS for human parenteral use except when separately specified in these Schedules.

4 INDACATEROL.

2 INDANAZOLINE.

4 INDAPAMIDE.

6 INDAZIFLAM

4 INDINAVIR.

4 INDOMETHACIN except when included in Schedule 2.

2 INDOMETHACIN in preparations for external use containing 1 per cent or less of indomethacin.

4 INDOPROFEN.

4 INDORAMIN.

6 INDOXACARB (Includes the R and S enantiomers) except when included in Schedule 5.

5 INDOXACARB (Includes the R and S enantiomers) in preparations containing 1 per cent or less of indoxacarb.

4 INFLIXIMAB.

4 INFLUENZA AND CORYZA VACCINES:
(a) for parenteral use; or
(b) for nasal administration.

4 INGENOL MEBUTATE.

3 INOSITOL NICOTINATE.

4 INSULIN GLARGINE

4 INSULIN-LIKE GROWTH FACTOR 1. (Appendix D)

4 INSULIN-LIKE GROWTH FACTORS except when separately specified in this Schedule. (Appendix D)

4 INSULINS.
INTERFERONS.
INTERLEUKINS except when separately specified in these Schedules.

Exempt INTRAOCULAR VISCOELASTIC PRODUCTS.
Exempt IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001 per cent or less of a poison included in Schedules 1 to 8.

IODINE:
(a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or
(b) in preparations for human external therapeutic use containing more than 2.5 per cent of available iodine (excluding salts, derivatives and iodophors), except in oral preparations for use in prophylaxis and treatment in the event of radioactive iodine exposure under an emergency plan approved by an appropriate authority.

IODINE (excluding its salts, derivatives and iodophors) except:
(a) when included in Schedule 2; or
(b) in solid or semi-solid preparations containing 2.5 per cent or less of available iodine.

IODOMETHANE.

IODOPHORS except in preparations containing 1.5 per cent or less of available iodine.

3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) except:
(a) when included in Schedule 5;
(b) in aqueous preparations not for cosmetic use containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate (Iodocarb); or
(c) in cosmetic preparations (other than aerosolised preparations) containing 0.1 per cent or less of 3-iodo-2-propynyl butyl carbamate.

3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) in preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate except:
(a) in aqueous preparations not for cosmetic use containing 10 per cent or less 3-iodo-2-propynyl butyl carbamate; or
(b) in cosmetic preparations (other than aerosolised preparations) containing 0.1 per cent or less of 3-iodo-2-propynyl butyl carbamate.

IODOSULFURON-METHYL-SODIUM.
IODOTHIOURACIL.
IOXYNIL.
IPAMORELIN.
IPCONAZOLE except when included in Schedule 5.
IPCONAZOLE in preparations containing 2 per cent or less of ipconazole.
IPILIMUMAB.
IPRATROPIUM except when included in Schedule 2.
IPRATROPIUM in preparations for nasal use.
IPRIFLAVONE.
IPRINDOLE.
IPRONIAZID.
IRBESARTEN.
IRINOTECAN.
IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1 per cent or less of total iron oxides) for human internal use except:
(a) when included in Schedule 4; or
(b) when labelled with a recommended daily dose of 24 mg or less of iron:
(i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or
(ii) in divided preparations:
(A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or
(B) containing 5 mg or less of iron per dosage unit.

IRON COMPOUNDS in injectable preparations for human use.

IRON COMPOUNDS (excluding up to 1 per cent of iron oxides when present as an excipient) for the treatment of animals except:
(a) when included in Schedule 5;
(b) in liquid or gel preparations containing 0.1 per cent or less of iron; or
(c) in animal feeds or feed premixes.

IRON COMPOUNDS:
(a) for the treatment of animals (excluding up to 1 per cent of iron oxides when present as an excipient):
(i) in preparations for injection containing 20 per cent or less of iron except in preparations containing 0.1 per cent or less of iron; or
(ii) in other preparations containing 4 per cent or less of iron except:
(A) in liquid or gel preparations containing 0.1 per cent or less of iron; or
(B) in animal feeds or feed premixes; or
(b) in garden preparations except in preparations containing 4 per cent or less of iron.

ISOAMINILE.

ISOAMYL NITRITE.

ISOBUTYL NITRITE.

ISOCARBOPHOS.

ISOCARBOXAZID.

ISOCONAZOLE except when included in Schedule 2, 3 or 6.

ISOCONAZOLE in preparations for vaginal use.

ISOCONAZOLE for external treatment of animals.

ISOCONAZOLE for human use in dermal preparations.

ISOCYANATES, free organic, boiling below 300°C, except in:
(a) viscous polyurethane adhesives; or
(b) viscous polyurethane sealants;
containing not more than 0.7 per cent of free organic isocyanates boiling below 300°C.

ISOETARINE.

ISOEUGENOL except:
(a) when included in Schedule 5; or
(b) in preparations containing 10 per cent or less of isoegenol.
ISOEUGENOL in preparations containing 25 per cent or less of isoeugenol except in preparations containing 10 per cent or less of isoeugenol.

ISOFENPHOS.

ISOFLURANE for therapeutic use.

ISOMETHADONE.

ISOMETHEPTENE.

ISONIAZID.

ISOPHORONE.

ISOPRENALINE.

ISOPRINOSINE.

ISOPROPAMIDE except when included in Schedule 2.

ISOPROPAMIDE in preparations for dermal use containing 2 per cent or less of isopropamide.

ISOPROTURON.

ISOSORBIDE DINITRATE except when included in Schedule 3.

ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.

ISOSORBIDE MONONITRATE.

ISOTRETINOIN. (Clauses 37, 52, 60)

ISOXABEN.

ISOXAFUTOLE.

ISOXICAM.

ISOXSUPRINE.

ISRADIPINE.

ITRACONAZOLE.

IVABRADINE.

IVACAFTOR.

IVERMECTIN except when included in Schedule 4 or 5.

IVERMECTIN for use in animals:
(a) in preparations for the prophylaxis of heartworm in cats and dogs;
(b) in intraruminal implants containing 160 mg or less of ivermectin;
(c) in preparations containing 3.5 per cent or less of ivermectin when packed in child-resistant packaging or in packaging approved by the relevant registration authority; or
(d) in other preparations containing 2 per cent or less of ivermectin.

IVERMECTIN:
(a) for human use; or
(b) for the treatment of mange in dogs.

IXABEPILONE.

JAPANESE ENCEPHALITIS VACCINE.

JUNIPERUS SABINE [savin(e)] for therapeutic use.

KANAMYCIN.

KAVA - see PIPER METHYSTICUM.

KEROSENE - see HYDROCARBONS, LIQUID

KETAMINE.
4 KETANSERIN except in topical veterinary preparations containing 0.5 per cent or less of ketanserin.
4 KETAZOLAM.
9 KETOBEMIDONE.
4 KETOCONAZOLE except:
   (a) when included in Schedule 2;
   (b) in preparations for dermal use containing 1 per cent or less of ketoconazole for the treatment of the scalp; or
   (c) in preparations for dermal use for the treatment of tinea pedis.
2 KETOCONAZOLE in preparations for dermal use except:
   (a) in preparations containing 1 per cent or less of ketoconazole for the treatment of the scalp; or
   (b) in preparations for the treatment of tinea pedis.
4 KETOPROFEN except:
   (a) in preparations for dermal use; or
   (b) when included in Schedule 3.
3 KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.
4 KETOROLAC (includes ketorolac trometamol).
4 KETOTIFEN except when included in Schedule 2.
2 KETOTIFEN for ophthalmic use in preparations containing 0.025 per cent or less of ketotifen.
4 KHELLIN.
4 KITASAMYCIN except:
   (a) when included in Schedule 5; or
   (b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.
5 KITASAMYCIN in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.
4 LABETALOL.
4 LACIDIPINE.
4 LACOSAMIDE.
7 LAMBDA-CYHALOTHрин except when included in Schedule 5 or 6.
6 LAMBDA-CYHALOTHрин:
   (a) in aqueous preparations containing 25 per cent or less of microencapsulated lambda-cyhalothrin; or
   (b) in other preparations containing 1.6 per cent or less of lambda-cyhalothrin, except when included in Schedule 5.
5 LAMBDA-CYHALOTHрин:
   (a) in aqueous preparations containing 1 per cent or less of lambda-cyhalothrin; or
   (b) in aqueous preparations containing 2.5 per cent or less of microencapsulated lambda-cyhalothrin.
4 LAMIVUDINE.
4 LAMOTRIGINE. (Appendix A)
4 LANATOSIDES.
4 LANREOTIDE.
4 LANSOPRAZOLE except when included in Schedule 3.
LANSOPRAZOLE in oral preparations containing 15 mg or less per dosage unit of lansoprazole for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days of supply.

LANTHANUM for therapeutic use.

LAPATINIB.

LARONIDASE.

LAROPIPRANT.

LASALOCID except in animal feeds containing 100 mg/kg or less of antibiotic substances.

LATAMOXEF.

LATANOPROST.

LAURETH CARBOXYLIC ACIDS (excluding its salts and derivatives) except:

(a) in leave-on preparations containing 1.5 per cent or less of laureth carboxylic acids;
(b) in wash-off preparations containing 30 per cent or less of laureth carboxylic acids and, if containing more than 5 per cent laureth carboxylic acids, when labelled with a warning to the following effect:
   IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or
in other preparations containing 30 per cent or less of laureth carboxylic acids and, if containing more than 5 per cent laureth carboxylic acids, when labelled with warnings to the following effect:
   IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and
   IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

LAUDEXIUM.

LAUROMACROGOLS in preparations for injection except:

(a) when present as an excipient; or
(b) when separately specified in these Schedules.

LAURYLISOQUINOLINIUM BROMIDE.

LEAD COMPOUNDS except:

(a) when included in Schedule 4 or 5;
(b) in paints, tinters, inks or ink additives;
(c) in preparations for cosmetic use containing 100 mg/kg or less of lead;
(d) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 100 mg/kg or less of lead; or
(e) in ceramic glazes when labelled with the warning statement:
   CAUTION - Harmful if swallowed. Do not use on surfaces which contact food or drink.
   written in letters not less than 1.5 mm in height.

LEAD for human therapeutic use.

LEAD COMPOUNDS in preparations for use as hair cosmetics.

LEAD COMPOUNDS in paints, tinters, inks or ink additives except in preparations containing 0.1 per cent or less of lead calculated on the non-volatile content of the paint, tinter, ink or ink additive.

LEDIPASVIR.

LEFETAMINE.

LEFLUNOMIDE.
LEMON OIL except:
(a) when steam distilled or rectified;
(b) in preparations for internal use;
(c) in preparations containing 0.05 per cent or less of lemon oil;
(d) in soaps or bath or shower gels that are washed off the skin;
(e) in preparations other than medicines for human therapeutic use, when packed in containers labelled with the statement: Application to skin may increase sensitivity to sunlight; or
(f) in medicines for human therapeutic use, when packed in containers and compliant with the requirements of the Required Advisory Statements for Medicine Labels.

LEMONGRASS OIL in cosmetic and household cleaning preparations except in preparations containing 5 per cent or less of 3,7-dimethyl-2,6-octadienal.

LENALIDOMIDE.
LENOGRASTIM.
LEPIRUDIN.
LEPTAZOL.
LEPTOPHOS.
LEPTOSPERMUM SCOPARIUM OIL (manuka oil) except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings: KEEP OUT OF THE REACH OF CHILDREN; and NOT TO BE TAKEN;
(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings: KEEP OUT OF THE REACH OF CHILDREN; and NOT TO BE TAKEN; or
(e) in preparations containing 25 per cent or less of Leptospermum scoparium oil.
LERCANIDIPINE.
LETROZOLE.
LEUPRORELIN.
LEVALLORPHAN.
LEVAMISOLE:
(a) for human therapeutic use; or
(b) in preparations for the prevention or treatment of heartworm in dogs.
LEVAMISOLE in preparations containing 15 per cent or less of levamisole for the treatment of animals except:
(a) when included in Schedule 4; or
(b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LEVAMISOLE for the treatment of animals except:
(a) when included in Schedule 4 or 5; or
(b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LEVAMPHETAMINE.
LEVETIRACETAM.
LEVOBUNOLOL.
LEVOBUPIVACAINE.
LEVOCABASTINE except when included in Schedule 2. (Appendix A)
LEVOCABASTINE in topical eye or nasal preparations.
LEVODOPA.
LEVOMEPROMAZINE.
LEVOMETHAMPHETAMINE.
LEVOMETHORPHAN (excluding its stereoisomers).
LEVOMORAMIDE.
LEVONORGESTREL except when included in Schedule 3.
LEVONORGESTREL for emergency post-coital contraception.
LEVOPHENACYLMORPHAN.
LEVORPHANOL (excluding its stereoisomers).
LEVOSIMENDAN.
LIDOFLAZINE.
LIGNOCAINE except:
(a) when included in Schedules 2 or 5;
(b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances per dosage unit; or
(c) in lozenges containing 30 mg or less of total anaesthetic substances per dosage unit
LIGNOCAINE in aqueous gel preparations containing 4.5 per cent or less of lignocaine, for the dermal spray-on treatment of wounds associated with 'mulesing' of sheep.
LIGNOCAINE in preparations for topical use other than eye drops:
(a) containing 10 per cent or less of total local anaesthetic substances, except in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
(b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
LIGULARIA DENTATA for therapeutic use.
LIME OIL except:
(a) when steam distilled or rectified;
(b) in preparations for internal use;
(c) in preparations containing 0.5 per cent or less of lime oil;
(d) in soaps or bath or shower gels that are washed off the skin;
(e) in preparations other than medicines for human therapeutic use, when packed in containers labelled with the statement:
Application to skin may increase sensitivity to sunlight; or
(f) in medicines for human therapeutic use, when packed in containers and
compliant with the requirements of the Required Advisory Statements for Medicine
Labels.

LINALOPEGITIN.
LINCOSMYCIN.
LINDANE except when included in Schedule 2, 4 or 5.
LINDANE in preparations containing 10 per cent or less of lindane except when
included in Schedule 2 or 4.
LINDANE for human therapeutic use except when included in Schedule 2.
LINDANE in preparations for human external therapeutic use containing 2 per cent
or less of lindane.
LINEZOLID.
LIOTHYRONINE.
LIRAGLUTIDE.
LISDEXAMFETAMINE. (Clauses 84,90,98,101,122, Appendix A)
LISINOPRIL.
LISURIDE.
LITHIUM for therapeutic use except:
(a) when included in Schedule 2;
(b) when present as an excipient in preparations for dermal use containing 0.25 per
cent or less of lithium; or
(c) in preparations containing 0.01 per cent or less of lithium.
LITHIUM in preparations for dermal use containing 1 per cent or less of lithium
except:
(a) when present as an excipient at 0.25 per cent or less of lithium; or
(b) in preparations containing 0.01 per cent or less of lithium.
LITHIUM PERFLUOROOCTANE SULFONATE except in sealed bait stations
containing 1 per cent or less of lithium perfluorooctane sulfonate.
LIXISENATIDE.
LOBELIA INFLATA except for smoking or burning.
LOBELINE except in preparations for smoking or burning.
LODOXAMIDE except when included in Schedule 2.
LODOXAMIDE in preparations for ophthalmic use.
LOFEXIDINE.
LOGIPARIN for internal use.
LOMEFLOXACIN.
LOMUSTINE.
LOPERAMIDE except:
(a) when included in Schedule 2; or
(b) in divided oral preparations containing 2 mg or less of loperamide per dosage
unit, in a primary pack containing 8 dosage units or less.
LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or
less except in preparations containing 2 mg or less of loperamide per dosage unit,
in a primary pack containing 8 dosage units or less.
LOPINAVIR.
LOPRAZOLAM.
LORACARbef.

LORATADINE except:
(a) when included in Schedule 2; or
(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
(i) in a primary pack containing 5 dosage units or less; and
(ii) labelled with a recommended daily dose not exceeding 10 mg of loratadine.

LORATADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
(a) in a primary pack containing 5 dosage units or less; and
(b) labelled with a recommended daily dose not exceeding 10 mg of loratadine.

LORAZEPAM. (Appendix A, Appendix D)

LORMETAZEPAM.

LOSARTAN.

LOTEPREDNOL.

LOXAPINE.

Exempt:
LUBRICANTS except soluble oils and solvent deposited lubricating agents.

LUFENURON except:
(a) in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or
(b) in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.

LUMEFANTRINE.

LUMIRACOXIB.

LURASIDONE. (Appendix A)

LUTEINISING HORMONE except in ovulation test kits. (Clauses 37, 52, 60)

LYMECYCLINE.

LYSERGIC ACID.

LYSERGIDE.

MACITENTAN.

MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.

MACROGOLS in preparations for oral use as a liquid concentrate for laxative use.

MADURAMICIN except:
(a) when included in Schedule 5; or
(b) in animal feeds containing 5 mg/kg or less of antibiotic substances.

MADURAMICIN in animal feed premixes containing 1 per cent or less of antibiotic substances.

MAFENIDE except when included in Schedule 6.

MAFENIDE when packed and labelled for the treatment of ornamental fish only.

MAGNESIUM CHLORATE except in preparations containing 10 per cent or less of magnesium chloride.

MAGNESIUM SULFATE for human therapeutic use in divided oral preparations except when containing 1.5 g or less of magnesium sulfate per recommended daily dose.
MALACHITE GREEN for veterinary use except when included in Schedule 5.
MALACHITE GREEN in preparations for veterinary use containing 10 per cent or less of malachite green.
MALATHION in preparations for human external use except in preparations containing 2 per cent or less of malathion.
MALATHION except:
(a) when included in Schedule 5;
(b) for human therapeutic use; or
(c) in dust preparations containing 2 per cent or less of malathion.
MALATHION in preparations containing 10 per cent or less of malathion except:
(a) for human therapeutic use; or
(b) in dust preparations containing 2 per cent or less of malathion.
MANCOZEB.
MANDIPROPAMID.
MANDRAGORA OFFICINARUM.
MANNITYL HEXANITRATE for therapeutic use.
MANNOMUSTINE.
MAPROTLINE.
MARAVIROC.
MARBOFLOXACIN.
MARJORAM OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning: KEEP OUT OF THE REACH OF CHILDREN; or
(c) in preparations containing 50 per cent or less of marjoram oil.
MAROPITANT.
Exempt MATCHES.
MAVACOXIB.
MAZINDOL. (Appendix A, Appendix D)
MAZIDOX.
MBCA - see METHYLENE BIS-(2-CHLOROANILINE)
MCPA except when included in Schedule 5.
MCPA
(a) in preparations containing 25 per cent or less of MCPA (acid); or
(b) in preparations containing 50 per cent or less of the salts and esters of MCPA.
MCPB.
MEASLES VACCINE.
MEBANAZINE.
MEBENDAZOLE for human therapeutic use.
MEBENDAZOLE for the treatment of animals except when included in Schedule 5.
MEBENDAZOLE for the treatment of animals;
(a) in divided preparations each containing 300 mg or less of mebendazole per
dosage unit; or
(b) in undivided preparations containing 25 per cent or less of mebendazole.

MEBEVERINE.
MEBHYDROLIN. (Appendix A)
MEBOLAZINE. (Appendix B, Appendix D)
MEBUTAMATE.
MECAMYLAMINE.
MECARBAM.
MECASERMIN.
MECILLINAM.
MECLOCYCLINE.
MECLOFENAMATE.
MECLOFENAMIC ACID for the treatment of animals.
MECLOFENOXATE.
MECLOQUALONE.
MECLOZINE except when included in Schedule 2. (Appendix A)
MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, except in preparations for the treatment of children under two years of age.
MECOPROP except when included in Schedule 5.
MECOPROP in preparations containing 2 per cent or less of mecoprop.
MECOPROP-P.
MEDAZEPAM. (Appendix A, Appendix D)
MEDETOMIDINE.

Exempt MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS.
Exempt MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the Therapeutic Goods (Medical Devices) Regulation 2002, as in force from time to time, except:
(a) injectable tissue reconstructive, augmentation and restoration materials, including collagen;
(b) medical devices which include anticoagulants;
(c) artificial tears;
(d) urinary catheters; or
(e) intra-articular fluids.
MECOPROP-P.
MEDROXYPROGESTERONE.
MEDRYSONE.
MEFENAMIC ACID except when included in Schedule 2.
MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhea.
MEFENOREX. (Appendix D)
MEFENPYR-DIETHYL.
MEFLOQUINE.
MEFLUIDIDE.
MEFRUSIDE.
MEGESTROL.
MELAGATRAN.

MELALEUCA OIL (Tea-tree oil) except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF THE REACH OF CHILDREN; and
NOT TO BE TAKEN;
(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
(e) in preparations containing 25 per cent or less of melaleuca oil.

MELATONIN for human use.

MELENGESTROL except when included in Schedule 6.
MELENGESTROL ACETATE when used as an animal feed additive.
MELIA AZEDARACH including its extracts and derivatives.
MELOXICAM.
MELPHALAN.
MEMANTINE.
MENAZON.
MENINGOCOCCAL VACCINE.
MENOTROPHIN.
MEPACRINE.
MEPENZOLATE.
MEPENESIN.
MEPHENTERMINE.
MEPINDOLOL.
MEPIQUAT.
MEPITIOSTANE. (Appendix B, Appendix D)
MEPIVACAINE.
MEPROBAMATE. (Appendix A, Appendix D)
MEPTAZINOL.
Mepyramine except when included in Schedule 2 or 3. (Appendix A)
Mepyramine in oral preparations. (Appendix A)
Mepyramine for dermal use.
MEQUITAZINE.
MERCAPTOMERIN.
2-MERCAPTOETHANOL in preparations for use as insect lures.
MERCAPTOPURINE.

MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes.

MERCURIC OXIDE for the treatment of animals, in preparations for ocular use.

MERCUROCHROME except when included in Schedule 2 or 6.

MERCUROCHROME in preparations for external use containing 2 per cent or less of mercurochrome except when included in Schedule 6.

MERCUROCHROME for the treatment of animals, in preparations for topical use.

MERCURY except:
(a) when separately specified in this Schedule;
(b) when included in Schedule 2, 4 or 6;
(c) in preparations containing 0.01 per cent or less of mercury in organic form as a preservative;
(d) mercury (metallic) in scientific instruments;
(e) dental amalgams; or
(f) in a sealed device, for therapeutic use, which prevents access to the mercury.

MERCURY for cosmetic or therapeutic use except:
(a) when separately specified in these Schedules; or
(b) in a sealed device which prevents access to the mercury.

MERCURY for external use in preparations containing 0.5 per cent or less of mercury.

MEROPENEM.

MERSALYL.

MESABOLONE. (Appendix B, Appendix D)

MESALAZINE.

MESNA.

MESOTRIONE.

MESTANOLONE (androstalone). (Appendix B, Appendix D)

MESTEROLONE. (Appendix B, Appendix D)

MESTRANOL.

METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals.

METAFLUMIZONE.

METALAXYL except when included in Schedule 5.

METALAXYL in preparations containing 35 per cent or less of metalaxyl.

METALDEHYDE except when included in Schedule 5.

METALDEHYDE in preparations containing 2 per cent or less of metaldehyde.

METANDIENONE. (Appendix B, Appendix D)

METARAMINOL.

METAZOCINE.

METENOLONE. (Appendix B, Appendix D)

METERGOLINE.

METFORMIN.

METHABENZTHIAZURON.

METHACHOLINE.

METHACRIFOS except when included in Schedule 6.
METHACRIFOS in preparations containing 60 per cent or less of methacrifos.
METHACYCLINE.
METHADONE. (Appendix A, Clauses 91 to 94A, 123)
METHALLENOSTRIL.
METHAM.
METHAMIDOPHOS.
METHANDRIOL. (Appendix B, Appendix D)
METHANOL (excluding its derivatives) except:
(a) when included in Schedule 5; or
(b) B2979 in preparations containing 2 per cent or less of methanol.
METHANOL (excluding its derivatives) in preparations containing 10 per cent or less of methanol except in preparations containing 2 per cent or less of methanol.
METHANTHELINIUM.
METHAPYRILENE.
METHAQUALONE.
METHAZOLAMIDE.
METHAZOLE.
METHCATHINONE.
METHDILAZINE except when included in Schedule 3. (Appendix A)
METHDILAZINE in oral preparations. (Appendix A)
METHENOLONE. (Appendix B, Appendix D)
METHICILLIN.
METHIDATHION.
METHIMAZOLE.
METHIOCARB except when included in Schedule 5 or 6.
METHIOCARB in preparations containing 20 per cent or less of methiocarb except when included in Schedule 5.
METHIOCARB in pelleted preparations containing 2 per cent or less of methiocarb.
METHISAZONE.
METHIXENE.
METHOCARBAMOL. (Appendix A)
METHOHEXITONE. (Appendix D)
METHOIN.
METHOMYL except when included in Schedule 6.
METHOMYL in fly-baits containing 1 per cent or less of methomyl and not less than 0.002 per cent of denatonium benzoate as a bittering agent.
METHOTREXATE.
METHOXAMINE except:
(a) when included in Schedule 2; or
(b) in preparations for external use containing 1 per cent or less of methoxamine.
METHOXAMINE in preparations for external use except containing 1 per cent or less of methoxamine.
2-METHOXYETHANOL and its acetates except in preparations containing 0.5 per cent or less of 2-methoxyethanol.
METHOXSALEN.
METHOXYPHENYL.
7 METHOXYETHYLMERCURIC ACETATE.
7 METHOXYETHYLMERCURIC CHLORIDE.
4 METHOXYFLURANE.
9 5-METHOXY- a -METHYLTRYPTAMINE *(5-MeO-AMT).
9 5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE *(MDMA).
9 4-METHOXY- a -METHYLPHENYLETHYLAMINE *(PMA).
2 METHOXYPHENAMINE.
4 METHOXYPHENETHYLAMINE - see MESCALINE.
9 2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE *(JWH-250).
4 METHSUXIMide.
4 METHYCLOTHIAZIDE.
9 METHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2H-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE *(SALVINORIN A).
4 METHYL AMINOLEVULINATE.
4 METHYLAMINOREX.
8 METHYLAMPHETAMINE. (Clauses 84,90,98,101,122)
4 METHYLANDROSTANOLONE. (Appendix B, Appendix D)
5 METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) except:
(a) when included in preparations or admixtures; or
(b) when packed in containers having a capacity of more than 5 litres.
7 METHYL BROMIDE.
4 METHYLBESTEHEL. (Appendix B, Appendix D)
7 METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL except:
(a) when included in Schedule 6;
(b) when used in laboratory analysis; or
(c) when packed for industrial use in containers with a nominal capacity of 100 L or more.
6 METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL in preparations containing 10 per cent or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a child-resistant closure.
9 METHYLDOPA.
4 METHYL-4,4'-METHYLENEBIS[2-CHLOROANILINE] (MOCA).
6 METHYLENE BISTHIOCYANATE except in preparations containing 1 per cent or less of methylene bisthiocyanate.
7 METHYLENE BLUE for veterinary use except when included in Schedule 4 or 5.
4 METHYLENE BLUE in preparations for injection.
5 METHYLENE BLUE in preparations for veterinary use containing 50 per cent or less of methylene blue.
9 3,4-METHYLENEDIOXYAMPHETAMINE *(MDA).
3,4-METHYLENEDIOXYPYROVALERONE *(MDPV).

METHYLEPHEDRINE.

METHYLERGOMETRINE.

METHYL ETHYL KETONE except in preparations containing 25 per cent or less of designated solvents.

METHYL ETHYL KETONE OXIME except:
   a. in viscous silicone adhesives or viscous silicone sealants containing 2.5% or less of methyl ethyl ketone oxime; or
   b. in other preparations containing 1 per cent or less of methyl ethyl ketone oxime.

METHYL ETHYL KETONE PEROXIDE.

METHYLEUGENOL except in preparations containing 1 per cent or less of methyleugenol.

3-METHYLFLUNITRILE.

METHYL ISOAMYL KETONE except in preparations containing 25 per cent or less of designated solvents.

METHYL ISOBUTYL KETONE except in preparations containing 25 per cent or less of designated solvents.

METHYL ISOTHIOCYANATE.

METHYL MERCURY for therapeutic use.

METHYL METHACRYLATE for cosmetic use except in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.

METHYL MERCURY for therapeutic use.

METHYL METHACRYLATE (excluding its derivatives) except:
   (a) for cosmetic use; or
   (b) in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.

METHYL MERCURY for therapeutic use.

METHYL NALTREXONE.

METHYL NEODECANAMIDE except in liquid preparations containing 2 per cent or less of methyl neodecanamide.

METHYL NORBORNYL PYRIDINE.

METHYL PENTYNOL.

METHYLPHENIDATE. (Clauses 84, 90, 98, 101, 122, Appendix A)

METHYLPHENOBARBITONE. (Appendix A, Appendix D)

1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (Pethidine intermediate C).

1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE *(MPPP).

METHYLPREDNISOLONE.

N-METHYL-2-PYRROLIDONE except:
   (a) when included in Schedule 5; or
   (b) in preparations containing 25 per cent or less of designated solvents.

N-METHYL-2-PYRROLIDONE:
   (A) when packed in single-use containers having a capacity of 2 mL or less; or
(b) in preparations containing 50 per cent or less of N-methyl-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-methyl-2-pyrrolidone, N-(N-octyl)-2-pyrrolidone or N-(N-dodecyl)-2-pyrrolidone except in preparations containing 25 per cent or less of designated solvents.

**5** METHYL SALICYLATE in preparations containing 25 per cent or less of methyl salicylate except:
(a) in preparations for therapeutic use; or
(b) in preparations containing 5 per cent or less of methyl salicylate.

**4** METHYL SALICYLATE in preparations for internal therapeutic use.

**6** METHYL SALICYLATE except:
(a) when included in Schedule 5;
(b) in preparations for therapeutic use; or
(c) in preparations containing 5 per cent or less of methyl salicylate.

**4** METHYLTESTOSTERONE. (Appendix B, Appendix D)

**9** 4-METHYLMETHAMPHETAMINE.

**9** 3-METHYLTHIOFENTANYL.

**5** 2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5-TRIAZINE.

**4** METHYLTHIOURACIL.

**4** 4-METHYLTRIENOLONE. (Appendix B, Appendix D)

**4** METHYPRYLONE. (Appendix D)

**4** MEFYSERGIDE.

**5** METIRAM.

**4** METOCLOPRAMIDE except when included in Schedule 3.

**3** METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.

**6** METOFLUTHRIN except when included in Schedule 5.

**5** METOFLUTHRIN in impregnated fabric mosquito repellent preparations for use in a vaporizer containing 15 mg or less of metofluthrin per disk.

**5** METOLACHLOR.

**4** METOLAZONE.

**9** METOPON.

**4** METOPROLOL.

**6** METOSULAM.

**6** METRAFENONE except when included in Schedule 5.

**5** METRAFENONE in preparations containing 50 per cent or less of metrafenone.

**4** METRIBOLONE. (Appendix B, Appendix D)

**6** METRIBUZIN.

**4** METRIFONATE (trichlorfon) for human therapeutic use.

**4** METRONIDAZOLE.

**4** METYRAPONE.

**7** MEVINPHOS.

**4** MEXILETINE.

**4** MEZLOCILLIN.

**4** MIANSERIN. (Appendix A)
MIBEFRADIL.

MIBOLERONE. (Appendix B, Appendix D)

MICAFUNGIN.

MICONAZOLE except:
(a) when included in Schedule 2, 3 or 6; or
(b) in preparations for dermal use for the treatment of tinea pedis.

MICONAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.

MICONAZOLE for human use in topical preparations
(a) for the treatment of oral candidiasis; or
(b) for vaginal use.

MICONAZOLE for the external treatment of animals.

MIDAZOLAM. (Appendix D)

MIDODRINE.

MIFEPRISTONE.

MIGLITOL.

MIGLUSTAT.

MILBEMECTIN except when included in Schedule 5.

MILBEMECTIN in preparations containing 1 per cent or less of milbemectin.

MILBEMYCIN OXIME except when included in Schedule 5.

MILBEMYCIN OXIME for the prophylaxis of heartworm in dogs and cats.

MILRINONE.

MINOCYCLINE.

MINOXIDIL except when included in Schedule 2.

MINOXIDIL in preparations for dermal use containing 5 per cent or less of minoxidil.

MIPAFOX.

MIRABEGRON.

MIREX.

MIRTAZAPINE. (Appendix A)

MISOPROSTOL.

MITOBRONITOL.

MITOMYCIN.

MITOTANE.

MITOXANTRONE.

MITRAGYNA SPECIOSA.

MITRAGYNINE.

MITRATAPIDE.

MIVACURIUM CHLORIDE.

MOCLOBEMIDE.

MODAFINIL.

MOLGRAMOSTIM.

MOLINATE.

MOLINDONE.

MOMETASONE except when included in Schedule 2.
MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.

MONENSIN except:
(a) when included in Schedule 5 or 6; or
(b) in animal feeds containing 360 mg/kg or less of antibiotic substances.

MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.

MONENSIN:
(a) in animal feed premixes containing 12.5 per cent or less of antibiotic substances; or
(b) in stockfeed supplements, blocks or licks containing 0.75 per cent or less of antibiotic substances.

MONOCLONAL ANTIBODIES for therapeutic use except:
(a) in diagnostic test kits; or
(b) when separately specified in these Schedules.

MONOBENZONE and alkyl ethers of hydroquinone for human therapeutic use or cosmetic use except in cosmetic nail preparations containing 0.02 per cent or less of monobenzene or alkyl ethers of hydroquinone.

MONOCLONAL ANTIBODIES for therapeutic use except:
(a) in diagnostic test kits; or
(b) when separately specified in these Schedules.

MONEPANTEL.

MONOCLONAL ANTIBODIES for therapeutic use except:
(a) in diagnostic test kits; or
(b) when separately specified in these Schedules.

MORANTEL except:
(a) when included in Schedule 5; or
(b) in preparations containing 10 per cent or less of morantel.

MORANTEL in preparations containing 25 per cent or less of morantel except in preparations containing 10 per cent or less of morantel.

MORAZONE.

MORICIZINE.

MORPHERIDINE.

MORPHINE. (Appendix A)

MORPHINE METHOBROMIDE.

MORPHINE-N-OXIDE.

(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE *(JWH-200).

Exempt MOTOR, HEATING or FURNACE FUELS except:
(a) when the contrary intention appears in any Schedule;
(b) when containing methanol;
(c) toy or hobby fuels; or
(d) petrol or kerosene when packed in containers having a capacity of 20 litres or less.

MOTRAZEPAM.

MOTRETINIDE.

MOXIDECTIN except when included in Schedule 4, 5 or 6.
MOXIDECTIN in preparations for injection containing 10 per cent or less of moxidectin except when included in Schedule 5.

MOXIDECTIN for external use:
(a) in preparations containing 2.5 per cent or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or
(b) in preparations containing 2 per cent or less of moxidectin for the treatment of animals, except when included in Schedule 5.

MOXIDECTIN:
(a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5 per cent or less of moxidectin;
(b) in preparations for external use for the treatment of cats and dogs, containing 2.5 per cent OR less of moxidectin packed in single dose tubes with a volume of 1 mL or less; or
(c) for internal use for the treatment of animals;
(i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or
(ii) in other preparations containing 2 per cent or less of moxidectin.

MOXIFLOXACIN.

MOXONIDINE.

MSMA except when included in Schedule 6.

MSMA in herbicide or defoliant preparations containing 10 per cent or less of MSMA.

MUMPS VACCINE.

MUPIROCIN.

MURAGLITAZAR.

MUROMONAB.

MUSCIMOL.

MUSTINE (nitrogen mustard).

MYCLOBUTANIL.

MYCOPHENOLIC ACID (including mycophenolate mofetil).

MYROPINE.

NAA except in preparations containing 25 per cent or less of NAA.

NABILONE.

NABIXIMOLS (botanical extract of Cannabis sativa which includes the following cannabinoids: tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acid, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinol and cannabinol (in approximately equal proportions) comprise not less than 90 per cent of the total cannabinoid content) in a buccal spray for human therapeutic use. (Clauses 84,90,98,101,122, Appendix A)

NABUMETONE.

NADOLOL.

NADROPARIN.

NAFARELIN.

NAFTIDROFURYL.

NALBUPHINE. (Appendix A, Appendix D)

NALED except when included in Schedule 5.
NALED when impregnated in plastic resin strip material containing 20 per cent or less of naled.

NALIDIXIC ACID.

NALMAFENE

NALORPHINE.

NALOXONE.

NALTREXONE.

NANDROLONE. (Appendix B, Appendix D)

NAPHAZOLINE.

NAPHTHALENE (excluding its derivatives) except in liquid hydrocarbons as an impurity.

NAPHTHALOPHOS except when included in Schedule 6.

NAPHTHALOPHOS in preparations containing 80 per cent or less of naphthalophos.

NAPHTHOYLINDOLES except when separately specified in these Schedules.

NAPHTHYLMETHYLINDOLES except when separately specified in these Schedules.

NAPHTHOYLPYRROLES except when separately specified in these Schedules.

NAPHTHYLMETHYLINDENES except when separately specified in these Schedules.

NAPROXEN except when included in Schedule 3 or in Schedule 2.

NAPROXEN in a modified release dosage form of 600 mg or less of naproxen per dosage unit in packs of 16 or less dosage units when labelled not for the treatment of children under 12 years of age.

NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.

NAPTALAM.

NAPTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE *(JWH-073).

NARASIN except:

(a) when included in Schedule 6; or
(b) in animal feeds containing 100 mg/kg or less of antibiotic substances.

NARASIN in animal feed premixes containing 12 per cent or less of narasin.

NARATRIPTAN.

NATALIZUMAB.

NATAMYCIN except for use as a food additive.

NATEGLINIDE.

NEBACUMAB.

NEBIVOLOL.

NEODOCROMIL.

NEFAZODONE.

NEFOPAM.

NELFINAVIR (includes nelfinavir mesylate).

NEOMYCIN.

NEOSTIGMINE.

NEPAFENAC.

NERIUM OLEANDER.

NESIRITIDE.
NETILMICIN.

NETOBIMIN for the treatment of animals except when included in Schedule 5.

NETOBIMIN for the treatment of animals, in preparations containing 12.5 per cent or less of netobimin.

NEVIRAPINE.

NIALAMIDE.

NICARDIPINE.

NICERGOLINE.

NICLOSAMIDE for human therapeutic use.

NICEL SULFATE.

NICOCODINE.

NICODICODINE.

NICOFURANOSE.

NICOMORPHINE.

NICORANDIL.

NICOTINE except:
(a) when included in Schedule 6;
(b) in preparations for human therapeutic use; or
(c) in tobacco prepared and packed for smoking.

NICOTINE in preparations for human therapeutic use except for use as an aid in withdrawal from tobacco smoking in preparations for oromucosal or transdermal use.

NICOTINE in preparations containing 3 per cent or less of nicotine when labelled and packed for the treatment of animals.

NICOTINIC ACID for human therapeutic use except:
(a) when contained in other Schedules;
(b) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
(c) nicotinamide.

NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit except:
(a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
(b) nicotinamide.

NICOTINYL ALCOHOL except in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit.

NICOUMALONE.

NIFEDIPINE.

NIFENAZONE.

NIKETHAMIDE.

NILOTINIB.

NILUTAMIDE.

NIMESULIDE.

NIMIDANE except when included in Schedule 6.

NIMIDANE in preparations containing 25 per cent or less of nimidane.

NIMODIPINE.

NIMORAZOLE.

NIRIDAZOLE.

NISIN - see exemption under ANTIBIOTICS
NISOLDIPINE.

NITENPYRAM except in divided preparations containing 100 mg or less of nitenpyram.

NITISINONE.

NITRATES, ORGANIC. see glycercyl trinitrate.

NITRAZEPAM. (Appendix A, Appendix D)

NITRENDIPINE.

NITRIC ACID (excluding its salts and derivatives) except:
(a) when included in Schedule 5; or
(b) in preparations containing 0.5 per cent or less of nitric acid (HNO3).

NITRIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of nitric acid (HNO3) except in preparations containing 0.5 per cent or less of nitric acid.

NITRIC OXIDE for human therapeutic use.

NITROBENZENE except:
(a) in solid or semi-solid polishes;
(b) in soaps containing 1 per cent or less of nitrobenzene; or
(c) in other preparations containing 0.1 per cent or less of nitrobenzene.

NITROFEN.

NITROFURANTOIN.

NITROFURAZONE.

NITROPHENOLS, ortho, meta and para, except when separately specified in these Schedules.

NITROPRUSSIDES except when included in Schedule 4 or 6.

NITROPRUSSIDES in preparations containing 2.5 per cent or less of nitroprussides except when included in Schedule 4.

NITROSCANATE for the treatment of animals.

2-NITROTOLUENE.

NITROUS OXIDE for therapeutic use.

NITROXOLINE.

NITROXYNIL.

NIZATIDINE except when included in Schedule 2.

NIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days supply.

NOMÆGESTROL.

NOMIFENSINE.

NONOXINOL 9 except:
(a) when included in Schedule 5;
(b) in preparations containing 25 per cent or less of nonoxinol 9 when labelled with the statements: IRRITANT; and
Avoid contact with eyes;
(c) in preparations containing 12.5 per cent or less of nonoxinol 9; or
(d) in preparations for human use.

NONOXINOL 9 in preparations containing 25 per cent or less of nonoxinol 9 except:
(a) when labelled with the statements:
IRRITANT; and
Avoid contact with eyes;
(b) in preparations containing 12.5 per cent or less of nonoxinol 9; or
(c) in preparations for human use.
9
NORACYMETHADOL.
4
NORADRENALINE.
4
19-NORANDROSTENEDIOL. (Appendix B, Appendix D)
4
19-NORANDROSTENEDIONE. (Appendix B, Appendix D)
4
NORANDROSTENOLONE. (Appendix B, Appendix D)
4
NORBOLETHONE. (Appendix B, Appendix D)
5
NORBORMIDE.
4
NORCLOSTEBOL. (Appendix B, Appendix D)
8
NORCODEINE.
4
NORELGESTROMIN.
4
NORETHANDROLONE. (Appendix B, Appendix D)
4
NORETHISTERONE.
4
NORFLOXACIN.
4
NORGESTREL.
4
NORIBOGAINE.
9
NORLEVORPHANOL.
4
NORMAL HUMAN IMMUNOGLOBULIN.
8
NORMETHADONE. (Appendix A)
4
NORMETHANDRONE. (Appendix B, Appendix D)
9
NORMORPHINE.
9
NORPIPANONE.
4
NORTRIPTYLINE. (Appendix A)
2
NOSCAPINE.
4
NOVOBIOCIN.
4
NOVUPIRYLINE.
5
NUTMEG OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a
nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant
with the requirements of the Required Advisory Statements for Medicine Labels;
(b) in preparations other than medicines for human therapeutic use, when packed in
containers having a nominal capacity of 25 mL or less fitted with a restricted flow
insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c) in preparations containing 50 per cent or less of nutmeg oil.
Exempt  NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL
ADMINISTRATION.
4
NYSTATIN except when included in Schedule 2 or 3.
3
NYSTATIN in preparations for topical use except when included in Schedule 2.
2
NYSTATIN in dermal preparations.
4
OCLACITINIB.
4
OCRIPLASMIN.
OCTAMYLAMINE.

OCTATROPINE.

1-OCTEN-3-OL except in preparations containing 5 per cent or less of 1-octen-3-ol.

OCTHILINONE except in paints, jointing compounds and sealants containing 1 per cent or less of octhilinone calculated on the non-volatile content.

OCTREOTIDE.

N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE except in preparations containing 10 per cent or less of N-octyl bicycloheptene dicarboximide.

OCTYL NITRITE.

N-(N-octyl)-2-pyrrolidone except:
(a) when included in Schedule 5; or
(b) in preparations containing 25 per cent or less of designated solvents.

N-(N-octyl)-2-pyrrolidone in preparations containing 50 per cent or less of N-(N-octyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-octyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or N-(N-dodecyl)-2-pyrrolidone except in preparations containing 25 per cent or less of designated solvents.

OESTRADIOL except when included in Schedule 5.

OESTRADION in implant preparations for growth promotion in animals.

OESTRIOL.

OESTROGENS except when separately specified in these Schedules.

OESTRONE.

OFATUMUMAB.

OFLOXACIN.

OILS, MINERAL AND PARAFFIN - see HYDROCARBONS, LIQUID.

OLANZAPINE. (Appendix A)

OLAQUINDOX except in preparations containing 10 per cent or less of olaquindox.

OLEANDOMYCIN except:
(a) when included in Schedule 5; or
(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

OLEANDOMYCIN in animal feed premixes for growth promotion.

OLEANDRIN.

N-OLEYL-1,3-DIAMINOPROPANE.

OLMESARTAN.

OLODATEROL.

OLOPATADINE.

OLSALAZINE.

OMALIZUMAB.

OMBITASVIR.

OMEGA-3-ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic use for the treatment of post-myocardial infarction and/or hypertriglyceridaemia.

OMEPRAZOLE except when included in Schedule 3.

OMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit of omeprazole for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days of supply.
OMETHOATE except when included in Schedule 5 or 6.  
OMETHOATE in preparations containing 30 per cent or less of omethoate except when included in Schedule 5.  
OMETHOATE in pressurised spray packs containing 0.2 per cent or less of omethoate.  
ONDANSETRON.  
OPIPRAMOL.  
OPIUM except the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4. (Appendix A)  
ORANGE OIL (BITTER) except:  
(a) when steam distilled or rectified;  
(b) in preparations for internal use;  
(c) in preparations containing 1.4 per cent or less of orange oil;  
(d) in soaps or bath or shower gels that are washed off the skin;  
(e) in preparations other than medicines for human therapeutic use, when packed in containers labelled with the statement: Application to skin may increase sensitivity to sunlight; or  
(f) in medicines for human therapeutic use, when packed in containers and compliant with the requirements of the Required Advisory Statements for Medicine Labels.  
ORBIFLOXACIN.  
ORCIPRENALINE.  
ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use except:  
(a) when separately specified in these Schedules; or  
(b) in preparations containing 2 per cent or less of malathion for external use.  
ORLISTAT except when included in Schedule 3.  
ORLISTAT in oral preparations for weight-control purposes containing 120 mg or less of orlistat per dosage unit.  
ORNIDAZOLE.  
ORNIPRESSIN.  
ORPHENADRINE.  
ORTHOPTERIN.  
OSELTAMIVIR.  
OUABAIN.  
OVANDROTONE. (Appendix B, Appendix D)  
OXABOLONE. (Appendix B, Appendix D)  
OXACILLIN.  
OXADIARGYL.  
OXADIAZON.  
OXADIPIXYL.  
OXALIC ACID except:  
   a. in dental care preparations, including mouthwashes, containing 3% or less of soluble salts of oxalic acid; or  
   b. its insoluble salts.  
OXALIPLATIN.  
OXAMYL.
OXANDROLINE. (Appendix B, Appendix D)
OXANTEL EMBONATE for the treatment of animals.
OXAPROZIN.
OXAZEPAM. (Appendix A, Appendix D)
OXCARBAZEPINE.
OXEDRINE for human internal use except in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.
OXETACAIN (oxethazaine) except when included in Schedule 2.
OXETACAIN (oxethazaine) in preparations for internal use.
OXFENDAZOLE for the treatment of animals.
OXIBENDAZOLE for the treatment of animals.
OXICONAZOLE except:
(a) when included in Schedule 2 or 3; or
(b) in preparations for the treatment of tinea pedis.
OXICONAZOLE for dermal use except in preparations for the treatment of tinea pedis.
OXICONAZOLE in preparations for vaginal use.
OXITROPIUM.
OXOLAMINE.
OXOLIC ACID.
OXPENTIFYLLINE (pentoxifylline).
OXPRENOLOL.
OXYBUPROCAINE.
OXYBUTYNIN.
OXYCARBOXIN.
OXYCLOZANIDE.
OXYCODONE. (Appendix A)
OXYDEMETON METHYL.
OXYMESTERONE. (Appendix B, Appendix D)
OXYMETAZOLINE.
OXYMETHOLONE. (Appendix B, Appendix D)
OXYMORPHONE.
OXYPHENBUTAZONE.
OXYPHENCYCLIMINE.
OXYPHENISATIN for therapeutic use.
OXYPHENONIUM.
OXYTETRACYCLINE except when included in Schedule 5.
OXYTETRACYCLINE in preparations:
(a) for topical application to animals for ocular use only; or
(b) containing 40 per cent or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
OXYTHIOQUINOX.
OXYTOCIN.
PACLITAXEL.
5 PACLOBUTRAZOL.
6 PAECILOMYCES LILACINUS STRAIN 251.
4 PALIFERMIN.
4 PALIPERIDONE. (Appendix A)
4 PALIVIZUMAB.
4 PALONOSETRON.
4 PAMAQUIN.
4 PAMIDRONIC ACID (includes disodium pamidronate).
4 PANCREATIC ENZYMES except:
   (a) in preparations containing 20 000 BP units or less of lipase activity per dosage unit; or
   (b) when separately specified in these Schedules.
4 PANCURONIUM.
4 PANITUMUMAB.
4 PANTOPRAZOLE except when included in Schedule 2 or 3.
3 PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2.
2 PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days’ supply.
2 PAPAVERINE except when included in Schedule 4.
4 PAPAVERINE in preparations for injection.
Exempt PAPER except:
   (a) when prepared for pesticidal use; or
   (b) when containing a poison included in Schedule 8.
4 PARACETAMOL:
   (a) when combined with aspirin or salicylamide or any derivative of these substances except when separately specified in these Schedules;
   (b) when combined with ibuprofen in a primary pack containing more than 30 dosage units;
   (c) in slow release tablets or capsules containing more than 665 mg of paracetamol;
   (d) in non-slow release tablets or capsules containing more than 500 mg of paracetamol;
   (e) in individually wrapped powders or sachets of granules each containing more than 1000 mg of paracetamol; or
   (f) for injection.
3 PARACETAMOL when combined with ibuprofen in a primary pack containing 30 dosage units or less.
2 PARACETAMOL for therapeutic use except:
   (a) when included in Schedule 4;
   (b) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine and/or guaiphenesin or when combined with effervescent agents) when:
      (i) enclosed in a primary pack that contains not more than 10 such powders or sachets of granules;
(ii) compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(iii) not labelled for the treatment of children 6 years of age or less; and
(iv) not labelled for the treatment of children under 12 years of age when combined with phenylephrine and/or guaiphenesin; or
(c) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine and/or guaiphenesin or when combined with effervescent agents) when:
(i) packed in blister or strip packaging or in a container with a child-resistant closure;
(ii) in a primary pack containing not more than 20 tablets or capsules;
(iii) compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(iv) not labelled for the treatment of children 6 years of age or less; and
(v) not labelled for the treatment of children under 12 years of age when combined with phenylephrine and/or guaiphenesin.

PARAFFIN LIQUID - see HYDROCARBONS, LIQUID.

PARAFORMALDEHYDE (excluding its derivatives):
(a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;
(b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;
(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or
(d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde except in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
CONTAINS FORMALDEHYDE.

PARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde except:
(a) for human therapeutic use;
(b) in oral hygiene preparations;
(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;
(d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
PROTECT CUTICLES WITH GREASE OR OIL;
(e) in all other cosmetic preparations; or
(f) in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
CONTAINS FORMALDEHYDE.

PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use except:
(a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or
(b) in other preparations containing 0.2 per cent or less of free formaldehyde.

PARALDEHYDE. (Appendix D)
PARAMETHADIONE.
PARAMETHASONE.
PARAQUAT.

PARATHION.

PARATHION-METHYL except when included in Schedule 6.

PARATHION-METHYL in aqueous preparations containing 45 per cent or less of microencapsulated parathion-methyl.

PARBENDAZOLE.

PARECOXIB.

PARICALCITOL.

PARITAPREVIR.

PAROMOMYCIN.

PAROXETINE.

PAZOPANIB.

PCE - see N-ETHYL-1-PHENCYCLOHEXYLAMINE.

PEBULATE.

PECAZINE.

PEFLOXACIN.

PEGAPTANIB.

PEGFILGRASTIM.

PEGINTERFERON.

PEGVISOMANT.

PEMBROLIZUMAB.

PEMOLINE.

PEMPIDINE.

PENBUTOLOL.

PENCICLOVIR except when included in Schedule 2.

PENCICLOVIR for external use for the treatment of herpes labialis.

PENCONAZOLE.

PENDIMETHALIN.

PENETHAMATE.

PENFLUFEN.

PENICILLAMINE.

PENICILLIN - see BENZYPENICILLIN, PHENETICILLIN AND PHENOXYMETHYLPENICILLIN.

PENNYROYAL OIL except:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings: KEEP OUT OF THE REACH OF CHILDREN; and NOT TO BE TAKEN;
(c) in preparations containing 4 per cent or less of d-pulgone.
7 PENTACHLOROPHENOL except when included in Schedule 6.
6 PENTACHLOROPHENOL in preparations containing 1.5 per cent or less of pentachlorophenol.
4 PENTAERYTHRITYL TETRANITRATE.
4 PENTAGASTRIN.
4 PENTAMETHONIUM.
4 PENTAMIDINE (includes pentamidine isethionate).
8 PENTAZOCINE. (Appendix A)
4 PENTHIENTE.
5 PENTHIOPYRAD except in preparations containing 20 per cent or less of penthiopyrad.
8 PENTOBARBITONE except when included in Schedule 4. (Appendix A)
4 PENTOBARBITONE when packed and labelled for injection. (Appendix A, Appendix B, Appendix D) (for animal destruction Clause 65)
4 PENTOLINIUM.
4 PENTOSAN POLYSULFATE SODIUM.
9 1-PENTYL-3-(4-METHYL-1-NAPHTHOYL)INDOLE *(JWH-122).
9 1-PENTYL-3-(1-NAPHTHOYL)INDOLE *(JWH-018).
6 PERACETIC ACID except when included in Schedule 5.
5 PERACETIC ACID in concentrations of 10 per cent or less of peracetic acid.
4 PERAMPANEL (Appendix A)
6 PERFLUIDONE.
4 PERGOLIDE.
4 PERHEXILINE.
4 PERICYAZINE. (Appendix A)
4 PERINDOPRIL.
6 PERMANGANATES except potassium permanganate in aqueous solutions containing 1 per cent or less of potassium permanganate.
6 PERMETHRIN except:
(a) when included in Schedule 4 or 5;
(b) in preparations for human therapeutic use containing 5 per cent or less of permethrin; or
(c) in preparations containing 2 per cent or less of permethrin.
4 PERMETHRIN for human therapeutic use except in preparations containing 5 per cent or less of permethrin.
5 PERMETHRIN (excluding preparations for human therapeutic use):
(a) in preparations containing 25 per cent or less of permethrin; or
(b) in preparations for external use, for the treatment of dogs, containing 50 per cent or less of permethrin when packed in single use containers having a capacity of 4 mL or less, except in preparations containing 2 per cent or less of permethrin.
4 PERPHENAZINE. (Appendix A)
4 PEROXIDES - see also HYDROGEN PEROXIDE.
4 PERTUSSIS ANTIGEN.
4 PERTUZUMAB.
7 PETASITES spp. for therapeutic use.
PETROL except preparations containing 25 per cent or less of petrol.

PETROLEUM DERIVATIVES - see HYDROCARBONS, LIQUID.

PHEDRAZINE.

PHENACEMIDE.

PHENACETIN for therapeutic use (excluding when present as an excipient).

PHENADOXONE.

PHENAGLYCODOL.

PHENAMPHROMIDE.

PHENAZOCINE.

PHENAZONE except when included in Schedule 2 or 5.

PHENAZONE for human external use.

PHENAZONE for the external treatment of animals.

PHENAZOPYRIDINE.

PHENCYCLIDINE * (PCP)

PHENDIMETRAZINE. (Clauses 84,90,98,101,122)

PHENELZINE. (Appendix A)

PHENETICILLIN.

PHENFORMIN.

PHENGLUTARIMIDE.

PHENINDIONE.

PHENIRAMINE except when included in Schedule 2 or 3. (Appendix A)

PHENIRAMINE in oral preparations except:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age. (Appendix A)

PHENIRAMINE:

(a) in eye drops; or

(b) when combined with one or more other therapeutically active substances in oral preparations when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing pheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper, except in preparations for the treatment of children under 2 years of age. (Appendix A)

PHENISATIN.

PHENISOPHAM.

PHENMETRAZINE. (Clauses 84,90,98,101,122)

PHENOBARBITONE. (Appendix A, Appendix D)

PHENOL, or any homologue boiling below 220°C, for human therapeutic use, except:

(a) when included in Schedule 4; or

(b) in preparations for external use containing 3 per cent or less of such substances.

PHENOL in preparations for injection.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, except:
(a) when separately specified in these Schedules;
(b) when included in Schedule 5; or
(c) in preparations containing 3 per cent or less of such substances.

5 PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15 per cent or less of such substances, except in preparations containing 3 per cent or less of such substances.

4 PHENOLPHTHALEIN for human therapeutic use.

9 PHENOMORPHAN.

8 PHENOPERIDINE. (Appendix A)

6 PHENOTHIAZINE (excluding its derivatives) except in preparations containing 10 per cent or less of phenothiazine.

4 PHENOXYPHENOL.

6 PHENOXYPHENOL except:
(a) in cosmetic preparations containing 1 per cent or less of 2-phenoxyethanol; or
(b) in other preparations containing 15 per cent or less of 2-phenoxyethanol.

4 PHENOXYMETHYLPHENICILLIN.

4 PHENSUXIMIDE.

4 PHENTERMINE. (Appendix A, Appendix D)

4 PHENTHIMENTONIUM.

4 PHENTOLAMINE.

4 PHENYLPHTHALEIN for human therapeutic use.

9 PHENYLACETYLINDOLES except when separately specified in these Schedules.

4 PHENYLACETYLINDOLES except when separately specified in these Schedules.

7 PHENYLENEDIAMINES, including alkylated, arylated and nitro derivatives, in preparations for skin colouration and dyeing of eyelashes or eyebrows except when included in Schedule 6.

6 PHENYLENEDIAMINES including alkylated, arylated and nitro derivatives not elsewhere specified in these Schedules:
(a) in preparations packed and labelled for photographic purposes;
(b) in preparations packed and labelled for testing water except tablets containing 10 mg or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenediamine in opaque strip packaging provided the directions for use include the statement, "Do not discard testing solutions into the pool";
(c) in hair dye preparations except when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height; or
(d) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:
WARNING - This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height.

4 PHENYLEPHRINE:
(a) in preparations for injection; or
(b) in preparations for human ophthalmic use containing 5 per cent or more of
phenylephrine.

2 PHENYLEPHRINE except:
(a) when included in Schedule 4;
(b) in oral preparations containing 50 mg or less of phenylephrine per recommended
daily dose in packs containing 250 mg or less of phenylephrine; or
(c) in topical eye or nasal preparations containing 1 per cent or less of
phenylephrine.

9 1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE *(PEPAP).

7 PHENYLMERCURIC ACETATE except in preparations containing 0.01 per cent or
less of mercury as a preservative.

5 PHENYL METHYL KETONE except in preparations containing 25 per cent or less of
designated solvents.

6 N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-
DIMETHANAMINE except in preparations containing 1 per cent or less of N,N-
bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine, or a combination
of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and N,N-
bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with
statements to the effect of:
IRRITANT;
REPEATED EXPOSURE MAY CAUSE SENSITISATION;
Avoid contact with eyes;
Avoid contact with skin;
Wear protective gloves when mixing or using; and
Ensure adequate ventilation when using.

6 N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-
DIMETHANAMINE except in preparations containing 1 per cent or less of N,N-
bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, or a combination
of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and N,N-
bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with
statements to the effect of:
IRRITANT;
REPEATED EXPOSURE MAY CAUSE SENSITISATION;
Avoid contact with eyes;
Avoid contact with skin;
Wear protective gloves when mixing or using; and
Ensure adequate ventilation when using.

5 ortho-PHENYLPHENOL except in preparations containing 5 per cent or less of o-
phenylphenol.

8 4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (Pethidine
intermediate B).

4 PHENYLPROPANOLAMINE.

4 PHENYLOXAZOLIN.

8 PHOLCODINE except when included in Schedule 2 or 4. (Appendix A)

4 PHOLCODINE:
(a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or
(b) in undivided preparations containing 2.5 per cent or less of pholcodine, (Appendix A) except when included in Schedule 2

2 PHOLCODINE:
(a) in liquid preparations containing 0.5 per cent or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or
(b) when compounded with one or more other therapeutically active substances, in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine. (Appendix A)

7 PHORATE.
6 PHOSALONE.
7 PHOSFOLAN.
6 PHOSMET.
7 PHOSPHIDES, METALLIC.
7 PHOSPHINE.
4 PHOSPHODIESTERASE TYPE 5 INHIBITORS except:
(a) when separately specified in these Schedules; or
(b) when present as an unmodified, naturally occurring substance.

5 PHOSPHONIC ACID (excluding its salts and derivatives) except in preparations containing 10 per cent or less of phosphonic acid (H3PO3).

6 PHOSPHORIC ACID (excluding its salts and derivatives) except:
(a) when included in Schedule 5;
(b) in preparations containing 15 per cent or less of phosphoric acid (H3PO4);
(c) in solid or semi-solid preparations; or
(d) in professional dental kits.

5 PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35 per cent or less of phosphoric acid (H3PO4) except:
(a) in preparations containing 15 per cent or less of phosphoric acid (H3PO4);
(b) in solid or semi-solid preparations; or
(c) in professional dental kits.

7 PHOSPHORUS, YELLOW (excluding its salts and derivatives).

Exempt PHOTOGRAPHIC PAPER or FILM.
6 PHOXIM.

ortho-PHTHALALDEHYDE except when included in Schedule 5.

5 ortho-PHTHALALDEHYDE in preparations containing 1 per cent or less of ortho-phthalaldehyde.
4 PHTHALYSULFATHIAZOLE.
4 PHYSOSTIGMINE.
5 PICARIDIN except in preparations containing 20 per cent or less of picaridin.
4 PICROTOXIN.

Exempt PIGMENTS when immobilised in a polymer.

4 PILOCARPINE except in preparations containing 0.025 per cent or less of pilocarpine.
4 PIMECROLIMUS.
9 PIMINODINE.
4 PIMOBENDAN.
PIMOZIDE. (Appendix A)
PINACIDIL.
PINDOLOL.
PINDONE.

PINE OILS when packed and labelled as a herbicide except when included in Schedule 5.
PINE OILS in preparations containing 25 per cent or less of pine oils when packed and labelled as a herbicide.
PINOXADEN except when included in Schedule 5.
PINOXADEN in preparations containing 10 per cent or less of pinoxaden.
PIOGLITAZONE.
PIPECURONIUM.
PIPEMIDIC ACID.
PIPENZOLATE.
PIPERACILLIN.

PIPERAZINE for human therapeutic use.
PIPERAZINE for animal use.
PIPERIDINE.

PIPERIDOLATE.

PIPER METHYSTICUM (kava) in preparations for human use except when included on the Australian Register of Therapeutic Goods in preparations:
(a) for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and:
(i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet or capsule; or
(ii) the amount of dried whole or peeled rhizome in the teabag does not exceed 3 g; and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome; or
(c) in dermal preparations.

PIPEROPHOS.
PIPOBROMAN.
PIPOTHIAZINE.
PIPRADROL. (Appendix D)
PIRACETAM.
PIRIBUTEROL.
PIRENOXINE (catalin).
PIRENZEPINE.
PIRETANIDE.

PIRIMICARB except when included in Schedule 5.
PIRIMICARB in preparations containing 0.5 per cent or less of pirimicarb.
PIRIMIPHOS-ETHYL.
PIRIMIPHOS-METHYL.
PIRITRAMIDE.
PIROXICAM except in preparations for dermal use.

PIRPROFEN.

PITAVASTATIN.

PITUITARY HORMONES except when separately specified in these Schedules.

PIVAMPICILLIN.

PIZOTIFEN. (Appendix A)

PLERIXAFOR.

PLICAMYCIN.

PNEUMOCOCCAL VACCINE.

PODOPHYLLOTOXIN for human use:
(a) internally;
(b) in preparations for the treatment of anogenital warts; or
(c) in other preparations except when included in Schedule 2 or 3.

PODOPHYLLOTOXIN in preparations containing 1 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.

PODOPHYLLOTOXIN in preparations containing 0.5 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLOTOXIN in preparations containing 1 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM EMODI (podophyllin) for human use:
(a) internally;
(b) in preparations for the treatment of anogenital warts; or
(c) in other preparations except when included in Schedule 2 or 3.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM PELTATUM (podophyllin) for human use:
(a) internally;
(b) in preparations for the treatment of anogenital warts; or
(c) in other preparations except when included in Schedule 2 or 3.

POLIDEXIDE.

POLIHEXANIDE except
(a) in preparations containing 5 per cent or less of polihexanide; or
(b) when packed and labelled for therapeutic use.

POLIOMYELITIS VACCINE.

POLIXETONIUM SALTS except:
(a) when included in Schedule 5; or
(b) in preparations containing 1 per cent or less of polixetonium salts.
POLIXETONIUM SALTS in preparations containing 60 per cent or less of polixetonium salts except in preparations containing 1 per cent or less of polixetonium salts.

POLYACRYLAMIDE in preparations for injection or implantation:
(a) for tissue augmentation; or
(b) for cosmetic use.

POLYCAPROLACTONE in preparations for injection or implantation:
(a) for tissue augmentation; or
(b) for cosmetic use.

POLYESTRADIOL.

POLYETHANOXY (15) TALLOW AMINE.

POLYACRYLIC ACID in preparations for injection or implantation:
(a) for tissue augmentation; or
(b) for cosmetic use.

POLYESTRADIOL.

PORACTANT.

POPPY STRAW- see CONCENTRATE OF POPPY STRAW.

PORCELAIN.

POSACONAZOLE.

POTASSIUM AZELOYL DIGLYCINATE except in preparations for cosmetic use containing 1 per cent or less of potassium azeloyl diglycinate.

POTASSIUM BROMATE except in preparations containing 0.5 per cent or less of potassium bromate.

POTASSIUM BROMIDE for therapeutic use.

POTASSIUM CHLORATE except:
(a) when included in Schedule 2; or
(b) in preparations containing 10 per cent or less of potassium chloride.

POTASSIUM CHLORATE for therapeutic use except in preparations containing 10 per cent or less of potassium chloride.

POTASSIUM CHLORIDE in oral preparations for human therapeutic use except:
(a) when containing less than 550 mg of potassium chloride per dosage unit;
(b) in preparations for oral rehydration therapy;
(c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or
(d) in preparations for enteral feeding.

POTASSIUM CYANATE.

POTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.

POTASSIUM HYDROXIDE (excluding its salts and derivatives) except:
(a) when included in Schedule 5;
(b) preparations containing 5 per cent or less of potassium hydroxide being:
(i) solid preparations the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
(ii) liquid or semi-solid preparations the pH of which is 11.5 or less, or
(c) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5, for domestic use.

5 POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of potassium hydroxide being:
(a) solid preparations the pH of which in a 10 g/L aqueous solution is more than 11.5; or
(b) liquid or semi-solid preparations, the pH of which is more than 11.5 except in food additive preparations for domestic use.

5 POTASSIUM METABISULPHITE when packed for domestic use except in preparations containing 10 per cent or less of potassium metabisulphite.

7 POTASSIUM NITRITE except:
(a) when included in Schedule 5 or 6;
(b) in preparations containing 0.5 per cent or less of potassium nitrite;
(c) when present as an excipient in preparations for therapeutic use; or
(d) in aerosols containing 2 per cent or less of potassium nitrite.

6 POTASSIUM NITRITE in preparations containing 40 per cent or less of potassium nitrite except:
(a) when included in Schedule 5;
(b) in preparations containing 0.5 per cent or less of potassium nitrite;
(c) when present as an excipient in preparations for therapeutic use; or
(d) in aerosols containing 2 per cent or less of potassium nitrite.

5 POTASSIUM NITRITE in preparations containing 1 per cent or less of potassium nitrite except:
(a) in preparations containing 0.5 per cent or less of potassium nitrite;
(b) when present as an excipient in preparations for therapeutic use; or
(c) in aerosols.

4 POTASSIUM PERCHLORATE for therapeutic use.

POTASSIUM PERMANGANATE - SEE PERMANGANATES.

6 POTASSIUM PEROXOMONOSULFATE TRIPLE SALT except:
(a) when included in Schedule 5;
(b) in solid orthodontic device cleaning preparations, the pH of which as an "in-use" aqueous solution is 2.5 or more, but not more than 11.5; or
(c) in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:
(i) solid preparations the pH of which in a 10 g/L aqueous solution is 2.5 or more; or
(ii) liquid or semi-solid preparations the pH of which is 2.5 or more.

5 POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:
(a) solid preparations the pH of which in a 10 g/L aqueous solution is less than 2.5; or
(b) liquid or semi-solid preparations the pH of which is less than 2.5.

6 POTASSIUM PERSULFATE in hair preparations.

5 POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.

4 PRACTOLOL.
PRADOFLOXACIN.
PRALATREXATE.
PRALIDOXIME.

PRALLETHRIN (cis:trans=20:80) except:
(a) when included in Schedule 5; or
(b) in insecticidal mats containing 1 per cent or less of prallethrin.

PRALLETHRIN (cis:trans=20:80) in preparations containing 10 per cent or less of prallethrin except in insecticidal mats containing 1 per cent or less of prallethrin.

PRAMORELIN (GROWTH HORMONE RELEASING PEPTIDE-2) (GHRP-2)

PRAMIPEXOLE.
PRAMOCaine.
PRAMPINE.
PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone). (Appendix B, Appendix D)
PRASUGREL.
PRAVASTATIN.
PRAZEPAM. (Appendix A, Appendix D)
PRAZIQUANTEL for human therapeutic use.
PRAZOSIN.
PREDNISOLONE.
PREDNISONE.
PREGABALIN.
PREGNENOLONE.
PRENALTEROL.
PRENLYLAMINE.
PRILOCAINE except when included in Schedule 2.
PRILOCAINE in preparations for dermal use containing 10 per cent or less of total local anaesthetic substances.
PRIMAQUINE.
PRIMIDONE.

Exempt PRINTING INKS or INK ADDITIVES except when containing a pesticide.

PROBENECID.
PROBUCOL.
PROCAINAMIDE.
PROCAINE.
PROCAINE PENICILLIN.
PROCARBAZINE.
PROCHLORAZ.
PROCHLORPERAZINE except when included in Schedule 3. (Appendix A)
PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.

PROCYCLIDINE except when included in Schedule 2.
PROCYCLIDINE in preparations containing 5 per cent or less of procyclidine for dermal use.
PROCYMIDONE.
PROFENOFOS.

PROFOXYDIM except in preparations containing 20 per cent or less of profoxydim.

PROGESTERONE except when included in Schedule 5.

PROGESTERONE:
(a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or
(b) in implant preparations for growth promotion in cattle.

PROGESTOGENS except when separately specified in these Schedules.

PROGLUMIDE.

PROGUANIL.

PROHEPTAZINE.

PROHEXADIONE CALCIUM.

PROLINTANE.

PROMACYL.

PROMAZINE. (Appendix A)

PROMETHAZINE except when included in Schedule 2 or 3. (Appendix A)

PROMETHAZINE in oral preparations except:
(a) when included in Schedule 2; or
(b) in preparations for the treatment of children under 2 years of age. (Appendix A)

PROMETHAZINE in oral preparations:
(a) in a primary pack containing 10 dosage units or less, for the prevention or treatment of motion sickness; or
(b) when combined with one or more other therapeutically active substances when:
(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(ii) in a day-night pack containing promethazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper, except in preparations for the treatment of children under 2 years of age. (Appendix A)

PROMETRYN.

PROMOXOLANE.

PROPACHLOR.

PROPAFENONE.

PROPAMIDINE for therapeutic use except when included in Schedule 2.

PROPAMIDINE for ophthalmic use.

PROPAMOCARB.

PROPANIDID.

PROPANIL.

PROPANTHELINE.

PROPAQUIZAFOP.

PROPARGITE.

PROPENTOFYLLINE.

PROPERIDINE.

PROPETAMPHOS.

PROPETANDROL. (Appendix B, Appendix D)

PROPICONAZOLE except when included in Schedule 5.
PROPICONAZOLE in preparations containing 20 per cent or less of propiconazole.

PROPINEB.

PROPIQUEMISTOMACRUM ACNES for therapeutic use.

PROPIONIC ACID (excluding its salts and derivatives) except:
(a) when included in Schedule 5;
(b) in preparations containing 30 per cent or less of propionic acid; or
(c) for therapeutic use.

PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80 per cent or less of propionic acid, except:
(a) in preparations containing 30 per cent or less of propionic acid; or
(b) for therapeutic use.

PROPIRAM.

PROPOFOL.

PROPOXUR except when included in Schedule 5.

PROPOXUR:
(a) when impregnated in plastic resin strip material containing 10 per cent or less of propoxur;
(b) in dust preparations containing 3 per cent or less of propoxur;
(c) in granular sugar-based fly baits containing 1 per cent or less of propoxur, a dark colouring agent and a separate bittering agent;
(d) in pressurised spray packs containing 2 per cent or less of propoxur; or
(e) in printed paper sheets for pest control containing 0.5 per cent or less of propoxur and in any case not more than 100 mg of propoxur per sheet.

PROPRANOLOL.

PROPYLENE OXIDE.

PROPYLHEXEDRINE. (Appendix A, Appendix D)

PROPYLTHIOURACIL.

PROPYLPHENAZONE.

PROPYLZAMIDE.

PROQUAZONE.

PROQUINAZID.

PROSCILLARIDIN.

PROSTAGLANDINS except when separately specified in this Schedule.

PROSTIANOL.

PROSULFOCARB.

PROSULFURON.

PROTAMINE.

PROTHIOCONAZOLE-DESCHLORO except in preparations containing 0.5 per cent or less of prothioconazole-deschloro.

PROTHIOCONAZOLE-TRIAZOLIDINETHIONE except in preparations containing 0.5 per cent or less of prothioconazole-triazolidinethione.

PROTHIOFOS.

PROTHIONAMIDE.

PROTHIPENDYL.

PROTIRELIN.

PROTOVERATRINES.
PROTRIPTYLINE. (Appendix A)

PROXYMETACAINE.

PRUCALOPRIDE.

PSEUDOEPHEDRINE except when included in Schedule 3. (Appendix D)

PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight-control purposes), when supplied in a primary pack:
(a) in liquid preparations containing 800mg or less of pseudoephedrine hydrochloride (or its equivalent); or
(b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent). (Clauses 15 & 24)

PSILOCYBINE.

PTERIDIDIUM spp. for therapeutic use.

d-PULEGONE except in preparations containing 4 per cent or less of d-pulegone.
PULMONARIA spp. for therapeutic use.

PYMETROZINE.

PYRACLOFOS.

PYRACLOSTROBIN.

PYRAFLUFEN-ETHYL.

PYRANTEL for human therapeutic use.

PYRASULFOTOLE.

PYRAZINAMIDE.

PYRASPHOS.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10 per cent of such substances.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids except:
(a) in preparations for human therapeutic use; or
(b) in preparations containing 10 per cent or less of such substances.

PYRIDABEN except when included in Schedule 5.

PYRIDABEN in preparations containing 25 per cent or less of pyridaben.

PYRIDALYL.

PYRIDATE.

PYRIDINOLOCARBAMATE.

PYRIDOSTIGMINE.

PYRIDOXINE, PYRIDOXAL or PYRIDOXAMINE for human therapeutic use except:
(a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or
(b) in oral preparations containing less than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.

PYRIFENOX.

PYRIMETHAMINE.

PYRINURON.

PYRIDOFENONE.
6 PYRIPROLE.
5 PYRITHIOBAC SODIUM.
6 PYRITHIONE COPPER.
6 PYRITHIONE ZINC except:
   (a) when included in Schedule 2 or 5;
   (b) for human use in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the Required Advisory Statements for Medicine Labels;
   (c) in semi-solid hair preparations for animal use;
   (d) in shampoos for animal use containing 2 per cent or less of pyrithione zinc when labelled with the statement "Keep out of eyes" and "If in eyes rinse well with water";
   (e) when immobilised in solid preparations containing 0.5 per cent or less of pyrithione zinc; or
   (f) in paints, jointing materials or sealants containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content.
2 PYRITHIONE ZINC for human therapeutic use, except in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the Required Advisory Statements for Medicine Labels.
5 PYRITHIONE ZINC in paints containing 0.5 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint except in paints containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint.
4 PYROXASULFONE.
6 PYROXSULAM.
4 PYRVINIUM.
6 QUATERNARY AMMONIUM COMPOUNDS except:
   (a) when separately specified in these Schedules;
   (b) when included in Schedule 5;
   (c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or
   (d) in preparations containing 5 per cent or less of such quaternary ammonium compounds.
5 QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20 per cent or less of quaternary ammonium compounds except:
   (a) when separately specified in these Schedules;
   (b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or
   (c) in preparations containing 5 per cent or less of such quaternary ammonium compounds.
4 QUAZEPAM.
4 QUETIAPINE.
4 QUINAGOLIDE.
8 QUINALBARBITONE. (Appendix A)
4 QUINAPRIL.
4 QUINBOLONE. (Appendix B, Appendix D)
5 QUINCLORAC.
4 QUINETHAZONE.
QUINIDINE.
QUININE for veterinary use except when included in Schedule 5.
QUININE for human therapeutic use except except when the maximum recommended daily dose is 50 mg or less of quinine.
QUININE in preparations for veterinary use containing 1 per cent or less of quinine.
QUINISOCaine (dimethisoquin).
QUINTOZENE.
QUINUPRISTIN.
QUISOCaine (dimethisoquin).
QUINISOCAINE (dimethisoquin).
QUINUPRISTIN.
QUIZALOFOP ETHYL except when included in Schedule 5.
QUIZALOFOP-P-ETHYL in aqueous preparations containing 40 per cent or less of quizalofop-p-ethyl.
QUIZALOFOP-P-TEFURYL except when included in Schedule 3.
QUIZALOFOP-P-TEFURYL in aqueous preparations containing 40 per cent or less of quizalofop-p-ethyl.
QUIZALOFOP-P-TEFURYL except when included in Schedule 5.
QUIZALOFOP-P-TEFURYL in aqueous preparations containing 40 per cent or less of quizalofop-p-ethyl.
RABEPRAZOLE except when included in Schedule 3.
RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days supply.
RABIES VACCINE.
RACEMETHORPHAN.
RACEMORPHAN.
RACEMORAMIDE.
RACTOPAMINE except when included in Schedule 5.
RACTOPAMINE in animal feed premixes containing 10 per cent or less of ractopamine.
Exempt RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use.
Exempt RADIOISOTOPES for therapeutic use.
RALOXIFENE.
RALTEGRAVIR.
RALTITREXED.
RAMIPRIL.
RANIBIZUMAB.
RANITIDINE except:
(a) when included in Schedule 2; or
(b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer's original pack containing not more than 14 dosage units.
RANITIDINE in preparations supplied in the manufacturer's original pack containing not more than 14 days' supply except in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit in the manufacturer's original pack containing not more than 14 dosage units.
RAPACURONIUM.
RASAGILINE.
RASBURICASE.
RAUWOLFIA SERPENTINA.
RAUWOLFIA VOMITORIA.
RAZOXANE.
REBOXETINE.
RED YEAST RICE for human therapeutic use.
REGORAFENIB.
REMIFENTANIL.
REMOXIPRIDE.
REPAGLINIDE.
RESERPINE.
RESMETHRIN except when included in Schedule 5.
RESMETHRIN in preparations containing 10 per cent or less of resmethrin.
RETAPAMULIN.
RETEPLASE.
RETIGABINE. (Appendix A)
RIBAVIRIN.
RIDAFOROLIMUS
RIFABUTIN.
RIFAMPICIN.
RIFAMYCIN.
RIFAPENTINE.
RIFAXIMIN.
RILPIVIRINE.
RILUZOLE.
RIMEXOLONE.
RIMITEROL.
RIMONABANT.
RIMSULFURON.
RIOCIGUAT
RISEDRONIC ACID.
RISPERIDONE. (Appendix A)
RITODRINE.
RITONAVIR.
RITUXIMAB.
RIVAROXABAN.
RIVASTIGMINE.
RIZATRIPTAN.
ROBENACOXIB.
ROBENIDINE except in preparations containing 20 per cent or less of robenidine.
ROCURONIUM.
ROFECOXIB.
ROFLUMILAST.
ROLICYCLIDINE * (PHP or PCPY).
ROLITETRACYCLINE.
ROMIDEPSIN.
ROMIFIDINE.
ROMIPLOSTIM.
RONIDAZOLE.
4 ROPINIROLE.
4 ROPIVACAINE.
4 ROSIGLITAZONE.
5 ROSIN when packaged for use as a soldering flux or in flux-cored solder.
4 ROSOXACIN.
4 ROSUVASTATIN.
6 ROTENONE except in solid or semi-solid preparations containing 2 per cent or less of rotenone.
4 ROTIGOTINE. (Appendix A)
4 ROXIBOLONE. (Appendix B, Appendix D)
4 ROXITHROMYCIN.
4 RUBELLA VACCINE.
4 RUBOXISTAURIN.
4 RUPATADINE. (Appendix A)
4 RUXOLITINIB.
7 SAFLUFENACIL except when included in Schedule 5.
5 SAFLUFENACIL in water dispersible granule preparations.
6 SAFROLE except:
   (a) for internal use; or
   (b) in other preparations containing 1 per cent or less of safrole.
7 SAFROLE for internal therapeutic use except in preparations containing 0.1 per cent or less of safrole.
6 SAGE OIL (Dalmatian) except:
   (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels; or
   (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
   KEEP OUT OF THE REACH OF CHILDREN; and
   NOT TO BE TAKEN; or
   (c) in preparations containing 4 per cent or less of thujone.
4 SALBUTAMOL except when included in Schedule 3.
3 SALBUTAMOL as the only therapeutically active substance:
   (a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or
   (b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.
4 SALCATONIN.
2 SALICYLAMIDE except when included in Schedule 4.
4 SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.
5 SALICYLANILIDE.
3 SALICYLIC ACID in preparations for dermal use except in preparations containing 40 per cent or less of salicylic acid.
4 SALINOMYCIN except:
(a) when included in Schedule 6; or
(b) in animal feeds containing 60 mg/kg or less of antibiotic substances.

6 SALINOMYCIN in animal feed premixes containing 12 per cent or less of antibiotic substances.
4 SALMETEROL.
9 SALVIA DIVINORUM.
3 SANTONIN.
4 SAPROPTERIN.
4 SAQUINAVIR.
6 SASSAFRAS OIL except:
   (a) for internal use; or
   (b) in other preparations containing 1 per cent or less of safrole.
4 SAXAGLIPTIN.
4 SCHOENOCAULON OFFICINALE (sabadilla) except in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of Schoenocaulon officinale.
7 SCHRADAN.
4 SCOPOLIA CARNIOLICA for therapeutic use.
8 SECBUTOBARBITONE. (Appendix A)
5 SEDAXANE.
Exempt SEEDS treated with seed protectants.
5 SELAMECTIN except in preparations containing 12 per cent or less of selamectin.
4 SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM). (Appendix D)
4 SELEGILINE.
4 SELENIUM:
   (a) for human oral use with a recommended daily dose of more than 300 micrograms; or
   (b) for the treatment of animals except:
      (i) when included in Schedule 6 or 7;
      (ii) in solid, slow release bolus preparations each weighing 100 g or more and containing 300 mg or less of selenium per dosage unit;
      (iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit;
      (iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or
      (v) in feeds containing 1 g/tonne or less of selenium.
7 SELENIUM except:
   (a) when included in Schedule 6;
   (b) as selenium arsenide in photocopier drums;
   (c) in preparations for therapeutic use other than:
      (i) drench concentrates containing 2.5 per cent or less of selenium; or
      (ii) pour-on preparations containing 0.5 per cent or less of selenium;
   (d) in paints or tinters containing 0.1 per cent or less of selenium calculated on the non-volatile content of the paint or tinter; or
   (e) in fertilisers containing 200 g/tonne or less of selenium.
6 SELENIUM:
   (a) in preparations containing 2.5 per cent or less of selenium when packed and labelled:
(i) for the blueing of gun barrels;
(ii) for photographic purposes; or
(iii) for the colouring of lead or lead alloys;
(b) in coated granules containing 1 per cent or less of selenium for application to pasture except in fertilisers containing 200 g/tonne or less of selenium; or
(c) for the treatment of animals:
(i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5 per cent or less of selenium;
(ii) in animal feed premixes containing 2 per cent or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium;
(iii) in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than 0.25 mg/day; or
(iv) as barium selenate in preparations for injection containing 5 per cent or less of selenium.

2 SELENIUM in preparations for human therapeutic use except:
(a) for topical use containing 3.5 per cent or less of selenium sulfide;
(b) when included in Schedule 4; or
(c) for oral use with a recommended daily dose of 150 micrograms or less.

7 SEMDURAMICIN except:
(a) when included in Schedule 6; or
(b) in animal feeds containing 25 mg/kg or less of antibiotic substances.

6 SEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5 per cent or less of antibiotic substances.

7 SENEcio spp. for therapeutic use.

4 SERELAXIN.
4 SERMORELIN.
4 SERTINDOLE.
4 SERTRALINE.
5 SETHOXYDIM.
4 SEVELAMER.
4 SEVOFLURANE.
4 SEX HORMONES and all substances having sex hormonal activity except when separately specified in these Schedules.
4 SIBUTRAMINE.
5 SIDURON.
4 SILANDRONE. (Appendix B, Appendix D)
4 SILDENAFIL.
6 SILICOFLUORIDES except:
(a) when included in Schedule 5; or
(b) in preparations containing 15 mg/kg or less of fluoride ion.
5 SILICOFLUORIDES in preparations containing 3 per cent or less of fluoride ion except:
(a) barium silicofluoride when separately specified in this Schedule; or
(b) in preparations containing 15 mg/kg or less of fluoride ion.
7 SILICONES for injection or implantation except when included in Schedule 4.
4 SILICONES for intra-ocular use.
2 SILVER for therapeutic use except:
(a) in solutions for human oral use containing 0.3 per cent or less of silver when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or
(b) in other preparations containing 1 per cent or less of silver.

6 SILVER NITRATE except:
(a) when included in or expressly excluded from Schedule 2; or
(b) in preparations containing 1 per cent or less of silver.

4 SILVER SULFADIAZINE.

4 SIMVASTATIN.

6 SINBIOALLETHRIN except:
(a) when included in Schedule 5; or
(b) in preparations containing 1 per cent or less of sinbioallethrin.

SINBIOALLETHRIN in preparations containing 10 per cent or less of sinbioallethrin except in preparations containing 1 per cent or less of sinbioallethrin.

Exempt SINGLE-USE TUBES for the estimation of alcohol content of breath.

4 SIROLIMUS.

4 SISOMICIN (sisomycin).

4 SITAGLIPTIN.

4 SITAXENTAN.

6 SODIUM ALUMINATE (excluding its salts and derivatives) except:
(a) in solid preparations the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
(b) in liquid preparations the pH of which is 11.5 or less.

SODIUM BORATE - see BORAX

6 SODIUM BROMATE except in preparations containing 0.5 per cent or less of sodium bromate.

4 SODIUM BROMIDE for therapeutic use.

SODIUM CARBONATE - see ALKALINE SALTS.

4 SODIUM CELLULOSE PHOSPHATE for human internal use.

5 SODIUM CHLORATE except in preparations containing 10 per cent or less of sodium chlorate.

4 SODIUM CROMOGLYCATE except when included in Schedule 2.

2 SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.

5 SODIUM DIACETATE except in preparations containing 60 per cent or less of sodium diacetate.

5 SODIUM DODECYLBENZENE SULFONATE except in preparations containing 30 per cent or less of sodium dodecylbenzene sulfonate.

5 SODIUM HYDROGEN SULFATE except in preparations containing 10 per cent or less of sodium hydrogen sulfate.

5 SODIUM HYDROSULFITE when packed for domestic use except in preparations containing 10 per cent or less of sodium hydrosulfite.

7 SODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.

6 SODIUM HYDROXIDE (excluding its salts and derivatives) except:
(a) when included in Schedule 5;
(b) preparations containing 5 per cent or less of sodium hydroxide being:
(i) solid preparations the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
(ii) liquid or semi solid preparations the pH of which is 11.5 or less; or
(c) liquid or semi-solid food additive preparations, the pH of which is more than 11.5, for domestic use.

5 SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of sodium hydroxide being:
(a) solid preparations the pH of which in a 10 g/L aqueous solution is more than 11.5; or
(b) liquid or semi-solid preparations, the pH of which is more than 11.5 except in food additive preparations for domestic use.

5 SODIUM LAURETH-6 CARBOXYLATE except in preparations containing 1 per cent or less of sodium laureth-6 carboxylate.

6 SODIUM LAURYL SULFATE (excluding its salts and derivatives) except:
(a) in wash-off preparations containing 30 per cent or less of sodium lauryl sulfate and, if containing more than 5 per cent of sodium lauryl sulfate, when labelled with a warning to the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER;
(b) in leave-on preparations containing 1.5 per cent or less of sodium lauryl sulfate;
(c) in toothpaste and oral hygiene preparations containing 5 per cent or less of sodium lauryl sulfate;
(d) in other preparations for animal use containing 2 per cent or less of sodium lauryl sulfate; or
(e) in other preparations containing 30 per cent or less of sodium lauryl sulfate and, if containing more than 5 per cent of sodium lauryl sulfate, when labelled with warnings to the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and
IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

5 SODIUM METABISULPHITE when packed for domestic use except in preparations containing 10 per cent or less of sodium metabisulphite.
SODIUM METASILICATE - see ALKALINE SALTS.

4 SODIUM MORRHUATE in preparations for injection.

7 SODIUM NITRITE except:
(a) when included in Schedule 2, 5 or 6;
(b) in preparations containing 0.5 per cent or less of sodium nitrite;
(c) when present as an excipient in preparations for therapeutic use; or
(d) in aerosols containing 2 per cent or less of sodium nitrite.

6 SODIUM NITRITE in preparations containing 40 per cent or less of sodium nitrite except:
(a) when included in Schedule 2 or 5;
(b) in preparations containing 0.5 per cent or less of sodium nitrite;
(c) when present as an excipient in preparations for therapeutic use; or
(d) in aerosols containing 2 per cent or less of sodium nitrite.

5 SODIUM NITRITE in preparations containing 1 per cent or less of sodium nitrite except:
(a) in preparations containing 0.5 per cent or less of sodium nitrite;
(b) when present as an excipient in preparations for therapeutic use; or
(c) in aerosols.

2 SODIUM NITRITE for therapeutic use (excluding when present as an excipient).

4 SODIUM NITROPRUSSIDE for human therapeutic use.
8 SODIUM OXYBATE for human therapeutic use.
SODIUM ORTHOSILICATE - see ALKALINE SALTS.
SODIUM PENTOBARBITONE - see PENTOBARBITONE.
6 SODIUM PERCARBONATE (CAS No. 15630-89-4) except:
(a) when included in Schedule 5; or
(b) in preparations containing 15 per cent or less of sodium percarbonate.
5 SODIUM PERCARBONATE (CAS No. 15630-89-4) in preparations containing 35 per cent or less of sodium percarbonate except in preparations containing 15 per cent or less of sodium percarbonate.
6 SODIUM PERSULFATE
(a) in hair preparations; or
(b) in products for the treatment of water for swimming pools and spas.
3 SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.
4 SODIUM PHOSPHATE in preparations for oral laxative use.
3 SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.
5 SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use except in preparations containing 10 per cent or less of sodium polystyrene sulphonate.
4 SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.
4 SODIUM SALICYLATE in preparations for injection for the treatment of animals.
SODIUM SILICATE - see ALKALINE SALTS.
5 SODIUM STANNATE except in preparations for cosmetic use containing 1 per cent or less of sodium stannate.
5 SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.
6 SODIUM SULFIDE in preparations for use as insect lures.
4 SODIUM TETRADECYSULFATE in preparations for injection.
4 SOFOSBUVIR.
4 SOLASODINE.
4 SOLIFENACIN.
4 SOMATOSTATIN.
4 SOMATOTROPIN EQUINE.
4 SOMATROPIN (human growth hormone). (Appendix D)
4 SONTQUINE.
4 SORAFENIB.
4 SOTALOL.
4 SPARFLOXACIN.
4 SPARTEINE.
4 SPECTINOMYCIN.
5 SPINETORAM.
5 SPINOSAD except in aqueous suspensions containing 25 per cent or less of spinosad.
4 SPIRAMYCIN.
4 SPIRAPRIL.
4 SPIRONOLACTONE.
6 SPIROTETRAMAT.
6 SPIROXAMINE.
2 SQUILL except in preparations containing 1 per cent or less of squill.
4 STANOLONE. (Appendix B, Appendix D)
4 STANZOLOL. (Appendix B, Appendix D)
5 STAR ANISE OIL except:
   (a) in medicines for human therapeutic use, when packed in containers having a
nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant
with the requirements of the Required Advisory Statements for Medicine Labels;
(b) in preparations other than medicines for human therapeutic use, when packed in
containers having a nominal capacity of 50 mL or less fitted with a restricted flow
insert, and labelled with the warning:
   KEEP OUT OF REACH OF CHILDREN; or
(c) in preparations containing 50 per cent or less of star anise oil.
4 STAVUDINE.
4 STENBOLONE. (Appendix B, Appendix D)
4 STEROID HORMONES except when separately specified in these Schedules.
4 STILBOESTROL (diethylstilboestrol).
4 STREPTODORNASE.
4 STREPTOKINASE.
4 STREPTOMYCIN.
4 STREPTOMYCES spp.
7 STRYCHNINE except when included in Schedule 4. (Clause 20)
4 STRYCHNINE in preparations containing 1.5 per cent or less of strychnine for the
treatment of animals.
4 STRYCHNOS spp except in preparations containing 1 milligram or less per litre or
per kilogram of strychnine.
4 STYRAMATE.
5 STYRENE (excluding its derivatives).
4 SUCCIMER.
8 SUFENTANIL.
4 SUGAMMADEX.
4 SULBACTAM.
7 SULCOFURON except:
   (a) when included in Schedule 6; or
   (b) in treated carpets.
6 SULCOFURON in preparations for the treatment of carpets during manufacture.
4 SULCONAZOLE except when included in Schedule 2.
2 SULCONAZOLE in preparations for dermal use.
4 SULFACETAMIDE except when included in Schedule 3 or 5.
3 SULFACETAMIDE in preparations for ophthalmic use containing 10 per cent or less
of sulfacetamide.
5 SULFACETAMIDE when packed and labelled for the treatment of ornamental caged
birds or ornamental fish only.
4 SULFADIAZINE except when included in Schedule 5.
SULFADIAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFADIMETHOXINE.

SULFADIMIDINE except when included in Schedule 5.

SULFADIMIDINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFADOXINE.

SULFAFURAZOLE.

SULFAGUANIDINE.

SULFAMERAZINE except when included in Schedule 5.

SULFAMERAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFAMETHIZOLE.

SULFAMETHOXAZOLE.

SULFAMETHOXYPYRIDAZINE.

SULFAMETROLE.

SULFAMIC ACID (excluding its salts and derivatives) except when included in Schedule 5.

SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of sulfamic acid (H₃NO₃S).

SULFAMONOMETHOXINE.

SULFAMOXOLE.

SULFAPHENAZOLE.

SULFAPYRIDINE.

SULFAQUINOXALINE.

SULFASALAZINE.

SULFATHIAZOLE except when included in Schedule 5.

SULFATHIAZOLE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFATROXAZOLE.

SULFENPyrARAZONE.

SULFURTROXAZOLE.

SULFUTROXAZOLE.

SULFAMETROLE.

SULFAMIC ACID (excluding its salts and derivatives) except when included in Schedule 5.

SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of sulfamic acid (H₃NO₃S).

SULFAMONOMETHOXINE.

SULFAMOXOLE.

SULFAPHENAZOLE.

SULFAPYRIDINE.

SULFAQUINOXALINE.

SULFASALAZINE.

SULFATHIAZOLE except when included in Schedule 5.

SULFATHIAZOLE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFATROXAZOLE.

SULFENPyrARAZONE.

SULFURTROXAZOLE.

SULFURIC ACID (excluding its salts and derivatives) except:

(a) when separately specified in this Schedule;
(b) when included in Schedule 3, 5 or 6; or
(c) when packed and labelled solely for use as a herbicide.

SULFONMETHANE (sulfonal) and alkyl sulfonals.

SULFOTEP.

SULFAFLOR except when included in Schedule 5.

SULFAFLOR in preparations containing 25 per cent or less of sulfoxaflor.

SULFURIC ACID (excluding its salts and derivatives) except:

(a) in fire extinguishers; or
(b) in preparations containing 0.5 per cent or less of sulfuric acid (H2SO4).

- SULFURYL FLUORIDE.
- SULINDAC.
- SULPROFOS.
- SULTAMICILLIN.
- SULTHIAME.
- SUMATRIPTAN.
- SUNITINIB.
- SUPROFEN.
- SUTILAINS.
- SUVOREXANT. (Appendix A)
- SUXAMETHONIUM.
- SUXETONIUM.
- SYMPHYTUM spp. (Comfrey) for therapeutic or cosmetic use except when included in Schedule 5.
- SYMPHYTUM spp. (Comfrey) for dermal use.
- SYNTHETIC CANNABINOMIMETICS except when separately specified in these Schedules.
- 2,4,5-T.
- TACRINE.
- TACROLIMUS.
- TADALAFIL.
- TAFLUPROST.
- TALIGLUCERASE ALFA.
- N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE ACETATES.
- TAMOXIFEN.
- TAMSULOSIN.
- TANACETUM VULGARE except in preparations containing 0.8 per cent or less of oil of tansy.
- TAPENTADOL. (Appendix A)
- TASONERMIN.
- TAZAROTENE.
- TAZOBACTAM.
- TAR ACIDS distilling within the range 230-290oC inclusive.
- 2,3,6-TBA.
- TCA - see TRICHLORACETIC ACID.
- T-CELL RECEPTOR ANTIBODY.
- TCMTB (2-[thiocyanomethylthio]benzothiazole).
- TCP - see 1-(1-(2-THIENYL)CYCLOHEXYL) PIPERIDINE.
- TDE (1,1-dichloro-2,2-bis [4-chlorophenyl] ethane) except when included in Schedule 5.
- TDE (1,1 dichloro-2,2-bis [4-chlorophenyl] ethane) in preparations containing 10 per cent or less of TDE.
- TEBUCONAZOLE.
- TEBUFENOXIDE.
TEBUFENPYRAD.
TEBUTHIURON.
TEFLUTHRIN except when included in Schedule 5.
TEFLUTHRIN in preparations containing 2 per cent or less of tefluthrin.
TEGAFUR.
TEGASEROD.
TEICOPLANIN.
TELAPREVID.
TELBIVUDINE.
TELITHROMYCIN.
TELMISARTAN.
TEMAZEPAM. (Appendix A, Appendix D)
TEMEPHOS except when included in Schedule 5.
TEMEPHOS:
(a) in liquid preparations containing 10 per cent or less of temephos; or
(b) in powders containing 2 per cent or less of temephos; or
(c) in preparations containing 40 per cent or less of temephos when packed in single
use containers having a capacity of 2 mL or less.
TEMOZOLOMIDE.
TEMSIROLIMUS.
TENECTEPLASE.
TENIPOSIDE.
TENOCYCLIDINE *(TCP).
TENOFOVIR.
TENOXICAM.
TEPOXALIN.
TEPP.
TEPRALOXYDIM.
TERAZOSIN.
TERBUTALINE except when included in Schedule 3.
TERBUTALINE as the only therapeutically active substance:
(a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered
dose; or
(b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per
dose.
TERBUTHYLAZINE except in preparations containing 5 per cent or less of
terbuthylazine.
TERBUTRYN.
TERFENADINE.
TERIFLUNOMIDE.
TERIPARATIDE.
TERLIPRESSIN.
Exempt TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting.
TERODILINE.
TEROPTERIN.
TERPENES, CHLORINATED.
TESTOLACTONE. (Appendix D)
TESTOSTERONE except when included in Schedule 6. (Appendix B, Appendix D)
TESTOSTERONE in implant preparations for use in animals.
TETANUS ANTITOXIN except when used for short-term protection or treatment of tetanus in animals.
TETANUS TOXOID for human use.
1,3,5,7-TETRAAZATRICYLO [3.3.1.1]$^3_7$ DECANE in cosmetic preparations, except in preparations containing 0.15 per cent or less of 1,3,5,7-tetraazatricyclo [3.3.1.1]$^3_7$ decane.
TETRABENAZINE.
TETRACHLOROETHANE.
TETRACHLOROETHYLENE except:
(a) when included in Schedule 2 or 5;
(b) in preparations containing 6 per cent or less of tetrachloroethylene when absorbed into an inert solid; or
(c) in preparations for the treatment of animals.
TETRACHLOROETHYLENE in preparations containing 5 per cent or less of tetrachloroethylene except:
(a) when included in Schedule 2;
(b) in preparations for the treatment of animals; or
(c) when absorbed into an inert solid.
TETRACHLOROETHYLENE for human therapeutic use.
TETRACHLORVINPHOS except in animal feeds containing 0.2 per cent or less of tetrachlorvinphos.
TETRACONAZOLE except when included in Schedule 5.
TETRACONAZOLE in preparations containing 20 per cent or less of tetraconzole.
TETRACOSACTRIN.
TETRACYCLINE except when included in Schedule 5.
TETRACYCLINE in preparations:
(a) for topical application to animals for ocular use only;
(b) containing 40 per cent or less of tetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
TETRADIFON.
TETRAETHYLAMMONIUM.
TETRAHYDROCANNABINOL and its alkyl homologues except:
(a) when separately specified in this Schedule;
(b) in hemp seed oil, containing 50 mg/kg or less of tetrahydrocannabinols, when labelled "Not for internal use" or "Not to be taken"; or
(c) in products for purposes other than internal human use containing 50 mg/kg or less of tetrahydrocannabinols. (Clause 105)

9 TETRAHYDROCANNABINOLS and their alkyl homologues except:
(a) when separately specified in this Schedule;
(b) when included in Schedule 4 or Schedule 8;
(c) in hemp seed oil, containing 50 mg/kg or less of tetrahydrocannabinols when labelled with a warning statement:
    Not for internal use; or
    Not to be taken; or
(d) in products for purposes other than internal human use containing 50 mg/kg or less of tetrahydrocannabinols.

2 TETRAHYDROZOLINE.

7 2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE except when included in Schedule 6.
6 2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE in amitraz formulations containing 2 per cent or less of 2,2',6,6'-tetraisopropyl-diphenyl-carbodiimide.

5 TETRAMETHRIN \[(R, \text{cis}) \):(R, \text{trans}) = 20:80\] except in pressurised spray packs.
6 TETRAMISOLE in preparations for the treatment of animals.
4 TETROXOPRIM.

5 TETRAMETHOXAM except when included in Schedule 5.
5 THIAZOPYR.
4 THIAZOSULFONE.
4 THIETHYLPERAZINE. (Appendix A)

TG147/98 Issue date: June 2015 Page 132 of 143
THIFENSULFURON.
THIOACETAZONE.
THIOBENCARB.
THIOCARLIDE.
THIODICARB except when included in Schedule 5.
THIODICARB in pelleted preparations containing 1.5 per cent or less of thiodicarb.
THIOFANOX.
THIOFENTANYL.
THIOGUANINE.
THIOMESTERONE (tiomesterone). (Appendix B, Appendix D)
THIOMETON.
THIOPENTONE. (Appendix D)
THIOPHANATE-METHYL except when included in Schedule 5.
THIOPHANATE-METHYL in preparations containing 25 per cent or less of thiophanate-methyl.
THIOPROPAZATE. (Appendix A)
THIOPROPERAZINE.
THIORDAZINE. (Appendix A)
THIOSTREPTON.
THIOTEPMA.
THIOTHIXENE. (Appendix A)
THIOUREA AND ALKYL THIOUREAS except:
(a) when separately specified in these Schedules; or
(b) for therapeutic use.
THIUREA for therapeutic use except in preparations containing 0.1 per cent or less of thiourea.
THIRAM except in paint containing 0.5 per cent or less of thiram.
THUJONE except in preparations containing 4 per cent or less of thujone.
THYME OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c) in preparations containing 50 per cent or less of thyme oil.
THYMOL when packed and labelled for the control of Varroa mites in bee hives.
THYMOXAMINE (includes thymoxamine hydrochloride).
THYROID except when separately specified in this Schedule.
THYROTROPHIN.
THYROXINE (includes thyroxine sodium).
TIAGABINE.
TIAMULIN.
TIAPROFENIC ACID.
TIARAMIDE.
TIBOLONE.
TICAGRELOR.
TICARCILLIN.
TICLOPIDINE.
TIEMONIUM.
TIENILIC ACID.
TIGECYCLINE.
TIGLOIDINE.
TILDIPROSIN.
TILETAMINE.
TILDINE.
TILMICOSIN.
TILUDRONIC ACID (includes disodium tiludronate).
Exempt TIMBER or WALLBOARD.
TIMOLOL.
TINIDAZOLE.
TIN ORGANIC COMPOUNDS, being di-alkyl, tri-alkyl and tri-phenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl except:
(a) when separately specified in this Schedule;
(b) in plastics;
(c) in semi-solid sealants, adhesives or elastomers containing 1 per cent or less of the dialkyl, trialkyl or triphenyl tin component; or
(d) in paint containing 1 per cent or less of such compounds calculated as tin in the non-volatile content of the paint.
TINZAPARIN (includes tinzaparin sodium).
TIOCARBAZIL.
TIOCONAZOLE except:
(a) when included in Schedule 2 or 3; or
(b) in preparations for dermal use for the treatment of tinea pedis.
TIOCONAZOLE in preparations for vaginal use.
TIOCONAZOLE in preparations for dermal use except in preparations for the treatment of tinea pedis.
TIOTROPIUM.
TIPRANAVIR.
TIRILAZAD.
TIROFIBAN.
TOBRAMYCIN.
TOCAINIDE.
TOCERANIB.
TOCILIZUMAB.
TOLCLOFOS-METHYL.
TOLAZAMIDE.
TOLAZOLINE.
TOLBUTAMIDE.
TOLCAPONE.
TOLFENAMIC ACID.
ortho-TOLIDINE except in solid-state diagnostic therapeutic reagents.
TOLMETIN.
TOLONIUM.
TOLPROPAMINE.
TOLRESTAT.
TOLTERODINE.
TOLTRAZURIL.
TOLUENE (excluding its derivatives) except in preparations containing 50 per cent or less of toluene or toluene and xylene.
TOLUENEDIAMINE in preparations for skin colouration and dyeing of eyelashes or eyebrows except when included in Schedule 6.
TOLUENEDIAMINE:
(a) in hair dye preparations except when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height; or
(b) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:
WARNING - This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height.
TOLVAPTAN.
2,4-TOLUENEDIAMINE in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows.
TOLYLFLUANID.
TOPIRAMATE.
TOPOTECAN.
TORASEMIDE.
TOREMIFENE.
TOXOIDS for human parenteral use except when separately specified in these Schedules.
TRALKOXYDIM.
TRAMADOL. (Appendix A)
TRAMAZOLINE.
TRAMETINIB DIMETHYL SULFOXIDE.
TRANDOLAPRIL.
TRANEXAMIC ACID except in preparations containing 3 per cent or less of cetyl tranexamate hydrochloride for dermal cosmetic use.
TRANSFLUTHRIN except:
(a) in preparations containing 1 per cent or less of transfluthrin; or
(b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge.

TRANYLCYPROMINE. (Appendix A)

TRASTUZUMAB.

TRASTUZUMAB EMTANSINE.

TRAVOPROST.

TRAZODONE.

TRENBOLONE (trienbolone, trienolone) except when included in Schedule 5. (Appendix B, Appendix D)

TRENBOLONE in implant preparations for growth promotion in animals.

TREOSULPHAN.

TREPROSTINIL.

TRESTOLONE. (Appendix B, Appendix D)

TRETAMINE.

TRETINOIN. (Clauses 37,52,60)

TRIACETYLOLEANDOMYCIN.

TRIADIFON except:
(a) when included in Schedule 5; or
(b) in fertilisers containing 5 g/kg or less of triadimefon.

TRIADIMEFON in wettable powders containing 25 per cent or less of triadimefon.

TRIADIMENOL.

TRIALLATE.

TRIAMCINOLONE except when included in Schedule 2 or 3.

TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

TRIAMCINOLONE for buccal use in preparations containing 0.1 per cent or less of triamcinolone in a pack of 5 g or less.

TRIAMPHOS.

TRIAMTERENE.

TRIAZBUTIL.

TRIAZIQUONE.

TRIAZOLAM. (Appendix D)

TRIBENURON-METHYL.

TRIBUFOS (s,s,s-tributylphosphorotrithioate).

TRICHLORETHYL except metrifonate included in Schedule 4.

TRICHLORMETHIAZIDE.

TRICHLOROACETIC ACID except:
(a) when included in Schedule 4 or 5; or
(b) in human dermal preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROACETIC ACID, alkali salts of.

TRICHLOROACETIC ACID for human dermal use except when in preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.
1,1,1-TRICHLOROETHANE in pressurised spray packs for therapeutic use.

1,1,1-TRICHLOROETHANE except:

(a) in preparations packed in pressurised spray packs;
(b) in preparations containing 25 per cent or less of designated solvents;
(c) in preparations, other than writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less; or
(d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:
   (i) the word "Trichloroethane" written in letters not less than 1 mm in height and in distinct contrast to the background; and
   (ii) the expression:
   WARNING - DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU;
   written in bold face sanserif capital letters not less than 1 mm in height and in distinct contrast to the background.

TRICHLOROETHYLENE except when included in Schedule 4.

TRICHLOROETHYLENE for therapeutic use.

TRICHLOROPHENOL.

TRICHODESMA AFRICANA for therapeutic use.

TRICLABENDAZOLE except in preparations containing 20 per cent or less of triclabendazole.

TRICLOFOS.

TRICLOPYR.

TRICLOSAN in cosmetic preparations for human use containing more than 0.3 per cent of triclosan.

TRICYCLAMOL.

TRIDIPHANE.

TRIDEMORPH.

TRIDIHEXETHYL.

TRIETHANOLAMINE when in preparations for tattoo removal.

TRIETHANOLAMINE (excluding its salts and derivatives) except in preparations containing 5 per cent or less of triethanolamine.

TRIETHYL PHOSPHATE.

TRIETHANOLAMINE (excluding its salts and derivatives) except in preparations containing 30 per cent or less of triethanolamine lauryl ether sulfate when labelled with the statements:
Avoid contact with eyes and skin; and
Wash hands after handling.
TRILOSTANE.

TRIMEPERIDINE.

TRIMEPRAZINE except when included in Schedule 2 or 3. (Appendix A)

TRIMEPRAZINE:
(a) in solid oral preparations except when included in Schedule 2; or
(b) in liquid oral preparations containing 10 mg or less of trimeprazine per 5 mL, except in preparations for the treatment of children under 2 years of age.

TRIMEPRAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:
(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b) in a day-night pack containing trimeprazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper, except in preparations for the treatment of children under 2 years of age. (Appendix A)

TRIMETAPHAN.

TRIMETHOPRIM.

3,4,5-TRIMETHOXY-a-METHYLPHENYLETHYLAMINE *(TMA).

3,4,5-TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally derived from methoxy-phenylethylamine except:
(a) methoxyphenamine; or
(b) when separately specified in this Schedule.

1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE.

TRIMIPRAMINE. (Appendix A)

TRIMUSTINE.

TRINEXAPAC-ETHYL except:
(a) when packed in a sealed water-soluble measure pack; or
(b) in solid preparations containing 25 per cent or less of trinexapac-ethyl in packs of 50 g or less.

TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.

TRINITROPHENOL (excluding its derivatives) except:
(a) in preparations for human therapeutic use; or
(b) in preparations containing 5 per cent or less or trinitrophenol.

3,6,9-TRIOXAUNDECANEDIOIC ACID except in preparations containing 5 per cent or less of 3,6,9-trioxaundecanedioic acid, the pH of which is 3.5 or greater.

TRIOXYSALEN.

TRIPARANOL for therapeutic use.

TRIPLEPPLENAMINE.

TRIPLE ANTIGEN VACCINE.

TRIPROLIDINE except when included in Schedule 2 or 3. (Appendix A)

TRIPROLIDINE in oral preparations except:
(a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age. (Appendix A)

TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:
(a) at least one of the other therapeutically active substances is a sympathomimetic
decongestant; or
(b) in a day-night pack containing triprolidine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper, except in preparations for the treatment of children under 2 years of age. (Appendix A)

TRIPTORELIN.

TRISODIUM NITRILOTRIACETATE except in preparations containing 20 per cent or less of trisodium nitrilotriacetate.

TRITICONAZOLE.

TROGLITAZONE.

TROMETAMOL in preparations for injection except in preparations containing 3 per cent or less of trometamol.

TROPICAMIDE.

TROPISETRON.

TROVAFLOXACIN.

TROXIDONE.

TRYPTOPHAN for human therapeutic use except in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.

TUAMINOHEPTANE.

TUBERCULIN.

TUBOCURARINE.

TULATHROMYCIN.

TULOBUTEROL.

TURPENTINE, MINERAL - see HYDROCARBONS, LIQUID.

TURPENTINE OIL except in preparations containing 25 per cent or less of turpentine oil.

TUSSILAGO FARFARA for therapeutic use.

TYLOSIN except:
(a) when included in Schedule 5;
(b) in animal feeds containing 50 mg/kg or less of antibiotic substances:
(i) for growth promotion;
(ii) for the prevention of liver abscesses in cattle; or
(iii) for the prevention of ileitis in pigs; or
(c) in milk replacers for calves, or starter rations for pigs, containing 100 mg/kg or less of antibiotic substances.

TYLOSIN in animal feed premixes containing 5 per cent or less of antibiotic substances:
(a) for growth promotion;
(b) for the prevention of liver abscesses in cattle; or
(c) for the prevention of ileitis in pigs.

TYMAZOLINE.

TYPHOID VACCINE.

ULIPRISTAL.

UMECLIDINIUM.

UNOPROSTONE.

URACIL.

URAPIDIL.
URETHANE (excluding its derivatives) for therapeutic use.
UROFOLLITROPIN. (Clauses 37, 52, 60).
UROKINASE.
URSODEOXYCHOLIC ACID.
USTEKINUMAB.
VACCINES for human therapeutic use except when separately specified in this Schedule.
VACCINES, veterinary live virus except:
(a) poultry vaccines;
(b) pigeon pox vaccine; or
(c) scabby mouth vaccine.
VACCINIA VIRUS VACCINE.
VALACICLOVIR.
VALDECOXIB.
VALGANCICLOVIR.
VALNOCTAMIDE.
VALPROIC ACID.
VALSARTAN.
VAMIDOTHION.
VANCOMYCIN.
VANDETANIB.
VARDENAFIL.
VARENICLINE.
VARICELLA VACCINE.
VASOPRESSIN.
VECURONIUM.
VEDAPROFEN.
VEDOLIZUMAB.
VELAGLUCERASE ALFA.
VEMURAFENIB.
VENLAFAXINE.
VERAPAMIL.
VERATRUM spp. except when separately specified in this Schedule.
VERNAKALANT.
VERNOLATE.
VERTEPORFIN.
VIDARABINE.
VIGABATRIN.
VILANTEROL.
VILDAGLIPTIN.
VILOXAZINE.
VINBLASTINE.
VINCAMINE.
VINCLOZOLIN.
VINCRISTINE.
VINDESINE.
VINFLUNINE.
VINORELBINE.
VINYL BROMIDE.
VINYL CHLORIDE.
VINYL ETHER for therapeutic use.
VIRGINIAMYCIN except when included in Schedule 5.
VIRGINIAMYCIN in animal feed additives containing 1 per cent or less of
virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.
VISMODEGIB.
VISNADINE.
VITAMIN A for human therapeutic or cosmetic use except:
(a) in preparations for topical use containing 1 per cent or less of vitamin A;
(b) in preparations for internal use containing 3000 micrograms retinol equivalents or
less of vitamin A per daily dose; or
(c) in preparations for parenteral nutrition replacement.
VITAMIN B - see NICOTINIC ACID.
VITAMIN D for human internal therapeutic use in preparations containing 175
micrograms or less of Vitamin D per recommended single weekly dose except in
preparations containing 25 micrograms or less of vitamin D per recommended daily
dose.
VITAMIN D for human internal therapeutic use except:
(a) in preparations containing 25 micrograms or less of less of Vitamin D per
recommended daily dose; or
(b) when included in Schedule 3
VITREOUS ENAMELS.
VORICONAZOLE.
VORINOSTAT.
VORTIOXETINE.
VORICONAZOLE.
WARFARIN except when included in Schedule 4 or 5.
WARFARIN for therapeutic use.
WARFARIN in rodent baits containing 0.1 per cent or less of warfarin.
WRITING CORRECTION pens which do not allow ingestion of the contents and
which contain no scheduled poison other than designated solvents included in
Schedule 5.
XAMOTEROL.
XANTHINOL NICOTINATE.
XIMELAGATRAN.
XIPAMIDE.
XYLAZINE.
XYLENE (excluding its derivatives) except in preparations containing 50 per cent or
less of xylene or xylene and toluene.
XYLOMETAZOLINE.
YOHIMBINE.
ZAFIRLUKAST.
ZALCITABINE.
ZALEPLON.
ZANAMIVIR.
ZERANOL except when included in Schedule 6.
ZERANOL in ear implants for use as a growth promotant in steer cattle.
ZETA-CYPERMETHRIN except when included in Schedule 6.
ZETA-CYPERMETHRIN in preparations containing 10 per cent or less of zeta-cypermethrin.
ZIDOVUDINE.
ZILPATEROL.
ZIMELDINE.
ZINC BORATE (excluding its derivatives) for use as an agricultural chemical.
ZINC CHLORIDE except:
(a) when included in Schedule 2; or
(b) in preparations containing 5 per cent or less of zinc chloride.
ZINC CHLORIDE for human dermal use except in preparations containing 5 per cent or less of zinc chloride.
ZINC COMPOUNDS for human internal use except:
(a) in preparations with a recommended daily dose of 25 mg or less of zinc; or
(b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the Required Advisory Statements for Medicine Labels.
ZINC para-PHENOLSULFONATE except in preparations containing 5 per cent or less of zinc para-phenolsulfonate.
ZINC SULFATE except:
(a) when included in or expressly excluded from Schedule 4; or
(b) in other preparations containing 5 per cent or less of zinc sulfate.
ZINEB.
ZIPRASIDONE. (Appendix A)
ZIRAM except when included in Schedule 6.
ZIRAM in granular preparations.
ZOLAZEPAM. (Appendix D)
ZOLEDRONIC ACID.
ZOLMITRIPTAN.
ZOLPIDEM. (Appendix A)
ZONISAMIDE. (Appendix A)
ZOPICLONE. (Appendix A)
ZOXAZOLAMINE.
ZUCLOPENTHIXOL.

For further information contact the Duty Pharmaceutical Officer, Pharmaceutical Services during office hours on (02) 9391 9944.